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Abstract
Enzymes are powerful tools that are capable of catalyzing reactions with high specificity
and efficiency. Many naturally occurring enzymes are used as tools in industry and medicine,
from food additives to pharmaceuticals to biofuel production. Protein engineering is used to
make enzymes more readily available, to gain new or improved catalytic function, or optimize
properties such as thermostability and enantioselectivity. In this thesis we will discuss the variety
of ways proteins can be modified to one day be able to be put to use in industrial and clinical
settings.
My goal has been to optimize proteins for industrial and clinical use by either a)
understanding how the protein evolved so that the knowledge can be applied to other protein
designs, b) finding new ways to express proteins so that they can be isolated and used more easily
in industrial and clinical settings, and c) creating new proteins that can be used for industrial and
clinical settings. In Chapter 2, through protein engineering, a new protein was made that
selectively binds lanthanides over its natural metal, calcium, with high affinity. This provides us
with important information into how metalloproteins evolve metal specificity, which can be
applied to designing new metalloproteins. In Chapter 3, we investigate a possible application of
this protein in therapeutics by attaching an antibody to the protein structure that is specific for
Hepatocellular Carcinoma cells and using the protein to bind and deliver radioisotopes. This
would allow us to not only create a new treatment option for this variety of cancer, but also allow
us to optimize the treatment more effectively and easily through protein evolution. In Chapter 4,
we discuss how changing the expression vector of an industrially relevant enzyme, formate

dehydrogenase, allows it to be synthesized and secreted by Pichia pastoris and can be an
important first step in creating a self-sustaining and environmentally safe method of producing
methanol biofuel. Chapter 5 focuses on investigating a new method of evolving designed proteins
that uses NMR by analyzing known mutations in an extensively evolved protein. This would one
day allow potential enzymes to be optimized readily and cheaply for commercial use. Finally,
Chapter 6 will focus on using amino acids as an alternative to traditional chiral ligands in
organometallic synthesis. These new ligands would be much cheaper to make, easier to produce,
and have the added benefit of forming fibrils that would make them easy to collect and attach to
surfaces. These studies contribute to a better understanding of the variety of methods proteins
can be optimized for use in our daily lives.
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Chapter 1 Introduction
1.1. Enzymes
1.1.1. Defined
Catalysts are capable of enabling otherwise kinetically unfavorable reactions to occur
more quickly and readily.1-4 They are characterized by their ability to perform this function
without changing the thermodynamic properties of the reaction or being consumed during the
catalytic process. They are one of the most powerful available tools in both the laboratory and in
the natural world. Many natural catalysts can be classified as enzymes, which are made up of
either amino acids or RNA (these are known as ribozymes). For the purposes of this dissertation,
we will only be discussing enzymes that are composed of amino acids or peptides, which are
shorter sequences of amino acids.
Enzymes and other catalysts function by lowering the energy required for a reaction to
occur.1-2, 5 Every chemical reaction carries with it an activation energy threshold that must be
overcome in order for the product to be formed (Figure 1.1).1-4 When a reaction is occurring in
favorable conditions, such as in a heated, acidic, or basic environment, or the reactant is highly
unstable, the reaction can often proceed forward without intervention. However, the presence
of an enzyme can help the reaction along by binding the reactant (or substrate) and changing the
conditions of the reaction to make it occur more easily.2

1

Figure 1.1. Transition state diagram of an uncatalyzed (red) and enzymatically catalyzed (blue) exothermic
reaction.1-4, 7 ES refers to the enzyme-substrate complex that is formed when the substrate binds to the enzyme.
ES+ refers to the transition state of the substrate as it is bound to the enzyme. EP is the enzyme-product complex
that is formed before the product is released from the protein. G+ is the Gibbs free energy required for the
substrate to reach the transition state between the substrate and product.

Enzymes are capable of performing this task in a number of ways. All enzymes have what
is known as an ‘active site’ where a substrate can bind.1-4, 7 Binding to this active site can change
the environment the substrate is in, can change its conformation, or can weaken bonds. The
active site also serves the purpose of making an enzyme selective; many enzymes are only
capable of catalyzing one reaction with one specific substrate to give one specific product. This
selectivity serves to allow the enzyme to regulate how much of a substance is in the environment
and when the catalyzed reaction will take place.
There are two popular theories about how a substrate binds in the active site (Figure 1.2).
The first is known as the lock-and-key theory, theorized by Emil Fischer in 1894.8-9 It hypothesizes
that each substrate fits perfectly with the enzyme like a key will fit into only one lock and vice
2

versa. While this theory is able to explain the specificity of enzymes for substrates, it does not
explain how an enzyme can have multiple substrates, nor does it explain how an enzyme is able
to stabilize the transition state of the substrate.

8, 10

Figure 1.2. Lock-and-key model of the active site hypothesizes that the active site (a, b, and c) of the protein
(yellow) is specific to the substrate (green) and they fit precisely to form the enzyme-substrate complex.8

The second theory is called “induced fit” proposed by Daniel Koshland in 1958 (Figure
1.3).1 The theory suggests that the enzyme and its active site are able to change conformation
when needed. This allows the enzyme to fit around different substrates as needed and also to
change the conformation of substrate to allow the reaction to proceed.
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Figure 1.3. Induced fit model suggests that the protein (yellow) is able to change shape fluidly and form around
the substrate (green) so that the points of contact in the active site (a, b, and c) fit with the substrate.10-11

Still others have proposed that both theories are at least partially true. 10-11 A flexible lockand-key motif suggests that the active site is rigid and fits substrates specifically. However, the
substrate is also able to alter the active site during the reaction and the substrate can even be
flexible.
The active site is not the only part of the enzyme that plays an important role in catalysis.
Proteins also utilize cofactors, which are either non-protein chemical compound or metallic ions
(Figure 1.4).12-13 Non-protein chemical compounds can refer to complex organic molecules such
as vitamins (known as coenzymes) or inorganic ions such as phosphate or iron-sulfur clusters.
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Organic

Coenzyme
(non-covalently
bound)
Prosthetic group
(covalently bound)

Cofactor
Inorganic

Metal ions

Figure 1.4. How cofactors are categorized. Organic molecules are usually derived from vitamins and can be
classified as either coenzymes (if non-covalently bound) or as prosthetic groups (if covalently bound). 13 Proteins
with metal ion cofactors are also known as metalloproteins and makeup approximately 40% of all known
proteins.12

Often an enzyme will not even be considered ‘active’ unless the cofactor is present (Figure
1.5).12,

14

Cofactors can help a reaction proceed by allowing a protein to attain the right

conformation for catalysis, providing energy, or storing and releasing electrons. Cofactors are
also another way that the organism is able to regulate the activity of enzymes within itself. 12, 14

Figure 1.5. An example of enzyme that requires a cofactor for catalysis.3-4 In this example, the active site is on
the cofactor (lavender) and can only be formed properly when bound to the protein (light blue). Other ways
cofactors are used by proteins include providing energy for the reaction, altering conformations, and acting as a
means of maintaining equilibrium

5

Many proteins also contain an allosteric domain.3-4 This is a domain separate from the
active site where cofactors and coenzymes can bind (Figure 1.6). Once the cofactor or coenzyme
are bound, the structure of the protein is changes. Allosteric domains are used to either activate
or inhibit an enzyme depending upon how the structure changes and if the structure allows for
catalysis.3-4, 12, 15

Figure 1.6. A diagram of allosteric inhibition and activation.1, 3, 16-18 Allosteric inhibition (a) is when an allosteric
inhibitor binds to the allosteric site and prevents the reaction from occurring by distorting the shape of the
active site so the substrate cannot bind. Allosteric activation (b) is when an allosteric activator binds to the
allosteric site and allows for the active site to bind to substrates.

Finally, competing substrate analogs can reduce or eliminate activity of enzymes.1, 3, 16-18
These analogs are known as inhibitors and can either bind directly to the active site (competitive
or irreversible) or allosterically (uncompetitive or noncompetitive) (Figure 1.7).1, 18 An inhibitor
that can be removed from an active site is known as competitive and one that cannot be removed
from the active site is an irreversible inhibitor.4, 16, 18-19 Uncompetitive inhibition refers to when
an inhibitor binds to the enzyme-substrate (ES) complex and cannot be reversed by increasing
6

the concentration of substrate.4, 17-18 Noncompetitive inhibition reduces the activity of an enzyme
and is able to bind to a protein both in the presence and absence of substrate. 3, 18 Usually, the
noncompetitive inhibitor will prefer either the enzyme state or the ES complex, which is a
phenomenon known as mixed inhibition.1

Figure 1.7. The different types of inhibition1-4, 20 (A) is an example of a protein and substrate in the absence of
any type of inhibition. (B) is a diagram of competitive inhibition where the inhibitor occupies the active site. (C)
is uncompetitive inhibition where the inhibitor binds outside of the active site to stop a reaction. (D) is
noncompetitive inhibition where an inhibitor binding outside of the active site reduces the activity of the
enzyme.

1.1.2. Enzyme kinetics
Enzyme catalysis can be analyzed in a number of ways. The most popular method is
through the Michaelis-Menten equation (Equation 1.1 and Figure 1.8).1-4, 20 This equation relates
the reaction velocity (v0) to the product turnover per unit time (kcat), the initial concentration of
enzyme ([E]0), the concentration of substrate ([S]), and the concentration of substrate when the
7

reaction is at half of its maximal velocity (KM). The product turnover multiplied by the
concentration of enzyme also gives the maximal velocity (v max) that the protein can accomplish.
Equation 1.1. Michaelis-Menten equation
𝒗𝟎 =

𝒌𝒄𝒂𝒕 [𝑬]𝟎 [𝑺]
𝒗𝒎𝒂𝒙 [𝑺]
=
𝑲𝑴 + [𝑺]
𝑲𝑴 + [𝑺]

Figure 1.8. Michaelis-Menten equation.1

1.1.3. Enzyme structure
As mentioned previously, proteins and enzymes are made up of 20 different amino acids
(Figure 1.9) that bind together in long polypeptide chains. Each amino acid is indicated by either
a three letter or one letter code. In addition to the common 20 amino acids, there are also several
amino acids that occur much less frequently in nature. Examples include selenocysteine (a

8

cysteine containing a selenium atom instead of a sulfur atom) and ornithine (a lysine with one
less carbon in its side chain).

9

Figure 1.9. The 20 most common amino acids found in nature. Each amino acid can be specified with either a
one letter or three letter code. The amino acids link together via peptide bonds to form long polypeptide chains
that can become proteins.
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Enzyme structure consists of four structural elements: primary, secondary, tertiary, and
quaternary (Figure 1.10).1-4, 7, 21 The primary structure is the linear amino acid sequence of the
polypeptide chain, including any posttranslational modifications the sequence might have
undergone.3 The amino acids join together to form amide bonds that link together from the Nterminus to the C-terminus. The primary sequence of the protein dictates the kinds of secondary
and tertiary folds that will ultimately form.

Figure 1.10. A summary of the categories of protein structure: primary, secondary, tertiary, and quaternary.22-25
The primary structure is the linear amino acid sequence of the protein. The secondary structure is the local
structure of the linear segments due to hydrogen bonds. The tertiary structure is the three-dimensional
arrangement of all the amino acids in the polypeptide chain, including the side chains. The quaternary structure
is the arrangement of single polypeptide chains (subunits) into a multi-subunit protein.

The secondary structure is the three dimensional fold that the sequence undergoes due
to hydrogen bonds and without regard for the conformation of the side chains (Figure 1.11).22-25
These structures can usually be classified as either an -helix or a -sheet and often a protein
can contain multiple of each.22 If the structure does not fit into either of these classifications or
falls between them then it is called a random coil. 22
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The first structure, -helix, is a spiral conformation where the NH and C=O bonds of the
main chain or backbone form hydrogen bonds.22 A single turn of the helix consists of 3.6 amino
acids and an -helix usually contains at least three turns total. In addition to the hydrogen bond,
there are also van der Waals interactions along the helical axis. The -helix is the most stable of
the secondary structures and the most common.
The -sheet occurs when the polypeptide chains arrange themselves in parallel ribbons
that connect via hydrogen bonds between the NH and C=O backbone.7 The amino acid side chains
lie perpendicular to the main chains where the hydrogen bonds occur. Each strand is usually five
to ten amino acids long.

Figure 1.11. The secondary structure of a protein can either be categorized as an -helix or a -sheet.7, 22, 24, 26

The tertiary structure of a protein refers to the intermolecular interactions in the protein
between its side chains (Figure 1.12).7, 22, 24, 26 This includes disulfide bonds between cysteine
residues, hydrogen bonds between polar amino acids, and van der Waals interactions. The
12

primary sequence is the sole dictator of tertiary structure. 7, 22 The quaternary structure of a
protein is the result of multiple subunits of the same protein coming together via intramolecular
interactions (Figure 1.13).7, 22 These subunits can either be identical or have varying structures.

Figure 1.12. The tertiary structure of proteins consists of intermolecular interactions such as ionic bonds or salt
bridges, disulfide bonds, hydrophobic interactions, and hydrogen bonding.7

Figure 1.13. Quaternary structure of hemoglobin.22 This protein consists of four subunits complexed together
into a final structure.
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Two proteins are considered similar, or homologous, if they share over 40% of the same
sequence.28 They tend to have similar secondary, tertiary, and quaternary structures despite
changes in the primary sequence. It is common to have homologous proteins between species;
for example, calmodulin, a calcium sensing protein, is present in all eukaryotes and functions
similarly between them despite varying primary structures.22 However, some mutations can be
more favorable than the parent sequence, which can result in new structures that are more
thermostable and/or catalytic.29-34 This is known as divergent evolution.

1.2. Protein Engineering
Enzymes have many advantages in comparison to organic and inorganic catalysts. They
are environmentally friendly because they can function in water at low temperature and are
biodegradable.29-34 In addition, enzymes are also stereoselective, have greater substrate
specificity, can have their activity regulated, and can often perform in neutral conditions.35-37
Furthermore, enzymatic catalysts are easy to obtain through by introducing the genetic code into
a variety of organism (this is discussed in Chapter 4).38-41 However, while enzymes are an excellent
alternative to organic and inorganic catalysts, there are a limited number of proteins that are
actually capable of doing reactions that we need.29-34 Protein design strives to not only create
new enzymes for these purposes, but also optimize natural enzymes for greater stability, catalytic
activity, stereoselectivity, or even metal binding (which is detailed in Chapter 2 and 3).29-34 Protein
engineers also have additional goals, such as creating new structural motifs and understanding
how evolution of enzymes occurred.33, 42-43
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Figure 1.14. Protein engineering strategies.44 Directed evolution refers to introducing mutations randomly and
screening to see which mutations ae successful. Rational design uses computational algorithms to determine the
most stable mutations of a protein and then characterizes them. Semi-rational design is a combination of the
two methods.

Protein engineering typically falls into one of three categories: directed evolution, rational
design, and semi-rational design (Figure 1.14).3 Each of these approaches requires the use of
mutagenesis to alter the genetic code and thus alter the protein sequence. The next section
details how one is able to alter the amino acid sequence of a protein and the various methods of
mutating said sequence.
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1.2.1. Polymerase chain reaction and mutagenesis
Proteins are encoded into DNA using codons. DNA is made up of four different nucleic
acids: adenine (A), guanine (G), cytosine (C), and thymine (T). A codon is a group of three
nucleotides that is read by the cell and transcribed into a specific amino acid (Figure 1.15). Some
amino acids, such as leucine, have multiple codons for the same amino acid, while others like
tryptophan only have one.45 Methionine is known as the ‘start’ codon and is the codon that
triggers protein synthesis, or translation. Stop codons signal the end of the protein and stop
translation.
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Figure 1.15. Codon Table. Each three-letter sequence of nucleotides encodes for a protein. Many amino acids
have multiple codons.
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The most common method of genetic sequencing is Sanger sequencing (Figure
1.16).45 A single stranded DNA is incubated with labelled nucleotides (dNTPs), ddNTPs
(nucleotides lacking the 3’-OH group necessary for chain elongation), and a DNA
polymerase. The ddNTPs are usually labelled with a fluorescent dye or a radioactive
phosphorous. By looking at where the DNA fragments have stopped synthesizing and the
size of the DNA, one is able to piece together the DNA sequence of the gene.

Figure 1.16. Description of Sanger sequencing.2-4, 23 ddNTPs are tagged and mixed with the template strand. If a
tagged ddNTP binds to the strand, then the sequence stops. In this way, one can eventually build a map of
where each codon and nucleic acid lie in respect to the gene.
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In 1985, the polymerase chain reaction (PCR) was published as a way to create
many copies of a segment of DNA (Figure 1.17).2-4, 23 PCR consists of three main steps that
are repeated multiple times. The first step, denaturation, applies heat to the sample to
separate the double stranded DNA into single strands. The next step, annealing, allows
for custom made primers to bind to complementary sequences on the two single strands.
The temperature is usually set to be a few degrees lower than the melting temperature
of the primers, or the temperature at which the primer would dissociate into two single
strands of DNA. The final step of the process, replication, allows for the complementary
strands of new DNA to be polymerized starting from the primers. Repetition of these
three steps allows one to obtain a lot of copies of a gene in a short amount of time.

Figure 1.17. Process of polymerase chain reaction.3, 46 PCR consists of three main steps: denaturation, annealing,
and replication. Over time, PCR yields multiple copies of a desired segment of DNA.

PCR allows for specific mutations to be made to a gene to alter protein sequence. By
customizing the primers to contain different codons than the template strand, multiple copies of
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new DNA are created. When done purposefully, this process is known as site-directed
mutagenesis. 3, 46 Site-directed mutagenesis allows for base pair substitution and/or introduction
of a new amino acid, insertion of new base pairs, or the deletion of specific base pairs (Figure
1.18). Site-directed mutagenesis can also randomize an amino acid in a specific position by using
a primer solution that contains a mixture of all dNTPs at that codon position, which is known as
random mutagenesis.

Figure 1.18. Site-directed mutagenesis by using base-pair substitution, insertion, and deletion.47

Error-prone PCR is used as a non-specific method of directed evolution.47 Error-prone PCR
introduces random mutations into the plasmid using DNA polymerase that is prone to errors
(Figure 1.19). Unfortunately, while error-prone PCR is good for creating a large library in multiple
20

positions of the plasmid quickly, since some amino acids only have one or two codons encoding
them, there is not an equal distribution of amino acids within the mutants.

Figure 1.19. Error-prone PCR and DNA recombination or shuffling.48

Finally, DNA recombination or shuffling is when separate DNA sequences randomly
recombine to create a single gene (Figure 1.19).49-51 This technique is similar to homologous
recombination, which is detailed in Chapter 4. The parent DNA is fragmented and purified, then
used as templates for PCR. This allows advantageous mutations between genes to be amplified
and combined while also removing detrimental mutations.
1.2.2. Directed evolution
Directed evolution is a method of protein engineering that is analogous to natural
selection (Figure 1.20). 49-51 Directed evolution is used to create vast libraries of different proteins
and genes that contain variations in sequence. Once these vast libraries are created, they can be
screened for activity or stability.10, 52 There are many methods of screening for hits such as
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fluorescent signaling, cell surface display, and activity assays. 48, 53 Positive hits are sequenced to
determine sequence and mutations.51 A single protein usually undergoes several rounds of
directed evolution to find the optimal sequence. Directed evolution, while powerful, carries
distinct challenges and limitations that will be discussed in Chapter 5.

Figure 1.20. A diagram of directed evolution.54-59 The inner circle indicates the three stages of directed evolution
with the natural equivalent in parenthesis. The outer circle indicates a typical experimental setup.

1.2.3. Rational design
Rational design involves determining the optimal mutation for a protein using physical
models.54-59 Rational design uses computational programs to determine a protein’s optimal
sequence that gives the lowest energy structure. These sequences can either be designed from
scratch using known peptide sequences or those inspired by nature (de novo) design.34,

60
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Computational design that uses the protein’s backbone as a scaffold and then calculates a
theoretical substrate transition state is known as theozyme-based computational design.37
Iterative based computation design takes the same technique and includes optimizing the active
site as well.62 While this is a powerful method, the proteins usually developed often have low
catalytic activity because of a missing component in the process; enzymatic catalysis frequently
relies on destabilizing substrates, which is not taken into account in computational methods since
they only calculate the lowest energy transition states.44 Furthermore, the reactions are highly
specific to a single substrate.
1.2.4. Semi-rational design
Semi-rational design manages to merge the best qualities of directed evolution and
computational design.60 Usually an amino acid or group of amino acids are identified using
computational algorithms and then a site-directed or random mutagenesis is done on the amino
acid(s).38-41 Then the protein is screened to determine if the desired traits have increased. A
round of directed mutagenesis will then follow that, or more computational design.

1.3. Methods of Protein Production
Once a gene is created, organisms can be used to produce the protein in bulk.38-4138-413841

Escherichia coli is the typical organism used to carry out protein expression since they grow

easily, multiply quickly, and are easy to mutate.52 First, the gene is spliced into a plasmid, which
is circular DNA specific for bacteria. Then the plasmid is introduced into the bacterium in a
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process known as transformation whereby the cell is coaxed into taking the plasmid in. 63
Transformation can be accomplished either by the use of heat or by the use of a gentle electrical
current (Figure 1.21).63

Figure 1.21. Protein transformation.15, 64-65 Plasmids with a desired gene can be introduced into bacteria such as
E. coli by first ‘shocking’ the bacterium with either heat or an electric shock, then allowing the cell to rest so it
will accept the plasmid into its body and recover.

After the plasmid is introduced into cells and colonies of plasmid-containing bacteria
grow, a single colony is picked and grown in large scale. This larger culture will be used to
synthesize and isolate the protein. The plasmid containing the protein gene also contains what is
known as the lac operon (Figure 1.22). 15, 64-65 Normally, an active repressor binds to the DNA that
prevents RNA polymerase binding and protein synthesis. However, in the presence of lactose,
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the bound repressor detaches from DovA and deactivates, exposing lac operon. RNA polymerase
is able to bind to this operon and begin protein synthesis. Analogs of lactose, such as IPTG are
used to ‘induce’ bacteria to express protein while they are growing. After several hours of growth,
the cells are collected by centrifugation and are used for protein purification.
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Figure 1.22. Diagram of protein induction.3 In normal conditions without lactose, a repressor binds to the
operon (the sequence that signals protein synthesis) and RNA polymerase is unable to attach. In the presence of
an inducing agent such as IPTG (bottom), it will bind to the repressor and allow protein synthesis to take place.

There are various methods of purifying proteins from cell paste but typically they consist
of steps to first get the protein into solution by splitting open the cells and treating them, then
purifying the protein from the supernatant.66 For the purposes of purification, many proteins
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have an extra sequence known as the His-tag attached to them. This His-tag consists of six
histidines and a domain linking the histidines and the protein (usually with a sequence that can
be cut by proteases such as tobacco etch virus or TEV).67 The histidines are able to bind to a
special resin known as Ni-NTA, which consists of nickel complexed with nitrilotriacetic acid that
is attached to a solid surface such as a bead (Figure 1.23).67 The histidine tags are able to bind to
the Ni2+ while other impurities are not. To remove the bound protein, imidazole is used to ‘elute’
the protein off by competing with the His-tag for binding (Figure 1.24). Any undesired salts or
buffers can then be removed using affinity chromatography.

Figure 1.23. Nickel-NTA resin.68 NTA chelates the nickel ion to the resin bead. When histidine is present, the
nickel ions bind the residues while allowing other impurities to pass by. To detach the histidine, a competing
compound such as imidazole is added to replace the histidine on the nickel.
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Figure 1.24. Affinity chromatography.1, 3 The protein binds to the affinity resin while all other impurities are
washed away, then the protein is eluted off using a competing molecule such as imidazole. To remove the
eluting agent, the protein can then be put on a desalting column which traps smaller ions on top while the
protein flows through, allowing the buffer to be ‘exchanged.’

To determine purity of the protein, the protein is usually visualized using gel
electrophoresis (Figure 1.25). 1, 3 The protein is loaded onto an acrylamide gel. Molecules that are
larger are not as able to travel through the porous gel as smaller molecules. A detergent is
employed, usually sodium dodecyl sulfate (SDS), that can break apart proteins in proportion to
their molecular weight (typically one molecule of SDS binds to every two amino acid residues)
and partially unfolds the proteins.1 SDS gives the protein a large net negative charge that helps it
travel through the polyacrylamide gel when a current is applied. Using this method, you can see
bands from all proteins (both desired and undesired) present in sample and determine

28

expression of the protein of interest by comparing to a protein ladder. To visualize the bands, a
dye such as Coomassie blue is added, which binds the proteins but not the gel polymer.

Figure 1.25. Gel electrophoresis.69-70 Protein samples are dyed and loaded onto a gel made of acrylamide
polymer. An electrical current is passed through the gel, and smaller macromolecules travel further down the
gel while larger ones stay near the top.

Concentration can be determined using UV-Vis spectroscopy (Figure 1.26). Specific amino
acids have specific molar absorptivity that can be used to calculate the extinction coefficient of a
protein at a specific wavelength (Figure 1.27). 69-70 Protein absorbance is usually measured at 280
nm, which can be calculated from the absorbance of the tryptophan and tyrosine residues in the
protein. At 280 nm, tryptophan and typrosine have extinction coefficients of 5690 M-1cm-1 and
1280 M-1cm-1, respectively.
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Figure 1.26. UV-Vis spectroscopy of proteins and nucleic acids.70 Nucleic acids have an absorbance maxima at
260 nm. Proteins have absorbance maxima at 280 nm due to tyrosine and tryptophan residues.

Figure 1.27. UV-Vis spectra of aromatic amino acids.71 Due to their aromatic groups, tryptophan and tyrosine
both peak at 280 nm. Phenylalanine peaks at 260 nm, the same wavelength as nucleic acids, making it an
unreliable measure of protein concentration.

To determine the exact mass of the isolated protein, mass spectrometry can be used.
MALDI-TOF is a common method of mass spectrometry where the protein is mixed with a matrix
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(Figure 1.28).71 A laser releases the sample from the matrix (which is responsible for ionizing the
sample) and the particles travel through an electric field generator towards a detector. Smaller,
lighter compounds are able to reach the detector before larger fragments. The detector is then
capable of determining the mass of the fragments based on how long a fragment takes to reach
the detector.

Figure 1.28. Diagram of Maldi-TOF.31 A laser releases sample bound to the matrix, which travels through an
electric field to a detector. The detector determines the size of the sample by calculating how long it took for the
sample to reach the detector.

31

1.4. Concluding Remarks
Enzymes are catalysts found in the natural world. They have a variety of functions due to
their unique structures.1 Because of their utility, scientists are constantly seeking new ways to
design, optimize and express proteins for novel functions. This chapter gives a brief overview of
how proteins function, the issues with designing proteins, and the most common ways to purify
and identify proteins; techniques essential to the research projects described in this thesis. This
dissertation will focus on how proteins can be made more viable for clinical and industrial uses.
Chapter 2 will focus on designing a new, metal-specific protein from an existing scaffold. Chapter
3 will then apply the newly made protein from Chapter 2 for clinical use as a method of imaging
and/or treating cancer. Chapter 4 focuses on how changing a protein’s expression system can aid
in making the protein more useable for industrial applications. Chapter 5 will focus on developing
a new method of directed evolution that can be applied for optimizing other proteins more
efficiently. Finally, Chapter 6 will highlight how peptide fragments can be used in conjunction
with organometallic catalysts to create new potential catalysts that are cheaper to make and
reuse.
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Chapter 2 Design of a Rare Earth Selective Calmodulin Derivative
2.0. Abstract
Even though metalloproteins account for at least half of all proteins in the body, strategies
for evolving specific metal ion selectivity are still relatively unknown. Calmodulin (Cam) is a
protein that undergoes a conformational change in presence of Ca2+ that allows for substrate
binding. In recent years, Korendovych and co-workers modified a non-catalytic wild type Cam to
enable the current generation, Ac7, to perform a Kemp elimination reaction upon addition of
calcium ions. The product of Kemp elimination produces a clearly visible yellow color that can be
read using a standard UV-Vis spectrometer. In addition, the Korendovych group successfully
evolved the “EF hands” of the catalytic Cam mutant to bind lanthanide ions with a moderate
preference over Ca2+. Using these same principles, an Ac7 mutant has been developed to strongly
prefer rare earth metals over Ca2+ and yet still catalyze the Kemp elimination.

2.1. Introduction
Approximately 40% of all proteins can be classified as metalloproteins, that is, proteins
that bind to one or more metal ions.1-6 The metal ion can be responsible for structure, electron
transfer, dioxygen binding, and/or catalysis by the protein.5 Metalloenzymes, the enzymatic
equivalent of metalloproteins, are responsible for some of the most important reactions in
nature, including photosynthesis, respiration, and nitrogen fixation.3
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Most metalloproteins bind to either alkaline metals (Group 1), alkaline earth metals
(Group 2), or transition metals (Groups 3-12).2, 7 This is believed to be due to the fact that these
elements are more prevalent in the environment and therefore proteins evolved to utilize the
already abundant resource (Figure 2.1). This theory is supported, for example, by methanol
dehydrogenase, a protein produced by Methylobacterium extorquens.8 This organism is capable
of living in volcanic mud pots and is able to covert methanol to formaldehyde. Mud pots contain
high amounts of soluble lanthanides, which are used in the protein as a cofactor alongside
pyrroloquinoline quinone (Figure 2.2).9 Without this lanthanum, the protein is incapable of
withstanding the extreme temperatures of its native environment.8, 10-11
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Figure 2.1. Summary of the most common metals used in metalloproteins.2, 7

In addition, rare metals are becoming more common in the environment due to human
influence. For example, due to toxic waste, there has been an increase in bacteria and other
organisms capable of living in these conditions. Cupriavidus metallidurans strain CH34 is a Gramnegative bacteria that has been found to grow in high levels of heavy metals such as mercury,
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cadmium, and lead (Figure 2.2).12-15 The bacterium relies on proteins that can selectively bind the
heavy metal ions over essential ions such as calcium or zinc.16-17 One protein in particular,
PbrR691 of the MerR family, is especially effective in binding to lead metal thanks to its three
conserved cysteine residues and its ability to allow Pb2+ to adopt a preferred hemi-directed
geometry while bound.13, 17

Figure 2.2. Examples of evolved organisms and proteins that bind non-typical metals specifically. Left:
Cupriavidas metallidurans, a bacterium that is able to live in toxic waste due to its ability to selectively bind
Pb2+ and ship it out of the cell before it does damage. 11 Right: The active site of Methanol dehydrogenase,
isolated from Methylobacterium extorquens, which coordinates with a La3+ ion to allow it to live in extreme
temperatures.10

It is the ambition of many scientists to be able to design metalloproteins from scratch. 3
Being able to evolve and design metalloproteins is an important step to understanding evolution
itself. One way to gain insight into this question is to transform a protein that binds a more
common metal, such as calcium, into a new derivative that can bind less common metals, such
as the rare earth elements. For this, we used calmodulin as a starting scaffold, and eventually
mutated it into HollEE, a selective lanthanide-binding protein that catalyzes an unnatural
reaction.
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2.1.1. Calmodulin
Calcium is the most prevalent metal ion within the body and as such calcium-binding
proteins are common and are widely found in eukaryotes.18-19 Of these calcium-binding proteins,
Calmodulin (Cam) is responsible for a myriad of functions in the body including inflammation,
muscle contraction, memory, nerve growth, and the immune response (Figure 2.3).20-21 Cam is a
highly conserved 148-residue (16.7 kDa) protein that has been extensively studied and has a well
characterized structure.

Figure 2.3. Examples of systems and proteins that calmodulin and calcium regulate. 21

Most calcium-sensing proteins, including Cam, use EF-hand motifs to coordinate calcium
ions.22 In the EF-hands of calcium-binding proteins, the amino acids are numbered according to
their relative position within the loop, positions 1-12 (Figure 2.4). Positions 1, 3, 5, 7, 9, and 12
coordinate with calcium to form a pentagonal bipyramidyl complex.20, 23-24 Loop positions 1, 3, 5,
and 12 consist of amino acids with carboxyl or hydroxyl groups in the side chains.24 Meanwhile,
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amino acid at position 7 coordinates from the main chain carbonyl, position 9 is a bridged water
molecule, and position 12 also acts as a bidentate ligand in the coordination complex. Residue 1
is almost exclusively Asp between species and is responsible for the maintaining the structure of
Cam.24-25 Residues 3 and 5 are predominantly Asp residues as well, though there is more variety
between eukaryotes.24 Position 6 is always a Gly residue in order for the folds in the -helix to
occur properly. Finally, position 12 is usually an aspartate or glutamate residue; options for
bidentate amino acids are limited.

Figure 2.4. Diagram of EF-hands in calcium-sensing protiens.21 Residues 1, 3, 5, 7, and 12 coordinate direction
with the Ca2+ ion to form a pentagonal bipyramidal complex. Nine represents a water molecule that is
coordinated to the Ca2+ ion with residue 9 in the EF-hand.

Cam contains two lobes, which contain two EF-hand sites each, that are linked by an αhelix.20, 26 Each lobe consists of a large hydrophobic section that is important for substrate
binding.26 When calcium binds to the EF-hands, it induces a change in the structure of Cam and
exposes the hydrophobic sections so that substrates may bind (Figure 2.5).
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Figure 2.5. Conformational change of calmodulin in the presence of calcium. 24

Calmodulin is a popular scaffold for protein engineering.27 Its thermostability, small size,
lack of intrinsic catalytic activity, the presence of a cavity sufficient for substrate binding, and the
spatial separation between the allosteric ligand-binding sites (in this case the EF-hands) and the
substrate binding pocket make it an ideal protein since it is easy to work with and examine with
NMR characterization.28
2.1.2. AlleyCat
In 2010, Ivan Korendovych of the DeGrado group at University of Pennsylvania was able
to engineer a Kemp eliminase by using calmodulin as the scaffold.28 Studies suggested that a
majority of the initial allosteric metal binding occurs in the C-terminal domain of calmodulin.4, 20
By removing the N-terminal domain of Cam, Korendovych was able to create a new protein
(cCam) with a similar structure to the parent scaffold, but with only 74 residues and two EF-hands
(meaning it only needs to bind two equivalents of calcium instead of four).28 The new protein
was then used to create a new Kemp eliminase known as AlleyCat (ALLostEricallY Controlled
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CATalyst). This protein has been the foundation for numerous studies in the Korendovych lab as
an evolvable enzyme and sensor.28-30 In addition, cCam has been used as a platform for other
catalytic enzymes, such as a retro-aldolase and an esterase.31-32

Figure 2.6. Schematic of calmodulin conversion to C-terminal calmodulin. Mutating the phenylalanine in the 92
position of C-term Cam to glutamate yields AlleyCat protein.1-4

Kemp elimination (Scheme 1) is a non-natural reaction for bacteria, meaning that any
observed reaction of the substrate must be due to the introduced mutations. 33 For this reason,
the Kemp elimination is a useful benchmark for protein engineering. 28, 30,

33-38

The reaction

requires a basic catalytic residue to break one of the C-H bonds, allowing for the formation of a
nitrile whose concentration is easily measured using visible spectroscopy at 380 nm.

Scheme 1. Kemp elimination reaction.
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AlleyCat’s catalytic activity is from the mutation of the phenylalanine at position 92 to
glutamate.28, 30 This residue is deep within the hydrophobic pocket, which raises the pK a of the
normally acidic Glu residue from 2.2 to 5.8 when substrate is not present.28, 39 In the presence of
a bound substrate, the pKa of the Glu becomes even more basic, approximately 6.9, allowing for
Kemp elimination to proceed.28

A

B

Figure 2.7. A) 3D representation of cell surface of AlleyCat. B) Comparison of catalytic activity between F92E
(black circles) and negative control mutant F92Q (black diamonds).25

AlleyCat has undergone many rounds of evolution in the Korendovych group in order to
optimize catalytic activity.30 The round of mutation is denoted by the terminal number of the
name AlleyCat (Ac); AlleyCat5 (Ac5) refers to the fifth round of mutation, AlleyCat3 (Ac3) refers
to the third round of mutation, and AlleyCat0 (Ac0) refers to the original protein. A
comprehensive list of all mutations and sequences of AlleyCat is available in Table S.4. of the
appendix. Further detail into the methods for further evolution of the AlleyCat series will be
covered in Chapter 5.
One of the major features of the AlleyCat series is that Kemp elimination only occurs in
the presence of calcium.30 This is due to the conformational change that occurs in Cam when
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calcium binds to the EF-hands.30, 40 The substrate binding pocket of AlleyCat is only exposed when
calcium is in place, and removing calcium from the environment will immediately stop catalysis
and vice versa (Figure 2.8).

Figure 2.8. Kinetic assay of Kemp elimination showing the allosteric regulation of AlleyCat7. 27 Removing calcium
ions from the reaction with chelator reduces kinetic activity and vice versa.

With this allosteric property in mind, AlleyCat has the potential to become a customizable
metal sensor.29, 41 Since Kemp elimination only occurs if the protein is bound to metal, modifying
what metals AlleyCat is able to bind to is a promising way to create this sensor (Figure 2.9). We
are able to utilize this property while characterizing the specificity of our evolved proteins, since
Kemp elimination will only occur if the protein is binding a metal ion.
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Figure 2.9. General mechanism of an engineered protein metal sensor.26
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2.1.3. Coordinating alternative metals in AlleyCat

Figure 2.10. Crystal structure of the EF-hand metal binding site of calmodulin when bound to (A) Ca 2+, (B) Pb2+,
(C) Sr2+, and (D) Ba2+.45

In addition to heavy metals, the binding of lanthanide ions is also well studied in regard
to their interactions with EF-hands.18, 42 Despite being trivalent ions, lanthanides have similar
ionic radii to calcium and seem to bind Cam similarly (Figure 2.10). There are relatively few
convenient methods to determine the concentration of lanthanide ions in solution. Most
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methods involve either the use of expensive and hard to obtain equipment or complex molecules
that will give out measurable readings when bound to the metals.43-44 The limited availability of
such methods is increasingly problematic. Rare earth metals are increasingly important in
modern society, used in products such as hybrid car batteries, smart phones, magnets, and even
medicines.8, 45-46
Analyzing the results of previous studies on lanthanide and heavy metal binding to EFhands, we hope to create new proteins that can be highly selective for binding and sensing by
catalyzing the Kemp elimination to provide a convenient colorimetric assay. A catalytic metal
sensor is advantageous over current methods such as using fluorophores since a catalyst would
require much less metal. The measurable output of a catalytic sensor is limited only by the
turnover rate of the catalyst, and will continually secrete a reading until it can be measured,
which means that even small amounts of metal will eventually be ‘sensed’ since they are not
being measured directly. Fluorophores and instrumental analysis measure concentrations of
metal ions directly, so if the metal concentration is below the threshold of an instrument’s range
or not concentrated enough to get a reliable reading from the fluorophore, the metal
concentration cannot be measured.
2.1.4. CuSeCat and previous work
In 2013, Korendovych lab published about a new variant of AlleyCat called CuSeCat
(CUstomizable SEnsor aided by CATalysis) that was able to bind lanthanides in the EF-hands29. In
order to accomplish this, residues S101 and N137 of the EF-hands were mutated into negativelycharged residues; this should increase the charge density of the metal binding site (Figure 2.11).
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Residue 9 in the EF-hands, which normally consists of neutral residues bridged by a water
molecule, is an ideal position to change since the residue itself is only loosely associated with
metal coordination. In principle, charge density at that site could be increased with theoretically
little change to the structure.19, 22, 29, 47 To accomplish the goal of increasing the negative charge
of the metal binding loop, S101 and N137 were mutated into Asp and Glu residues, CuSeCatDD
and CuSeCatEE, respectively.29 The results are promising.

Figure 2.11. Modeling of S101 and N137 positions of AlleyCat.28 The green ribbon represents the structure of
CuSeCat, the blue sticks represent the active residues in the metal binding site, the red spheres represent the
F92E mutation responsible for Kemp elimination, the orange spheres represent the S101E and N137E mutations
that were introduced to CuSeCat, and the gray spheres represent a trivalent metal ion.

In this particular case, the goal was not to create a more efficient enzyme, but rather an
enzyme that would (a) be active in the presence of the desired metal and (b) not be active in the
presence of high amounts of calcium. Metal dependence assays, which measure the maximum
kcat/KM at different concentrations of metal, are a practical way to visualize selectivity. When the
Kemp elimination with CuSeCatEE was run in the presence of CaCl2 and YbCl3, it was clear that
CuSeCatEE was more active with the lanthanide (Figure 2.12) reflecting stronger metal binding
to Yb3+.
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Figure 2.12. Metal dependence assay of CuSeCatEE. 28 In low concentrations of YbCl3 and CaCl2, CuSeCatEE is
more active in the presences of lanthanide.

While these results are promising, increasing the concentration of CaCl 2 results in the
significant increase in Kemp elimination activity (Figure 2.13). While intracellular calcium levels
can be as low as 50-100 nM, outside the cell there can be anywhere from 1-3 mM free calcium
ions.48 This means that CuSeCat could not be used because there would be too much interference
from background calcium. Furthermore, due to the nature of ytterbium and other lanthanides,
higher concentrations (typically exceeding 0.1mM) result in precipitation of protein.
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Figure 2.13. Metal dependence assay of CuSeCat series with 10,000-fold excess of CaCl2 to protein.28

2.2. Designing a Selective AlleyCat
2.2.1. Position 9 - S101 and N137
We are particularly interested in designing Kemp elimination assays that respond to heavy
metals or lanthanides due to the potential applications as to environmental sensors or chelating
linkers for radioimmunotherapy. AlleyCat7, the most active of the AlleyCat series to date, was
used as a DNA template for all mutations. To mimic CuSeCat, aspartate and glutamate mutations
were introduced into the S101 and N137 positions to create AcDD and AcEE respectively. Due to
the poor solubility of lead(II) nitrate in water and the tendency for lanthanides such as yttrium(III)
nitrate to precipitate proteins at higher concentrations, concentrations of metal had to be kept
below 100 M.49-50 Unlike CuSeCat, AcDD and AcEE were not selective for lead or yttrium over
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calcium; in all cases, all mutants exhibited higher activity for calcium at equal concentration
(Table 2.1).
Cysteine is residue that binds strongly to heavy metal ions. 13,

20

However, cysteine

mutantions can be difficult to work with due to their ability to make disulfide bonds, which can
cause proteins to dimerize or aggregate. Cysteine mutations to the S101 and N137 positions were
expressed and purified. Unfortunately, there was evidence of dimer formation by SDS-PAGE gel
(Figure S.0.2). Upon adding an equivalent of the reducing agent β-ME, the dimers broke down
into the monomeric form of the protein. Nonetheless, neither the dimers nor the presence of βME had much effect on the activity of the proteins. S101C and N137C showed much greater
activity in the presence of calcium than lead or yttrium (Table 2.1). We therefore moved on to
other positions in the EF-hands.

Table 2.1. Summary of activity of mutations to position 9 after the addition of 0.1 mM Ca(NO 3)2, 0.1 mM
Pb(NO3)2, or 0.1 mM Y(NO3)3. All assays were run in 20mM Hepes at pH 7.0 with 5.0 M protein and can be
found in Table S.7-S.12.

kcat/KM (M-1s-1) Ca2+

Pb2+

Y3+

Ac7

462±24 M-1s-1 403±62 M-1s-1 32±48 M-1s-1

AcDD

555±25 M-1s-1 254±56 M-1s-1 18 M-1s-1

AcEE

309±29 M-1s-1

---

---

AcS101C

327±40 M-1s-1

---

5 M-1s-1

AcN137C

410±49 M-1s-1

---

18 M-1s-1
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2.2.2. Position 7- Y99 and Q135
Position 7 is also responsible for calcium-binding in Cam and is the next logical target for
a set of mutations.16 Even though position 7 binds metals through the main chain, we reasoned
that changes to the side chain may alter the tertiary structure enough to have an impact on metal
binding. The Y99 and Q135 residues were targeted for mutation into either Glu or Cys. However,
the Q135C site-directed mutagenesis failed in multiple attempts and the Q135E mutation, while
successful, failed to express in cells. Kemp assays were performed but showed that Y99E and
Y99C exhibited decreased activity in the presence of calcium (Table 2.2). Y99E and Y99C mutants
were not active with lead(II) or yttrium(III).

Table 2.2. Summary of activity of position 7 mutants after addition of 0.1 mM Ca(NO3)2, 0.1 mM Pb(NO3)2, or 0.1
mM Y(NO3)3. All assays were run in 20mM Hepes at pH 7.0 with 5.0 M protein.

kcat/KM (M-1s-1) Ca2+

Pb2+

Y3+

Ac7

462±24 M-1s-1 403±62 M-1s-1 32±48 M-1s-1

AcY99E

195±18 M-1s-1

---

3 M-1s-1

AcY99C

369±93 M-1s-1

---

5 M-1s-1

2.2.3. Position 3 – D95 and D131
We know that positions 1, 3, and 5 are directly involved in binding calcium ions. Previous
work in our lab has showed that position 5 mutations result in proteins that are completely
inactive and position 1 is essential for protein structure.25 However, little information was
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available on the consequences of mutating position 3. When consulting the crystal structures of
calmodulin bound to calcium vs lead (Figure 2.14), position 3 showed a difference of 0.6
angstroms between the two ions.51 This lead us to believe that this position might give us the
selectivity we desired.

Figure 2.14. Three-dimensional structure of HollEE constructed in PyMol using Cam structure (pdb code 1cll) as a
template. The yellow spheres represent yttrium ions.1

Preliminary data showed that mutating D95 and D131 into either Glu or Cys almost
completely eliminated activity of the protein in the presence of calcium (Table 2.3). However,
while activity was decreased in comparison to Ac7, the EE and CC mutations of Ac7, called HollEE
and ReCCes respectively, showed significant activity in yttrium when compared to calcium. While
ReCCes also showed potential selectivity for Pb2+, the difficulty in expressing and working with
this protein caused us to set it aside in favor of HollEE.
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Table 2.3. Activity of HollEE and ReCCes in presence of calcium, lead, and yttrium. All assays were run in 20 mM
Hepes at pH 7.0 with 5.0 M protein.

kcat/KM (M-1s-1) AlleyCat 7 HollEE ReCCes
0.1 mM Ca2+

526

0.3

0

0.25 mM Ca2+

580

1.7

0.5

0.1 mM Pb2+

--

1.0

3.6

0.25 mM Pb2+

286

0

4.0

0.1 mM Y3+

190

47

32

0.25 mM Y3+

102

14

0

An important property to note from Table 2.3 is that the activity of AlleyCat7, HollEE, and
ReCCes all significantly decrease as the concentration of yttrium increases. This is due to solubility
issues. If concentrations exceeding 0.1 mM of lanthanide, the protein begins to precipitate out
of solution (observed as a white powder) which decreases the measured activity.
2.2.4. MALDI-TOF
A MALDI-TOF analysis was also performed on the protein (Figure 2.15) to confirm its
identity. The m/z of the protein on the MALDI spectrum matched the predicted molecular weight,
indicating that the isolated protein was most likely HollEE and not misidentified.
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Figure 2.15. MALDI-TOF of cut HollEE. The calculated mass of HollEE is 8530 Da.

2.3. Characterizing HollEE with different lanthanides
2.3.1. Kinetic assays
Kemp elimination assays of HollEE were run with a total of ten different lanthanides:
yttrium, lanthanum, cerium, neodymium, praseodymium, samarium, gadolinium, terbium,
ytterbium, and lutetium. By examining the influence of these lanthanides on Michaelis-Menten
kinetics of Kemp elimination, along with calcium, it can be concluded that HollEE is highly
selective for lanthanides even in concentrations of calcium typically found in the body (Figure
2.16 and Table 2.4).
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Figure 2.16. Catalytic efficiency of Kemp elimination with HollEE in the presence of various lanthanides. The left
graph pictures all the metals tested while the right graph only features lutetium, ytterbium, and calcium. All
samples were run in 20 mM Mops, 100 mM NaCl, pH 7.0 with 0.08 mM metal unless otherwise noted. The
concentration of HollEE was 1.0 M. All kcat/KM are reported in Table 2.4. (MT7081)
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Table 2.4. Summary of HollEE activities in 20 mM Mops, 100 mM NaCl at pH 7.0. The concentration of all metals
was 0.08 mM unless otherwise noted. (MT7081)

2mM Ca2+

Y3+

La3+

Ce3+

Pr3+

Nd3+

Sm3+

Gd3+

Tb3+

Yb3+

Lu3+

123

176

236

231

199

133

94
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3.7

2.9

Ca2+
kcat/KM

0.03

0.03

(M-1s-1)

When the catalytic activity is correlated to the ionic radius of the +3 charged lanthanide,
there is a clear trend of increased activity with increased ionic radius (Figure 2.17).52 Because
different lanthanides have different optimal concentrations with protein, it is difficult to find one
metal concentration to measure all kcat/KM at, which can explain why the yttrium is higher than
the trend estimates (Y-HollEE complex is most active at 80 M metal) and lanthanum is lower
than expected (La-HollEE complex is most active at higher metal concentrations).
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Figure 2.17. Correlation between ionic radius (pm) and catalytic activity with 0.08 mM metal concentration. All
ionic radii for the lanthanides are calculated for six-coordinate octahedral geometry.52 (MT7081)

It is possible that the larger ions allow the protein to conform to a more optimal shape
for catalysis than smaller ions (Figure 2.18). Since catalytic activity of HollEE is dependent upon
the exposure of the substrate binding pocket, which in turn is dependent upon the position of
the EF-hands, a smaller ion might change shape so that Kemp elimination is harder to occur.
However, this hypothesis does not necessarily mean that the binding of HollEE to smaller ions is
weaker that HollEE to larger ions, merely that catalysis is not ideal.
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D95

E95

Figure 2.18. Active site of AlleyCat (left) and HollEE (right) in the presence of calcium (cyan sphere). Both
figures were generated in PyMol using 1cll as a template.

The data show that larger ions tend to retain more activity at higher concentrations of
metal than smaller ions (Figure 2.19). For most of the smaller ions, higher ion concentrations are
needed to achieve maximum catalytic activity, but higher concentrations of the metal tend to
cause protein precipitation. Meanwhile, larger lanthanides are less likely to precipitate out
protein at higher concentrations. These issues with precipitation do limit the scope of the protein
to smaller concentrations of metal ion, which is desirable from a sensor standpoint, but make
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comparison between metals difficult since each metal has a different optimum metal
concentration.

Figure 2.19. Catalytic efficiency of Kemp elimination using 2.5 M HollEE in 20 mM Mops at pH 7.0. Kinetic
activity was measured in the presence of different metals and varying concentrations. (MT7047)
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2.3.2. pH profiling
Attempts were made to determine the pKa of HollEE using pH profiles and determine the
effective pH range of HollEE. Unfortunately, due to precipitation issues with even low
concentrations of lanthanides, none of the data could be fit to a curve (described in chapter
2.5.6). The pH profile graphs of HollEE with different metals can be found in the Appendix I,
section S.2.3.
2.3.3. Isothermal Titration Calorimetry
A byproduct of chemical and physical change in reactions is the release or absorbance of
heat.53-54 Isothermal titration calorimetry (ITC) is a favored method for determining proteinligand interactions since it requires no labelling, is highly sensitive, and can be used with
substrates that are undetected by spectroscopic methods. ITC works by slowly titrating ligand (or
in this case, a metal ion) into a protein and measuring the heat released or absorbed by the how
much energy is required for the instrument to maintain a temperature that is consistent with
that of the solution in a reference cell (Figure 2.20).54-55 As the protein’s binding sites become
saturated, the heat absorbed/released approaches zero. From this isotherm, a number of
properties can be determined such as the enthalpy of binding ( H), the entropy of binding ( S),
the dissociation constant (Kd), binding stoichiometry, the free energy of binding ( G), and
cooperativity (site-site interactions).55
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Figure 2.20. Schematic of basic experimental setup for ITC (left) and the typical data acquired from ITC (right).55

Our expectation was that when aliquots of Ca(NO3)3 were added to HollEE, the heat of
reaction would either remain at 0 kJ/mol or would quickly level off to zero (Figure 2.20).
Meanwhile, in the presence of increasing amounts of Y(NO3)3, we expected an isotherm much
like that seen in AlleyCat7 when titrated with calcium (Figure S.25). The AlleyCat7 isotherm curve
is indicative of either a macromolecule with two identical and independent binding sites for
substrate, a macromolecule with two nonidentical binding sites, or a macromolecule with two
identical sites that display negative cooperativity (the binding in the first site decreases the
macromolecule’s affinity for binding in the second site).56 Since different EF-hands in Cam are
known to have different binding affinities for calcium, we expect the second case to be true.20
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Figure 2.21. ITC data of HollEE titrated with Ca(NO3)2 (left) and Y(NO3)3 (right). The sample cell contained 0.1 mM
HollEE in 20 mM Mops pH 7.0 at 25 C and was slowly titrated with either 5 mM Ca(NO3)2 or Y(NO3)3 in 5 L
injections with an equilibration time of 240 seconds. (MT6155)

HollEE releases very minimal amounts of heat when titrated with calcium as expected and
shows no binding affinity for calcium. The results obtained from titrating HollEE with yttrium
were not consistent with Ac7 (Figure S.25) or a protein with two nonidentical binding sites. The
results are inconclusive. We know that binding must occur since HollEE is able to catalyze the
Kemp elimination reaction in the presence of yttrium but not in calcium. However, the ITC data
for yttrium titration never reaches 0 kJ/mol, thus signaling the completion of reaction, even in
the presence of saturating concentrations of yttrium. It was expected that HollEE would have a
2:1 binding ratio of metal:protein, but this is not shown in Figure 2.21. Furthermore, calcium
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binding in Ac7 is an exothermic process, but the positive values of yttrium titration suggest an
endothermic process.
We ultimately decided that using ITC to determine dissociation coefficient, Kd, of metal
ions to HollEE is not a viable route. We were able to conclude that calcium does not bind to
HollEE, but little else. We believe that our unusual results are likely due to HollEE’s tendency to
precipitate at metal concentrations exceeding 100 M, which could impact our readings greatly
since the concentration of protein is already 100

M in our experiments.57 Unfortunately,

experimental costs limited our ability to test this hypothesis. This prompted us to determine a
new method to calculate Kd using other measurable parameters.58-59
2.3.4. Circular Dichroism analysis of binding
Another way to determine the binding efficacy of HollEE with metals is to observe the
secondary structure of HollEE for different metal ions. This can be measured using circular
dichroism (CD), a technique that allows us to visualize secondary structure. As stated above, the
EF-hands responsible for metal binding consist of -helices. Secondary structures such as -helix,
-sheet, disordered or random coils, and even denatured proteins have unique signatures in the
CD spectrum (Figure 2.22).60-61

71

Figure 2.22. Secondary structures visualized by circular dichroism.61 Each secondary structure has a unique
readout that can be used to analyze protein and peptide samples.

When CD spectra of HollEE are measured using 100 M concentration of different metals,
there is a distinct difference between the structure of HollEE without metal added and with metal
(Figure 2.23). Without metal, HollEE is more disordered and thus, not expected to be catalytically
active for Kemp elimination based on the properties of Cam. However, HollEE exhibits significant
-helical structure in the presence of rare earth metals. There also appears to be a correlation
between Kemp elimination activity and the degree of -helicity; metals that give greater activity
tend to exhibit lower mean residue ellipticity (MRE) compared to lower activity metals. HollEE in
the presence of EDTA (a metal chelator) and calcium exhibits a similar curve to that of HollEE
without any metal added at all.
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Figure 2.23. Circular dichroism of HollEE (25 M, 4 mM Mops, pH 7.0, 22 C) with 100 M of different metals.
(MT7011)

When HollEE is titrated with a metal ion, lutetium for example, there is a clear trend in
MRE as a function of metal ion concentration (Figures 2.24 and 2.25). Because HollEE has two EFhands, it requires at least two metal ions to bind to it to be fully functional. The data in Figure
2.24 shows that once the concentration of lutetium reaches 50 M, any concentration higher
than that has roughly similar MRE values (until precipitation starts to occur). This is further shown
in Figure 2.25.
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Figure 2.24. Circular dichroism of HollEE (25 M) in 4 mM Mops pH 7.0 with varying concentrations of LuCl3,
which are listed in the legend (except in the case of EDTA which added a concentration of 0.1 mM EDTA
instead). An increase in the concentration of metal ions results in increasingly negative MRE at 207 nm and 220
nm. (MT7026)

74

Figure 2.25. Analysis of metal titration of Figure 2.24 at 220 nm. The MRE is calculated by subtracting mean
residue ellipticity at 220 nm from the MRE at 220 nm of HollEE in 0.1 mM EDTA. (MT7026)

Since there is a measurable in mean residue ellipticity with change in metal concentration,
it is possible that these measurements can be used to calculate Kd.58-59 We can fit Figure 2.25 to
the following curve: MRE=(Y1[E]K1x + Y2[E]K12x2)/(1 + K1x + K12x2), where [E] is the concentration
of HollEE, x is the concentration of metal ions added, Y1 represents the MRE value when one
metal ion is bound to HollEE, K1 represents the association coefficient of the first metal ion to
HollEE, Y2 represents the MRE value when the second metal ion binds to HollEE, and K2 represents
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the association coefficient when the second metal ion binds.59 The association coefficient, Ka, can
be found by multiplying K1 and K2 and by assuming that K1 is equal to K2, this equation can be
further simplified.Then to find the dissociation coefficient Kd, the inverse of Ka is calculated
(Figure 2.26).

Figure 2.26. Kd analysis of HollEE (25 M, 4mM Mops, pH 7.0, 22 C) with LuCl3 titration using mean residue
ellipticity at 220nm. (MT7026)
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Unfortunately, once again due to HollEE’s tendency to precipitate, it is difficult to saturate
HollEE enough to create a curve that can obtain a reasonable value. While CD metal titration is a
promising method for determining Kd, this method still needs to be optimized.

2.4. Conclusions
Designing proteins that are capable of binding non-typical metals is challenging.41 The
design of metalloproteins is particularly difficult but being able to control metal binding gives
important clues to how metalloproteins can and may have developed metal ion specificity. By
taking an existing scaffold such as Cam, we were able to alter the sequence at the metal binding
site to accept exclusively rare earth metals, something not previously done with such great
success. This also paves the way to creating proteins that could bind other metals, such as heavy
metals, another important goal. A protein that can bind rare earth metals exclusively could have
many applications, for example, as a metal sensor, in reclamation of materials, and even in clinical
treatments; the latter topic is discussed in the next chapter.

2.5. Experimental
2.5.1. Site-directed Mutagenesis
AlleyCat7 gene was previously cloned into Champion pET-SUMO/CAT vector (Invitrogen).
Plasmid contains a N-terminal His6-tag separated from the gene of interest by a SUMO protease
recognition fragment (GG).
The appropriate mutations were made using a standard mutagenesis protocol for iProof
High-Fidelity DNA Polymerase, which was provided by the manufacturer. After PCR, the template
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was digested with DpnI restriction enzyme and transformed into E. coli XL-10 cells. DNA was
extracted from colonies using EZ-10 Spin Column Plasmid DNA kit and mutated sequences were
confirmed by Genescript using Sanger sequencing technique.
2.5.2. Expression of AlleyCat7 mutants
The plasmid with a gene coding for AlleCat7 or its mutants were transformed into E. coli
BL21(DE3) pLysS cells and expressed using LB broth. After cells reached an OD 600 of ~0.5, IPTG
was added to a final concentration of 0.5 mM and the temperature was lowered to 30oC. After
four hours, the cells were collected by centrifugation and stored at -80oC until needed.
Cell pellet was resuspended in lysis buffer containing 25 mM Tris (Tris was used instead
of Tris-HCl due to worries of precipitation of metal when combined with chlorine ions), 20 mM
imidazole, 0.5 mM PMSF, and 300 mM NaCl (pH 8). In addition, 5 L of Benzonase (25 U/ L,
Novagen) is added for every 1 g of cell pellet. Cells were lysed by sonication, and then allowed to
rock gently at room temperature for 30 min. The crude cell lysate was centrifuged at 20,000xg
for 30 minutes. The supernatant was applied to a Ni-NTA (His60 Ni Superflow resin, TaKaRa)
column and washed with lysis buffer (without PMSF). The protein was then eluted with buffer
containing 25 mM Tris, 250 mM imidazole, and 300 mM NaCl (pH 8). The sample was exchanged
into buffer containing 50 mM Tris, 75 mM NaCl (pH 8) by applying it onto a Bio-Rad 10 DG
desalting column. Protein concentration was determined using UV-Vis spectroscopy where ε280=
5445 cm-1M-1.

78

2.5.3. Removal of His6-tag
SUMO protease was transformed into E. coli BL21 RP cells and expressed using LB broth
at 30 C. After cells reached OD600 ~0.5, culture was induced with 0.5 mM IPTG and the cells
harvested by centrifugation (4000xg, 20 min) after 4 hours. Cells were resuspended in 25 mM
Tris, 5% glycerol, 10 mM -ME, pH 7.6 and lysed using sonication (20 sec intervals). Debris was
collected by centrifugation (4 C, 20,000xg, 30 min). Streptomycin sulfate was then added
dropwise to 0.1% and stirred on ice for 30 minutes. Debris was once again collected by
centrifugation (4 C, 20,000xg, 30 min). Supernatant was loaded onto Ni-NTA column and eluted
off using buffer containing 25 mM Tris, 5% glycerol, 250 mM imidazole, pH 7.6. Fractions with
protein were loaded onto a Q-Sepharose column and washed with original lysis buffer, then
eluted with buffer containing 25 mM Tris, 10 mM -ME, 5% glycerol, 200 mM NaCl, pH 7.6.
Samples were stored at -80 C until needed.
To cleave His-tag, uncut AlleyCat sample was incubated with 1.0 mM DTT, 0.5 mM EDTA,
and SUMO protease at a 200:1 ratio (absorbance ratio at 280 nm) overnight at 30oC. To ensure
integrity, cleavage solution was filter sterilized using 0.22 μM PES filter before incubation.
After incubation, DTT and EDTA were removed by applying sample onto a Bio-Rad 10 DG
desalting column with 50 mM Tris, 75 mM NaCl (pH 8) buffer. Desalted samples were then
applied to Ni-NTA column equilibrated with same buffer and allowed to sit on column for
minimum one hour. Afterwards, protein was collected in flow through and wash and the
presence of protein was determined using UV-Vis spectroscopy.
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To thoroughly remove metal, approximately 5 equivalents of EDTA was added to the
collected fractions. The sample was then exchanged into 20 mM Mops (pH 7.0) twice using a BioRad 10 DG desalting column to ensure removal of excess calcium ions and EDTA.
The purity of the protein was established by SDS-PAGE using a 15% acrylamide gel with
Unstained Precision Protein Plus ladder. Protein concentration was determined using UV-Vis
spectroscopy where ε280 = 2967 cm-1M-1.
2.5.4. Kinetic assays
Kemp substrate was synthesized using protocol outlined in Casey et al.62
Kinetic measurements were done with either a Thermo Lab-systems Multiskan Spectrum
Platereader or a BioTek Eon Micro Platereader monitoring the absorbance at 380 nm at 22oC
using at least three independent measurements. The final protein concentration (determined by
UV-Vis spectroscopy using ε280= 2967 M-1 cm-1) for kinetic measurements was 1.0 μM. Final
substrate concentrations ranged from 0.12 to 0.96 mM. Kinetic parameters (kcat/KM) were
obtained by fitting the linear portion of data to the Michaelis-Menten equation: [v0 =
kcat[E]0[S]0/(KM + [S]0)] using Kaleidagraph 4.5 (Synergy Software) or by fitting the data to a linear
curfe using Kaleidagraph 4.5.
2.5.5. Metal Dependence Assays
Kinetic measurements were done with either a Thermo Lab-systems Multiskan Spectrum
Platereader or a BioTek Eon Micro Platereader monitoring the absorbance at 380 nm at 22oC
using at least three independent measurements. The final protein concentration (determined by
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UV-Vis spectroscopy using ε280= 5445 M-1 cm-1 for uncut protein and ε280= 2967 M-1 cm-1 for cut
protein) for kinetic measurements was 2.5 μM. Final metal concentrations ranged from 0.001 to
0.25 mM. In addition, a concentration of 15 μM EDTA was used to establish activity without metal
ions present.
2.5.6. pH profiles
Kinetic measurements were done with either a Thermo Lab-systems Multiskan Spectrum
Platereader or a BioTek Eon Micro Platereader monitoring the absorbance at 380 nm at 22oC
using at least three independent measurements. The final substrate concentration was 0.6 mM.
The extinction coefficient of 15,800 cm-1M-1 was used to determine product concentration at pH
5.5 and above. At pH 4.5 and 5.0, the product coefficients of 12,480 cm-1M-1 and 14,220 cm-1M1,

respectively, were used. Samples were run in acetate buffer (pH 4.5-5.5), Mes (pH 6.0-6.5),

Mops (pH 7.0-7.5), and Tris (pH 8.0-8.5) with concentrations of 50 mM. The final protein
concentration (determined by UV-Vis spectroscopy using ε280= 5445 M-1 cm-1 for uncut protein
and ε280= 2967 M-1 cm-1 for cut protein) for kinetic measurements was 1.0 μM. The curves were
fit to [(kcat/KM)max=(kcat/KM)protonated+(kcat/KM)deprotonatedx10-pKa/(10-pH+10-pKa)], where pKa is the
apparent pKa value of the active residue, using Kaleidagraph 4.5 (Synergy software).
2.5.7. Circular Dichroism
The CD spectra were collected on the Jasco J-715 CD spectrometer, using a step scan
mode (4 sec averaging time) averaging over three runs, using a quartz cuvette with a 0.1 cm path
length. Each sample contained 25 μM protein in 4 mM Mops pH 7.0 and the final volume of each
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sample was 300

L. Samples contained varying amounts of metal chloride salts and were

measured within five minutes of addition of metal ions.
Care was taken so the sample absorbance never exceeded 1.8 at all wavelengths to
produce reliable ellipticity values.
2.5.8. MALDI-TOF Mass Spectrometry
MALDI-TOF spectrometry was performed on a Bruker Autoflex III instrument. The
instrument was calibrated with standard samples provided by the manufacturer and sinapinic
acid was used as a matrix. Protein (~10 M) was mixed with matrix at a 1:2 volume ratio.
2.5.9. Isothermal Titration Calorimetry
Apo Ac7 and HollEE were freshly purified and buffer exchanged into 20 mM Mops pH 7.0
using dialysis (Slide-A-Lyzer Dialysis Casettee G2, 10k MWCO, ThermoScientific). Samples were
frozen with liquid N2 until the night before, then thawed at 4 C overnight. Each sample used 100
M of protein at 25 C and were titrated with 5 mM metal nitrate stock in 5 L increments. Each
measurement was allowed to equilibrate for 240 s.
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The following chapter was co-authored with Z. Lengyel and A. Kulesha of the Korendovych lab.
Z. Lengyel and A. Kulesha designed the 2E10-HollEE construct.

Chapter 3 Applications of HollEE: Designing a Selective HCC-targeting
Treatment Using Monoclonal Antibodies
3.0. Abstract
Hepatocellular carcinoma (HCC) is currently the sixth most diagnosed cancer in the world
and has a very low survival rate. HCC is difficult to diagnose early and is even more difficult to
treat when it finally is caught. One of the most effective treatments is using 90Y radioisotopes to
destroy the cancer cells. Currently, the only method of delivery is to attach the

90Y

to

microspheres and deliver them directly to the blood supply of the tumor using a transarterial
catheter. However, this process is dangerous, invasive, and can only be used if the tumor is
already large and inoperable. Using our previously mentioned HollEE protein, which is selective
for lanthanides including yttrium, and attaching it to an antibody fragment that is specific for HCC
tumor cells, we propose a new method of 90Y delivery. This would allow the 90Y to be delivered
to the cancer cells much less invasively and also potentially reach metastasized cells. In this
chapter we report the success of the antibody-HollEE fusion (2E10-HollEE) in achieving selectivity
with 90Y and highlight some of the issues that have currently come up regarding purification.
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3.1. Introduction
3.1.1. Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC) is currently the sixth most diagnosed cancer in the world
and the third most responsible for cancer-related deaths (Figure 3.1).1 It is most commonly
caused by cirrhosis of the liver and/or infection by the hepatitis virus.2-5 HCC is most prevalent in
eastern Asia and Sub-Saharan Africa where Hepatitis B infection rates are the highest.1 However,
HCC diagnosis rates in the United States are increasing in correlation with the rising rates of
Hepatitis C. Aside from the hepatitis virus, HCC risk factors include obesity, diabetes, alcohol
related liver disease, and fatty liver disease.1, 3

Figure 3.1. Documented incidences of hepatocellular carcinoma for all ages and genders in 2013 worldwide.6
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It is estimated that 94% of patients diagnosed with HCC will die within the next five
years.1-2, 6 One of the reasons this cancer is so deadly is due to its low diagnosis rates in the early
stages of the disease. A patient with earlier diagnosis is ten times more likely to receive and
respond to potentially curative options of treatment.5 Once the disease progresses to later
stages, the survival rate is reduced significantly. The best curative treatment for HCC is either
resection of the liver, where the infected portion of the liver is removed, or liver transplantation.
However, once the tumor(s) becomes too big or spreads, these options become impossible and
less reliable means must be employed (Figure 3.2).

Figure 3.2. Algorithm for determining treatment options for HCC. 7

Low diagnosis rates are due to HCC’s lack of symptoms.1, 8 HCC is usually diagnosed from
acute or chronic pain in the abdomen, which only occurs in the later stages of the disease.
Furthermore, diagnosing HCC is very difficult (Figure 3.3). Liver biopsy can be intrusive and
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inconclusive, and if the correct section of the liver is not biopsied, then HCC can remain
undetected.8 -Fetoproteins from tumor cells can act as an indicator, but screening is unreliable
and non-specific to HCC.1 CT/MRI findings can be hard to distinguish and diagnose, and MRI is
not an option for people with metallic implants. PET imaging faces a similar challenge by being
unable to differentiate HCC cells from regular hepatic cells in the early stages of the cancer. 9 In
addition, these methods all have the disadvantage of not being able to diagnose metathesized
cancer cells.

Figure 3.3. Algorithm for diagnosis of HCC.10

Once HCC is diagnosed, there are few available treatment options (Figure 3.2). If the
cancer is caught early enough, resection or transplantation of the liver may be enough to cure
the patient completely. However, once the disease has progressed, this no longer becomes an
94

option.1 Thermal or chemical ablation where chemicals or energy such as radio frequencies are
applied to the surrounding tumor tissue to induce necrosis can be utilized if the tumor is small
enough. Otherwise, transarterial chemoembolization (TACE), where a catheter is fed through the
aorta and hepatic artery to deliver medication directly to the blood supply of the tumor, can be
used if other options are not available. This technique can be very effective in reducing the size
of tumors but cannot be used if the tumor is not of sufficient size or has spread to another part
of the body. One of the most common drugs used with this technique is 90Y microspheres that
release radiation to kill the tumor cell directly (Figure 3.4).1, 11

Figure 3.4. Transarterial chemoembolization of HCC using 90Y.12

The key to reducing the mortality rate of HCC is two-fold: increase the ability to diagnose
the disease and increase the ability to treat the disease, especially in later stages. Antibodies can
be utilized as a targeted therapy for HCC tumors, and when coupled with HollEE and 90Y, could
prove to be a successful new method of diagnosis and/or treatment.
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3.1.2. Antibodies
The immune system is capable of responding to a wide range of threats in the body,
including bacteria, viruses, parasitic helminths, and even tumors.13-14 The immune system
consists of a variety of natural barriers, such as mucosal membranes and stomach acid, and
specific defenses created over the lifetime of the individual known as the immune response.13
The immune response consists of -lymphocytes, which can further be divided into B-cells, Tcells, Helper T-cells, and cytotoxic T-cells, antigen-presenting cells, phagocytic and cytotoxic cells,
and natural killer cells.
Antigens and antibodies are responsible for inducing the immune response within an
individual.13-14 Antigens are compounds (including proteins, peptides, and polysaccharides) that
are recognized by B-cell and T-cell receptors to elicit the immune response. Antibodies are
globulin proteins that act in response to these antigens.14 Antibodies protect the individual from
pathogens by preventing attachment to mucosal surfaces, neutralizing toxins, facilitating
phagocytosis to quarantine the foreign invader, and binding to the antigen to activate further
immune responses (Figure 3.5).13-15
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Figure 3.5. Three mechanisms of antibody defense.15 The first mechanism is when the antibodies bind to
bacterial toxins so they do not damage cells and then trigger macrophages to ingest the antibody-toxins. The
second method involves the antibody attacking the bacteria in the extracellular space and triggering ingestion
by macrophages. The final method is when antibodies bind to bacterium in the plasma and trigger macrophages
to break apart and digest the bacteria.

Antibodies consist of two identical ~55 kDa glycoproteins and two identical ~25 kDa
glycoproteins that combine together to form a distinctive Y-shape (Figure 3.6).14 The chains are
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known as “heavy” and “light” chains in accordance to their relative weights. This complex is held
together by a collection of disulfide bonds between both heavy chains, and between the heavy
and light chains. In addition, each polypeptide chain consists of a variable region on the Nterminus and a constant region on the C-terminus consisting of two amino acid sequences. The
constant region of the heavy chain plays an important role in enabling the antibody to fulfill its
various functions. Meanwhile, the variable regions are responsible for the specific binding of
antibodies to antigens.

Figure 3.6. General structure of antibody. Heavy chains are featured in green and light chains are featured in
yellow.15 Disulfide bonds between the chains are used to create the distinctive structure of the antibody.

Antibodies (Abs) have many diagnostic and clinical uses due to their specificity.14 They are
used in immunofluorescence assays, enzyme immunoassays, radioimmunoassays, chemoluminescence assays, and Western blotting. More recently, antibodies have been explored and
used for therapeutic purposes.16 There are currently over 20 FDA-approved Abs used in the
treatment of various maladies such as rheumatoid arthritis, Crohn’s disease, and certain types of
cancer.16-17 Most therapeutic antibodies are known as monoclonal antibodies (mAb) because
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they made by identical immune cells from a single parent cell.15, 18 They are harvested from mice
that have formed an immune response to the antigen and the cells that produce the antibodies
are harvested and isolated.17

Figure 3.7. How monoclonal antibodies are made.18 Monoclonal antibodies are used because they all bind to a
single epitope and are highly specific for the tumor cells. If polyclonal antibodies were used, then there would
be much less specificity and even the possibility that the Ab could bind to a healthy cell instead.

Due to the high specificity of the antibody-antigen interaction and the antibodies long
half-life within the host, therapeutic antibodies are an appealing alternative to chemotherapy for
the treatment of tumors and cancer.17,

19-20

Several strategies have been employed to use

antibodies to treat cancer; these are summarized and explained in Figure 3.8.17 Tumor cells
produce unique antigens from regular cells, so complementary antibody-based drugs should be
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extremely selective at either targeting the cancer cells primary survival functions, introducing
treatments directly to the cancer cells, or redirecting the body’s own immune cells to target the
cancer cells.17, 20-21

Figure 3.8. Strategies of cancer therapeutic monoclonal antibodies.17 a) The mAb binds to target and triggers
antibody-dependent cytotoxicity, complement-mediated cytotoxicity, or directly signals cancer cell death. b)
The mAb inhibits the development of new blood vessels that feed the tumor cells. c) The mAb elicits a response
from antitumor T cells by blocking signals that would normally protect the tumor from the bodies own immune
system. d) The mAb is used to deliver radioisotopes directly to cancer cells for selective radiation treatment. e)
The mAb is used to deliver drugs directly to the cancer cells. f) A small portion of the mAb is used to both
recognize cancer cells on one end and activate antigens to trigger immune effector cells on the other end. g) The
mAb variable region is attached to a signaling peptides that is transferred to T cells and makes them chimeric
antigen receptor (CAR) T cells that are specific for the tumor the peptide is specific for.
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Further innovations into antibody engineering have provided exciting new platform for
drug design. The large size of the antibody makes it difficult to diffuse within a tumor, hindering
the therapeutic antibody’s ability to treat it.22 However, by removing fragments and/or chains
from the original antibody structure, new “bodies” can be made that exhibit similar activity but
present much higher diffusion rates within tumors and be easier to manipulate (Figure 3.9).23-25
Since the variable region is solely responsible for antigen selectivity, these fragmented bodies
can still retain similar sensitivity while being much easier to deliver to tumors. 26-27

Figure 3.9. Structure of various antibody derivatives.27 As long as the structure contains the variable region that
is responsible for binding to antigens, the fragment will successfully bind. Smaller bodies have the advantage of
being more soluble and cell permeable.

101

3.1.3. Radioimmunotherapy
Radioactive ions are becoming an increasingly frequent method of cancer treatment. 28-30
They have been found to be effective diagnostic tools and/or therapeutic treatment for a variety
of cancers such as thyroid, non-Hodgkin’s lymphoma, prostate, and breast.
There are several types of radioactive decay.31-32 Alpha radioactive elements, upon
excitation, releases an -particle consisting of two protons and two neutrons. --emitters release
a high energy electron, while

+-emitters,

also known as positron emission, release a high energy

positively charged particle known as a positron. Gamma emission releases gamma rays, which
have very high energy and frequency and great penetrative power. Finally, while not as common
or widely used, the Auger effect occurs when an electron from an inner-valence shell is emitted
from the cell.32-33 Most clinical radiotherapy uses -, -, -emitters, although there has been
considerations about using Auger elements, which are normally too cytotoxic, as a way to treat
residual cancer cells to prevent resurgence. The isotope yttrium-90 is a common radionuclide in
cancer treatment.11,

34-35

When it decays,

90Y

emits a

--particle

and the daughter ion

90Zr.

Yttrium-90 is especially known for its use in effectively treating HCC via radioembolization (Figure
3.10). 36-38
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Figure 3.10. Diagram of radioimmunotherapy.36

One challenge in synthesizing radioimmunotherapeutics is attaching radionuclides to the
antibody with linkers.32, 37 Streptavidin, polymers, and short chemical linkers are all popular
solutions to this problem with varying rates of success and difficulty. 29, 38-40 Given the success of
the HollEE protein in binding lanthanides selectively, we propose that the protein could be used
as a way to bind 90Y to a selective antibody fragment, 2E10, to deliver the radionuclide for PET
imaging and/or therapeutic purposes.41 2E10 is a glypican-3 specific variable fragment. Glypican3 is expressed in the cell membranes of HCC tumors and inhibiting glypican-3 in these cells can
reduce proliferation of this cell line. Using a scFv of a glypican-3 specific antibody also allows the
advantage of being easier to mutate since it is smaller and being less likely to trigger rejection by
the immune system before it reaches its target.
Using a protein chelator also allows the advantage of production via bacteria or yeast and
allows us to evolve the protein for selectivity or stability using directed evolution rather than
making each individual chelator synthetically. If this is successful, other antibody fragments could
also be combined with HollEE to provide treatment for other types of cancer since many
lanthanides have anticancer properties (Figure 3.11).
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Figure 3.11 Periodic Table highlighting radionuclides of interest for cancer treatment.32

3.2. Isolation of 2E10-HollEE Construct
The 2E10-HollEE fusion protein was prepared, but unfortunately, it could only be isolated
from inclusion bodies. Inclusion bodies occur when a protein is overexpressed and insoluble,
leading to aggregates of the protein.42 These can be difficult to manage and purify. In order to
isolate protein from fusion bodies, the protein must be first denatured in high concentrations of
guanidine chloride and then refolded with urea. Nonetheless, small amounts of 2E10-HollEE was
isolated (~0.3 g) and metal binding was tested using Kemp elimination. Much like the results
described in Chapter 2, Kemp elimination activity only occurred in the presence of yttrium.
Indeed, when activity was compared between calcium and yttrium, there was a clear distinction.
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2E10-HollEE had no activity in the presence of calcium (the negative slope is due to noise) (Figure
3.12).

Figure 3.12. Catalytic efficiency of Kemp elimination using HollEE (0.5 M) in the presence of yttrium (0.08 mM)
and calcium (0.08 mM) in 20 mM MOPS, 100 mM NaCl, pH 7.0. The kcat/KM of 2E10-HollEE was 8.0 M-1s-1 in the
presence of yttrium. (MT7021)

However, it is important to note that comparing 2E10-HollEE and HollEE, there is a
significant decrease in activity (Figure 3.13). While both proteins have absolutely no activity in
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the presence of calcium, 2E10-HollEE has a 10-fold decrease in activity compared to HollEE in the
presence of yttrium. This is possibly due to the antibody portion either blocking the active site or
interfering with the metal binding portion of the protein. Even with decreased activity, the fact
that 2E10-HollEE is capable of binding yttrium is promising, although further improvement will
be needed.
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Figure 3.13. Catalytic efficiency of Kemp elimination using 2E10-HollEE (0.5 M) in the presence of yttrium (0.08
mM) and calcium (0.08 mM) in 20 mM MOPS, 100 mM NaCl, pH 7.0. The kcat/KM of 2E10-HollEE was 8.0 M-1s-1 in
the presence of yttrium and the kcat/KM of HollEE was 101 M-1s-1 in the presence of yttrium. (MT7021)
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The next question that we asked was if 2E10 still bound to HCC cells selectively. However,
when attempts were made to purify the protein for testing, issues came up after cleavage of the
His6-tag with TEV protease (Figure 3.14). It appears that despite the low concentration of protein
used (~2 mg), precipitation occurred after TEV cleavage since the protein band was now absent.

Figure 3.14. 10% acrylamide SDS-PAGE gel of 2E10-HollEE purification: Lane 1) cells before induction, 2) cell
pellet before purification, 3) supernatant after sonication, 4) supernatant before loading onto Ni-NTA column, 5)
Ni-NTA column flow through, 6) Ni-NTA column wash, 7) uncut 2E10-HollEE before TEV cleavage, 8) uncut 2E10HollEE after incubation overnight with TEV, 9) final sample after removing TEV. The calculated mass of 2E10HollEE with His6-tag is 39,725 Da and without His6-tag is 37,260 Da.

3.3. Conclusions
Radioimmunotherapeutics provide a powerful method of delivering radioisotopes to
cancer cells selectively. By attaching our lanthanide-selective protein HollEE to a HCC-specific
antibody fragment, 2E10, we hope to create a new treatment for HCC that is selective, effective,
and evolvable. We have shown that 2E10-HollEE is selective for yttrium. Currently, we are
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working towards isolating enough protein to test 2E10-HollEE’s selectivity towards HCC cells. The
initial results are promising and further work is needed to develop and test the hypothesis. Work
is also being done to determine the binding affinity of 2E10-HollEE to yttrium as well as using
other expression vectors such as yeast or insect cells to express protein.

3.4. Experimental
3.4.1. Expression and Purification of 2E10-HollEE
Plasmid was transformed into Rosetta pLysS cells and grown overnight at 37 C in LB
media. A 100 mL seed culture was grown at 37 C for approximately 8 hours before being used to
inoculate 1 L of Zym-5052 autoinduction media. The culture was grown for 16-18 hours at 30 C
and the cell pellet was collected (approximately 2 g).
Cell pellet was resuspended in lysis buffer containing 25 mM Tris-HCl (used since chloride
ions were determined to be a non-issue for HollEE), 20 mM imidazole, 0.5 mM PMSF, and 500
mM NaCl (pH 8). Cells were lysed by sonication, and then the crude cell lysate was centrifuged at
20,000xg for 30 minutes. The supernatant was decanted and the cell pellet was resuspended in
Wash 2UT buffer (25 mM Tris-HCl, 20 mM imidazole, 500 mM NaCl, 2 M urea, pH 8.0). Urea
resuspension was then sonicated until solids were broken up and then centrifuged at 20,000xg
for 30 minutes. The urea wash was repeated 2-3 times. The inclusion bodies were then washed
with lysis buffer and centrifuged at 20,000xg for 30 minutes. The supernatant was decanted and
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the inclusion body pellet was resuspended in 6G buffer (25 mM Tris-HCl, 20 mM imidazole, 500
mM NaCl, 6 M guanidinium chloride) and allowed to rock gently overnight at room temperature.
The supernatant was centrifuged at 20,000xg for 30 minutes the following morning and
applied to a Ni-NTA column. The Ni-NTA was allowed to stand for at least one hour to ensure
binding occurred. The column was then washed with 6G buffer. To refold the protein, the column
was washed with urea refolding buffer (25 mM Tris-HCl, 20 mM imidazole, 500 mM NaCl, 6 M
urea) and was then washed with decreasing concentrations of urea (6-0 M) in lysis buffer. The
protein was then eluted with buffer containing 25 mM Tris-HCl, 250 mM imidazole, and 500 mM
NaCl (pH 8). The sample was exchanged into buffer containing 20 mM Mops and 100 mM NaCl
(pH 7) by applying it onto a Bio-Rad 10 DG desalting column.
3.4.2. Removal of His6-tag
Sample was incubated with 1.0 mM DTT, 0.5 mM EDTA, and TEV protease at a 10:1
absorbance (280 nm) ratio overnight at 34oC. The cleavage solution was purified using a 0.22 μM
PES sterile filter before incubation.
After incubation, DTT and EDTA were removed by applying sample onto a Bio-Rad 10 DG
desalting column with 50 mM Tris, 75 mM NaCl (pH 8) buffer. Desalted samples were then
applied to Ni-NTA column equilibrated with same buffer and allowed to sit on column for
minimum one hour. Afterwards, protein was collected in flow through and wash and the
presence of protein was determined using UV-Vis spectroscopy.
Sample was briefly incubated with 10-fold molar excess of EDTA and then exchanged into
100 mM bicarbonate buffer (pH 8.5) twice using a Bio-Rad 10 DG desalting column to ensure
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removal of excess calcium ions and EDTA. Bicarbonate buffer was used because a basic
environment is necessary to properly use the fluorescent labels that would be needed for the
next step. The purity of the protein was established by SDS-PAGE using a 10% acrylamide gel with
Unstained Precision Protein Plus ladder (BioRad). Protein concentration was determined using
UV-Vis spectroscopy where the ε280 of cut protein is 62,800 cm-1M-1.
3.4.3. Kinetic assays
Kinetic measurements were done with either a Thermo Lab-systems Multiskan Spectrum
Platereader or a BioTek Eon Micro Platereader monitoring the absorbance at 380 nm at 22 oC
using at least three independent measurements. The final protein concentration (determined by
UV-Vis spectroscopy using ε280= 64,290 M-1 cm-1 for uncut protein) for kinetic measurements was
0.5 μM. Final substrate concentrations ranged from 0.12 to 0.96 mM. Kinetic parameters (kcat/KM)
were obtained by fitting the data to a linear fit using Kaleidagraph 4.5 (Synergy Software).
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Chapter 4 Functional Formate Dehydrogenase Secretion in Pichia
pastoris
4.0. Abstract
Biofuels are an important way to reduce carbon dioxide and other greenhouse emissions.
Unfortunately, current methods of biofuel production require large amounts of land and energy
that can create significant amounts of its own pollution and waste. Self-regenerating systems
using select enzymes have been proposed in the past to convert CO 2 to the biofuel methanol,
which are less costly in terms of space and energy, but are limited by their expression in bacteria
and the following purification. We have successfully expressed and secreted formate
dehydrogenase (FDH), a key enzyme that converts CO 2 to formate, which can subsequently be
converted to methanol, in Pichia pastoris. This provides an important first step in creating a selfsustaining system of organisms capable of producing biofuels with minimal resources.
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4.1. Introduction
4.1.1. Common Methods of Biofuel Production
Biofuels are a diverse class of fuels that are produced from biomasses that contain
photosynthesis-fixed carbons.1 They are an important strategy to keeping CO 2 greenhouse gas
emissions to a minimum, reducing atmospheric greenhouse gas concentrations, and stabilizing
fuel prices. Already both the United States and European Union require fuel for cars to
incorporate a percentage of renewable biofuels to reduce carbon emissions. In the last decade,
many countries have focused on researching new ways to produce and/or refine biofuels. 2-3
Current methods of producing biofuels can be divided into four generations (Figure 4.1).12

First generation biofuels use sugar and oil feedstocks to produce alcohols and alkyl esters. One

prominent example of this is the corn industry in the Midwest. Much of the corn grown by
farmers is currently converted to ethanol and mixed with current fuel reserves. However, this
method of biofuel production comes at a serious cost.4 In order to grow the amount of corn
needed to make a sufficient quantity of ethanol, large amounts of land are required that compete
directly with corn that would normally be used for food.2, 4-5 This poses problems as converting
grasslands into corn fields can incur a carbon debt of up to 93 years just be clearing the land for
use. Using already existing land designated for corn fields, which already has a large portion of
its nutrients depleted, competes directly with food production and would still incur a carbon debt
of almost 50 years.4 This problem is even worse in places like Brazil where healthy rainforests
would have to be cut down in order to produce biofuels.5
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Figure 4.1. Summary of the production methods for the four generations of biofuels. 1

The second generation of biofuels is produced from lignocellulose waste such as wood
and switchgrass.1 Lignocellulose is found in all plants and consists of cellulose, hemicellulose, and
lignin.5 It is available throughout the world and there is little cost for raw materials since waste
products can be used and no land needs to be dedicated to growth. 6 The biomass can be
converted to alcohols, hydrocarbons, and alkyl esters through a variety of means including
fermentation, pyrolysis, and acid or alkaline hydrolysis.1, 6 The downside to lignocellulose as a
biofuel is that the feedstocks require pretreatment so that they are more readily digestible and
can be more easily converted into sugars for enzymatic hydrolysis, minimizes inhibitors to slow
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or stop enzymatic hydrolysis, the ability to recover lignin, and to reduce overall costs. 5 Each
method of processing has distinct disadvantages: pyrolysis releases carbon emissions into the
environment, dissolving the lignin in ammonia can be harmful to the environment if not recycled
properly, chemical treatments results in inhibitors that can lower yields, and using fungi and
bacteria to degrade feedstocks can result in slow rates and low yields. 6
The third generation of biofuels, algae, utilizes single-celled, photosynthetic organisms
that produce lipids, hydrocarbons, and oils that can be converted into biofuels. 7 Algae requires
large amounts of water to live, but it can produce products even in waste water, making it
economically viable.8 It might also be possible to use algae to reduce CO2 in the environment by
dissolving CO2 in the water.9 It is efficient because algae contains RuBisCO (ribulose-biphosphatecarboxylase-oxygenase) which fixates carbon dioxide during photosynthesis. Even a 5-10%
increase of RuBisCO’s fixation activity would greatly reduce the current atmospheric levels of
CO2. However, after two decades, there has still been no progress in making this enzyme more
active. Algae biofuel production is still relatively new, but the main challenge it faces is the
massive amounts of land and water it would take to produce enough algae to sustain even the
United States, as well as the processing required to make the lipids and other products into
useable biofuels.1, 7-9
There is a fourth, yet unrealized generation of biofuels that shows much promise: using
solar energy to convert CO2 to alcohols using enzymes.1, 9 It has been proposed that a sequence
of three enzymes: formate dehydrogenase (FDH), formaldehyde dehydrogenase (FlDH), and
alcohol dehydrogenase (ADH) can be used for this conversion (Scheme 2).9-10
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Scheme 2. Overview of enzymatic conversion of carbon dioxide to methanol.

While partial hydrogenation of carbon dioxide has been accomplished through multiple
pathways including heterogeneous catalysis, electrocatalysis, and photocatalysis, the proposed
enzymatic process is advantageous due to its ability to operate at ambient temperatures and
atmospheric pressure11-12. However, this multi-step reduction of carbon dioxide faces its own
challenges. The synthesis requires low pH and elevated temperature for maximum efficiency,
which can cause the enzymes to degrade in turn.13
We propose that by using Pichia pastoris, a methyllotrophic yeast capable of expressing
and secreting non-native proteins, to produce FDH, FlDH, and ADH. If such a system can be
created, it has the potential to be both economic and renewable14. The yeast will continuously
secrete the protein into media, replacing enzymes as they degrade and extending the lifetime of
the biofuel-producing system. This approach eliminates the time-consuming step of growing,
expressing, and purifying the desired proteins from bacteria.

4.1.2. Secretory pathway of Pichia pastoris
In the early 1970’s, Phillips Petroleum utilized Pichia pastoris (also sometimes known as
Komagataella pastoris) as a method of producing single cell protein (SCP) as an additive for
animal feed.15 By exploiting the ability of P. pastoris to use of methanol as a carbon source Phillips
was able to make SCP in large quantity. Years later, Cregg et al successfully transformed P.
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pastoris into a host for DNA transformations.16 Since that development, this yeast has been
utilized for the industrial production of over twenty different proteins to date, including several
biopharamaceuticals.17-18
P. pastoris has several important characteristics that make it an ideal platform for protein
production.19 One characteristic is the alcohol oxidase I (AOX1) gene that controls the expression
of foreign proteins is activated upon the addition of methanol (Figure 4.2). Another factor is that
P. pastoris prefers respiratory growth that allows it to grow at high cell densities much like other
popular fermenting yeasts such as Saccharomyces cerevisiae. The final major advantage P.
pastoris has over other expression systems is the presence of the -mating factor (Figure 4.2).15
This gene signals for the organism to secrete folded (and sometimes even post-translationally
modified) protein outside the yeast cell into the media where it can be more easily collected.

Figure 4.2. A summary of the mechanisms Pichia pastoris uses in order to express and secrete protein.

There are many ways to insert the desired gene into our eukaryotic factory. 20 One of the
most common ways is to use a vector known as pPic9 (Figure 4.4). This 8 kilobase vector contains
AOX1 which is necessary for methanol induction and the

-factor necessary to secrete the

expressed protein outside into media. It also contains the His4 gene, which codes for histinol
upon recombination into the yeast genome.19 First, one clones the desired gene using any of the
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five restriction enzymes: XhoI, SnaBI, EcoRI, AvrII, and NotI.20 After the gene has been successfully
cloned into the vector, the entire vector is cut with either SalI or StuI, which essentially cuts the
His4 gene in half. The cut vector is then transformed into a strain of yeast known as GS115 (Figure
4.3). This strain is incapable of producing histidine on its own, so when the cut vector recombines
with the yeast genome, it completes the His4 gene and allows the yeast to be self-sufficient in
histidine production. This allows for screening of the gene in transformed yeast cells.

Figure 4.3. a) The pPic9 vector used in yeast transformation; b) Summary of homologous recombination of pPic9
into GS115 genome: the gene of interest is cloned into the pPic9 vector. Upon transformation, the pPic9 vector
will integrate itself into the yeast genome, which contains a mutation that does not allow for the production of
histidine in yeast. Addition of the pPic9 vector into the genome allows for yeast to produce histidine, which
allows for screening of yeast colonies for the desired gene. 20

Once the gene is inserted into the yeast genome, the protein can then be expressed and
secreted by P. pastoris by growing it in a mixture of yeast extract, peptone or tryptone, dextrose,
and 0.5% methanol.20 Protein synthesis occurs in the ribosome of the cell and is then moved to
the endoplasmic reticulum (ER) where glycosylation and other post-translational modifications
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can occur.21 The protein is then transported to the Golgi in vesicles (Figure 4.4). If the protein is
not secreted, it will be released into the cytosol of the cell.

Figure 4.4. Protein synthesis in yeast from the nucleus to the Golgi apparatus (where glycosylation may occur) to
outside the cell.21

Since yeast are eukaryotic cells that are surrounded by cell walls, the Golgi must make
further modifications to the vesicles carrying the protein so that they may leave (Figure 4.5).22
From there, the vesicles are transported to the cell wall, where exocytosis occurs and the protein
is released.
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Figure 4.5. Secretory pathway of yeast.22

4.1.3. Constructing a biofuel producing apparatus
Normally, FDH, FlDH, and ADH require the coupled oxidation of cofactor NADH to NAD +
to catalyze the reaction of CO2 to CH3OH.12, 23-24 Our collaborators at Lehigh University are
creating a method to replace the cofactors with electrons generated photochemically by
quantum dots (QDs) (Figure 4.6).14 The advantage to this method is that QDs can be continuously
regenerated by bacteria and will absorb energy from visible light to create electron-hole pairs
that act as cofactor equivalents.20 The QDs will act as a photocatalyst for splitting water and the
resulting electrons generated by splitting the water will be captured by a reduced graphene oxide
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(rGO) surface.14, 25 The enzymes will be modified to have affinity tags that can bind to the rGO
surface.14

Figure 4.6. Model of QD-protein system.

The overall result of this process yields a self-sustaining system that can use light as an
energy source and requires minimal space (Figure 4.7). The methanol produced by the system
will go in part to signal the secretion of more protein so that it is continually being renewed
without outside interference. Meanwhile, the QD surface will act as a place for protein to attach
as well as providing an electron source to replace NADH.
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Figure 4.7. Summary of self-sustaining QD-protein system.

4.2. Design and Screening pPic9 Vector of FDH Secretion
Formate dehydrogenase is a 42 kDa protein that is normally expressed in Candida biodinii
(Figure 4.8).26 It catalyzes the conversion of formate into carbon dioxide with the cofactor NAD +.
It is commonly used as a means of regenerating the NADH cofactor in various systems. 27
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Figure 4.8. Crystallography structure of formate dehydrogenase (pdb 5DNA).28

The construct consisting of the FDH sequence was successfully integrated into the chosen
plasmids. FDH-N was tagged at the 5’ end with a six histidine coding sequence in the pMCSG49
vector and, likewise, FDH-C was tagged at the 3’ end with a His6 coding sequence in the pET28a
vector. Both expressed upon induction with 0.4 mM IPTG, which was visualized in a well-defined
protein band at ~45 kDa. The protein was successfully isolated after Ni-NTA and Q-sepharose.
The specific activity was dependent upon the placement of the His6-tag, where FDH-N
was more active than FDH-C in the oxidation of NAD+ to NADH as assayed by the subsequent
conversion of formate to carbon dioxide (Figure 4.9).
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Figure 4.9. Catalytic efficiencyof FDH-C and FDH-N proteins (0.5 μM) measuring the conversion of NAD+ (1 mM)
to NADH during the oxidation of sodium formate (160 mM) to carbon dioxide in 100 mM sodium phosphate
buffer, pH 7. The specific activity was calculated to be 0.526 U/mg for FDH-C and 2.77 U/mg for FDH-N.29

Preliminary experiments were also done to test the conversion of CO 2 to formate, the
desired direction of our reaction. Sodium bicarbonate was used as a substitute for carbon dioxide
since it is easier to control the concentration of bicarbonate versus aqueous CO 2 and bicarbonate
anions are dominant at neutral pH where we want our reaction to take place. 30 As expected, the
conversion of bicarbonate to formate was much lower than its preferred direction, however,
some conversion did take place (Figure 4.10).
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Figure 4.10. Catalytic efficiency of conversion of NADH (1.2 mM) to NAD+ by FDH-N (0.75 mM) using sodium
bicarbonate (200 mM) in 100 mM sodium phosphate buffer, pH 7.0. The specific activity of FDH-N for NaHCO3 to
formate conversion is 0.005 U/mg. (MT2051)

4.3. Characterization of Yeast-Secreted Formate Dehydrogenase
4.3.1. Time Elapsed Activity of Secreted Yeast
We cloned both a version of FDH that used an N-terminal His6 (FDH-N) affinity tag instead
of a C-terminal tag (FDH-C) since FDH-N had greater activity than FDH-C when expressed in E.
coli. The proteins were secreted by yeast into media over the course of five days and visualized
by SDS-PAGE (Figure 4.10). After 48 hours, the approximate concentration of protein in media
was 8-10 mg/L. Upon purification of FDH from the BMMY media, there was no evidence of
cleavage or degradation of protein from natural yeast proteases on SDS-PAGE gel (Figure 4.11).11
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Figure 4.11. Continuous secretion of FDH from yeast over 120 hours. Empty pPic9 vector was also cloned into
yeast as a control.29

Proteins were purified from yeast media by Ni-NTA column and their specific activities
were measured in the conversion of formate to carbon dioxide using UV-Vis spectroscopy. To
measure kinetics, the absorbance of NAD+/NADH (340 nm) was measured over a period of time
and the slope is then used to calculate specific activity. Specific activity is used to measure the
amount of catalytically active protein present. One unit of activity (U) is defined as the production
or consumption of 1 mol of NADH per minute. The specific activity of the proteins was measured
at 24, 48, and 120 hours and found to be consistent over time (Figure 4.12).
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Figure 4.12. Catalytic efficiency of FDH-C-y (0.5 μM) measuring the conversion of NAD+ (1.0 mM) to NADH during
the oxidation of sodium formate to carbon dioxide in 100 mM sodium phosphate, pH 7. The specific activity of
FDH at 24 hours is 0.11 U/mg, at 48 hours is 0.13 U/mg, and at 120 hours is 0.10 U/mg. 29

Table 4.1. Summary of specific activities of enzymes for FDH.

Enzyme
Formate → CO2
FDH-N (E. coli)
2.710 U/mg
FDH-N (P. pastoris)
393 U/ g
FDH-C (E. coli)
590 U/ g
FDH-C (P. pastoris)
19 U/ g
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4.3.4. Investigating the Decreased Activity of Secreted Formate Dehydrogenase
When the activities of FDH expressed in bacteria and FDH secreted by media were
compared, there was found to be an almost ten-fold difference in activity as shown in Figure
4.13. This is not an unusual problem in proteins secreted by yeast and can usually be attributed
to either unwanted glycosylation of the protein,20 denaturing proteases in the media,25 or
incomplete cleavage of the -mating factor.31
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Figure 4.13. Catalytic efficiency of FDH-N (0.5 μM) from E. coli and P. pastoris constructs measuring the
conversion of NAD+ (1 mM) to NADH during the oxidation of sodium formate (160 mM) to carbon dioxide in 100
mM sodium phosphate buffer at pH 7. The specific activity of FDH from bacteria is 2.71 U/mg and the specific
activity of FDH from yeast is 0.4 U/mg.29

4.3.4.1. Glycosylation
Mass spectrometry of formate dehydrogenase protein as it is secreted by yeast reveals
that glycosylation, a form of post-translational modification that can be quite common with
secreted proteins, was not occurring with our protein. As Figure 4.14 shows MALDI-TOF mass
spectrometry shows the molecular weight matches that of an unmodified FDH, ca 43 kDa.
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Figure 4.14. MALDI-TOF of secreted FDH C-term. The matrix used was sinapic acid. The molecular weight
matches the weight of the FDH if it were unmodified (43.3 kDa).29

4.3.4.2. Proteases
Another common issue in protein secretion from P. pastoris is undesired and
uncontrolled proteolysis of the product protein.15, 25 This can occur either during transport of the
recombinant protein outside of the cell in vesicles, by proteases in the extracellular space of the
cell wall, or by proteases in the culture medium.15 This can be a very serious issue since not only
does it lower protein yield, but the degradation products can be difficult to separate from the
desired product.
There are several methods of reducing proteolytic activity during yeast secretion. The first
way is to employ PMSF.25 PMSF is commonly used when purifying proteins from bacterial cell
pellets by inhibiting proteases that may be released from the cells during lysis. EDTA is a metal
chelator that can inhibit metalloproteases. Casamino acids, which is a mixture of amino acids and
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small peptides obtained by hydrolyzing casein, can reduce proteolytic activity by competing with
the secreted protein for proteolysis.
When cultures were grown with either no additives (control), PMSF, EDTA, casamino
acids, or all three, there was no change in appearance on the protein gel at 24 and 48 hours
(Figure 4.15). In addition, when the catalytic activity of these proteins was tested, with the
exception of the sample with all three protease inhibitors, there was little difference in activity
between the four (Table 4.2). The combination of the SDS-page and kinetic assay led us to
conclude that proteases played a minor role in the decreased activity of the secreted FDH, if at
all.

Figure 4.15. 10% acrylamide SDS-PAGE gel. Lanes: 1) control 48 hr, 2) PMSF 24hr, 3) PMSF 48 hr, 4) EDTA 24 hr,
5) EDTA 48 hr, 6) casamino acids 24 hr, 7) casamino acids 48 hr, 8) all three 24 hr, 9) all three 48 hr.
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Table 4.2. Comparison of specific activity of secreted FDH in the presence of protease inhibitors.

Specific activity
(U/ g)

Control PMSF

EDTA

Casamino
acids

All three

19

22

25

8

17

4.3.4.3. Incomplete cleavage
With several possibilities for low specifc activity of the secreted FDH discounted, we
looked to other possible implications to why our protein might have reduced activity in
comparison to protein we previously expressed in bacteria. Since previous experiments had
shown that time did not seem to be a factor towards the protein’s efficity, we concluded that the
problem must lie in the secretion method of the protein.
Other non-natural proteins that have secreted by yeast have been reported to
incompletely cleave the α-secretion factor.31 To test whether this was true for our protein, we
used tryptic digestion of our purified FDH to determine if any fragments would correspond to the
α-secretion factor (Figure 4.16).32 The advantage to this approach was that α-secretion factor
would have a very distinct Maldi spectra at 7624 Da compared to the rest of the fragmented
protein, which would be very small in comparison (the list of all fragments is included in the
appendices). Indeed, our hypothesis was proved correct and the Maldi spectrum of the tryptic
digest did prominently show that key peak at 7624 m/z.
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Figure 4.16. MALDI-TOF of FDH C-term digested by trypsin. The peak at 7624 Da corresponds to a digested factor.29

4.3.5. Formaldehyde dehydrogenase and Alcohol dehydrogenase
FlDH (derived from both P. aeruginosa and P. putida) and ADH (from S. cerevisae) were
also cloned into E. coli and their specific activities were determined. The summary of their specific
activities can be found in Table 4.3 below and in the appendix (S.34-S.38).

137

Table 4.3. Summary of specific activities of FlDH proteins and ADH in the conversion of NADH. Kinetic assays can
be found in S.34 to S.38.

Protein

Reaction

Specific activity
(U/mg)

FlDH-aeru

formaldehyde → formate

2.6

FlDH-aeru

formate → formaldehyde

0.026

FlDH-puti

Formaldehyde → formate

3.1

FlDH-puti

formate → formaldehyde

0.0003

ADH

formaldehyde → methanol

84

The same protocol for yeast transformation for FDH was used for FlDH and ADH. FlDH (EC
1.2.1.1) is responsible for the conversion of formate into formaldehyde in Pseudomonas putida.23
This particular protein strain is of special interest because unlike other FlDH subtypes it does not
require the cofactor glutathione (GSH). Finally, ADH (EC 1.1.1.1), also called methanol
dehydrogenase, is found in Saccharomyces cerevisiae and oxidizes methanol into
formaldehyde.24 The colonies on minimal media were screened. Despite growing without
histidine, only two colonies had the actual FlDH gene and no ADH colonies contained the gene
based on Sanger sequencing. The positive FlDH-yeast strains were grown for 120 hours and then
purified using Ni-NTA. No protein was visible on UV-Vis or gel before or after purification (Figure
4.17).
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Figure 4.17. SDS-PAGE (10% acrylamide) of the secretion of FlDH-puti protein cloned into yeast. A band is
expected at ~35 kDa. Lanes 1-6 represent the media secretion of different “positive” hits of FlDH-puti cloned
into yeast. Even though the gene was present in the plasmids, there was no expression.

The cloning of ADH and FlDH into P. pastoris where secretion occurs is an ongoing effort.
It is possible that other strains of yeast would be capable of this process, but they have not been
investigated at this time.17, 33

4.4. Conclusions
In a proof-of-principle study, we cloned the FDH gene from Candida biodinii into the
vector pPic9, which incorporates into the P. pastoris genome via homologous recombination.
With the addition of 0.5% methanol every 24 hours, the yeast cells continuously secrete FDH into
media. The FDH can be separated from the media using a His 6-tag on FDH. Pichia pastoris is
capable of expressing and secreting proteins into media. We found the activity of FDH remained
consistent, but low due to incomplete cleavage of the α-secretion factor, over an extended
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period of time. Nonetheless, this study demonstrates partial proof-of-concept and sets the stage
for future studies for this multi-enzymatic pathway of biofuel production.

4.5. Experimental
4.5.1. Ligation-independent Cloning of FDH-N into pMCSG49
The pMCSG49 expression vector was digested using SspI restriction enzyme in Cutsmart
buffer (New England Biolabs (NEB)). The mixture was incubated at 37oC for 1.5 h. Digested
plasmid was purified using Nucleospin Extract II (Machery-Nagel) low yield plasmid protocol.
Gene of interest and digested plasmid blunt ends were made separately using T4 DNA
Polymerase in 10X T4 DNA Polymerase buffer (NEB) supplemented with 5 mM dithiothreitol
(DTT), 0.05 ng/μL Bovine Serum Albumin (BSA), and 10 mM dGTP (for pMCSG49) or 10 mM dCTP
(for genes of interest). The reactions were incubated at 22oC for 30 min, followed by incubation
at 75oC for 20 min. Digested vector was added to gene insert in a 1:8 ratio (based upon mass)
and incubated at room temperature for 5 min. The reaction was stopped with addition of 1.2 mM
EDTA and incubating the mixture for 5 min. Plasmid was transformed into E. coli XL-10 cells and
purified using EZ-10 Spin Column Plasmid DNA kit (Bio Basic) low plasmid yield protocol. The
sequence was confirmed using Sanger sequencing provided by Genescript.
4.5.2. Cloning of FDH-C into pET-28a
The pET28a vector and gene of interest were both digested using SalI and NcoI restriction
enzymes in Buffer 3.1 (NEB). Digests were purified using Nucleospin Extract II low yield protocol.
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Ligation of pET28a and gene insert was done using T4 DNA ligase manufacturer protocol (NEB)
with a 1:8 vector to insert ratio (based on mass) and incubating for 4 h at room temperature.
Plasmid was transformed into E. coli XL-10 cells and purified using EZ-10 Spin Column Plasmid
DNA kit low plasmid yield protocol. The sequence was confirmed using Sanger sequencing
provided by Genescript.
4.5.3. Protein Expression and Purification
4.5.3.1. FDH in E. coli
The appropriate vectors containing FDH were transformed into E. coli BL21(DE3) cells and
expressed in LB. After cells reached an OD 600 of ~0.6, IPTG was added to a final concentration of
0.4 mM and the temperature was lowered to 30oC. After four hours, the cells were collected by
centrifugation and resuspended in lysis buffer containing 50 mM Hepes and 5% glycerol (pH 7.6).
PMSF was added to a final concentration of 0.5 mM. Cells were lysed by sonication, and then the
crude cell lysate was centrifuged at 20,000xg for 30 min. A 5 mL solution of streptomycin sulfate
diluted in lysis buffer was added to supernatant (on ice) at a final concentration of 1% w/v and
allowed to stir for 15 min. Cells were pelleted by centrifugation at 20,000xg for 30 min. The
supernatant was applied onto a Ni-NTA column and washed with lysis buffer. The protein was
eluted with increasing concentrations of imidazole in 50 mM Hepes, 5% glycerol (pH 7.6) buffer
with concentration ranging from 30-300 mM. Protein fractions were diluted two-fold and applied
onto a Q-sepharose Fast Flow column, then washed with lysis buffer. Protein was eluted with 50
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mM Hepes, 5% glycerol, and 300 mM NaCl (pH 7.6). The presence and purity of the protein was
confirmed using SDS-PAGE.
4.5.3.2. FlDH-aeru, FlDH-puti, and ADH
The same procedure as 4.5.3.1. was used to clone and purify FlDH-aeru, FlDH-puti, and
ADH.
4.5.4. Cloning of FDH Genes into pPic9
The E. coli vectors containing the genes of interest and the empty pPic9 vector were
digested using EcoRI and NotI restriction enzymes in Buffer 3.1 (NEB) at 37oC overnight. Digested
vector was purified using Nucleospin Extract II kit per the manufacturer’s protocol.
The digested pPic9 vector and gene of interest were ligated using a 1:20 vector to gene
ratio (based on mass) with T4 DNA Ligase and T4 ligase buffer. The reaction incubated at room
temperature for four hours. After ligation, transformed into E. coli XL-10 cells. DNA was extracted
from colonies using EZ-10 Spin Column Plasmid DNA kit low plasmid yield protocol and mutated
sequences were confirmed by Genescript using Sanger sequencing technique.
4.5.5. Protein Expression and Purification of FDH in P. pastoris
The pPic9 vector containing the genes of interest was cut using SalI restriction enzyme in
buffer 3.1 (NEB) at 37oC for 2 h. Cut vector was purified using Nucleospin Extract II kit protocol.
The transformation setup is outlined by Invitrogen.20 GS115 yeast cells were grown in YPD
(1% yeast extract, 2% tryptone, and 1% dextrose) at 28.5oC until OD600 reached ~1.5. Culture was
pelleted at 3,000xg. The cell pellet was resuspended in LiAc-DTT buffer (100 mM lithium acetate,
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10 mM dithiothreitol, 600 mM sorbitol, 10 mM Tris pH 7.5) and allowed to incubate at room
temp for 40 minutes. Cells were centrifuged at 3,000xg and pellet was washed twice with 1 M
sorbitol. Cells were resuspended in 1 M sorbitol until the concentration at OD 600 was between
100-200. Approximately 3.5 g of plasmid was mixed with GS115 cells and a 1.5 kV was applied
to the cells using an Eppendorf 2510 electroporator. Cells were plated onto Regeneration
Dextrose Base (RDB-) plates (1 M sorbitol, 2% dextrose, 1.34% Yeast Nitrogen Base (YNB), 4 x 105%

biotin, 0.005% amino acids, 2% agar) according to the protocol set forth by Invitrogen.8 These

plates lack histidine, so only successful recombinations will be able to grow on these plates. To
determine if our sequence was present, colonies that grew on the RDB- plates were suspended
in 20 L of sterile water and analyzed by running PCR. The sample contained 10 L of DNA
template (in the inoculated water), 1.2 L of forward primer (T7 promoter, 100 ng/ml), 1.2 L of
reverse primer (100 ng/mL) and 12 L of GoTaq Polymerase master mix (Promega). PCR was run
using an initial denaturation cycle of 2 min (95 C), 15 cycles 30 seconds denaturation (95 C), 30
seconds annealing (57 C), and 45 seconds extension (72 C) and a final extension cycle of ten
minutes (72 C). Samples that contained the gene displayed a band at approximately 300 bp on a
10% acrylamide gel were deemed positive hits and used to inoculate YPD according to protocol
from Invitrogen.20
Cells were pelleted at 2,000xg and resuspended in buffered methanol-complex medium
(BMMY; 1% yeast extract, 2% tryptone, 100 mM sodium phosphate pH 6.0, 1.34% YNB, 4 x 10-5%
biotin, 0.5% methanol) and allowed to grow from 120 hours at 28.5oC. Every 24 hours, methanol
was added to BMMY to a final concentration of 0.5%.
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To purify secreted protein in BMMY, culture was centrifuged at 5,000xg for 2 min. Ni-NTA
was equilibrated with lysis buffer containing 50 mM Hepes and 5% glycerol (pH 7.6). Ni-NTA was
added to media and rocked on ice for 2 h. Media-resin mixture was washed with lysis buffer.
Protein was eluted with buffer containing 50 mM Hepes, 5% glycerol, and 300 mM imidazole (pH
7.6). Presence and purity of protein was confirmed using UV-Vis spectrophotometry and SDSPAGE.
4.5.6. Kinetic Assays for FDH
4.5.6.1. Conversion of formate to carbon dioxide
All kinetic measurements were done on an Agilent 8453 UV-Vis Spectrophotometer
monitoring absorbance at 340 nm with a background absorbance at 800 nm. Unless specifically
stated, kinetic measurements were recorded every 20 s over a period of 10 min. Enzyme activity
was characterized in a buffer containing 100 mM phosphate (pH 7) with 1.0 mM NAD+ and 160
mM formate. Unless specifically stated, the final concentration of proteins in the enzymatic assay
was 1.0 μM FDH (ε280= 54,445 M-1cm-1). To calculate specific activity, all kinetics measurements
were fit to a linear model and calculated with the following equation: [specific activity =
((slope/6220 M-1)*60s/min*Vf)/mf] where Vf is the final volume of the enzymatic assay and mf is
the mass (in mg) of the final concentration of protein. The molecular weight used to calculate
specific activity was 43,845 g/mol.
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4.5.6.2. Conversion of sodium bicarbonate to formate
All kinetic measurements were done on an Agilent 8453 UV-Vis Spectrophotometer
monitoring absorbance at 340 nm with a background absorbance at 800 nm. Unless specifically
stated, kinetic measurements were recorded every 20 s over a period of 20 min. Enzyme activity
was characterized in a buffer containing 100 mM phosphate (pH 7) with 0.12 mM NADH and 120
mM mM bicarbonate. Unless specifically stated, the final concentration of proteins in the
enzymatic assay was 10.0 μM FDH (ε280= 54,445 M-1cm-1). To calculate specific activity, all kinetics
measurements were fit to a linear model and calculated with the following equation: [specific
activity = ((slope/6220 M-1)*60s/min*Vf)/mf] where Vf is the final volume of the enzymatic assay
and mf is the mass (in mg) of the final concentration of protein. The molecular weight used to
calculate specific activity was 43,845 g/mol.
4.5.7. Kinetic Assays for FlDH-aeru
4.5.7.1. Conversion of formaldehyde to formate
All kinetic measurements were done on an Agilent 8453 UV-Vis Spectrophotometer
monitoring absorbance at 340 nm with a background absorbance at 800 nm. Unless specifically
stated, kinetic measurements were recorded every 10 s over a period of 2.5 min. Enzyme activity
was characterized in a buffer containing 100 mM phosphate (pH 7) with 1.0 mM NADH and 100
mM formaldehyde. Unless specifically stated, the final concentration of proteins in the enzymatic
assay was 0.25 μM FlDH (ε280= 44,544 M-1cm-1). To calculate specific activity, all kinetics
measurements were fit to a linear model and calculated with the following equation: [specific
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activity = ((slope/6220 M-1)*60s/min*Vf)/mf] where Vf is the final volume of the enzymatic assay
and mf is the mass (in mg) of the final concentration of protein. The molecular weight used to
calculate specific activity was 34,755 g/mol.
4.5.7.2. Conversion of formate to formaldehyde
All kinetic measurements were done on an Agilent 8453 UV-Vis Spectrophotometer
monitoring absorbance at 340 nm with a background absorbance at 800 nm. Unless specifically
stated, kinetic measurements were recorded every 10 s over a period of 5 min. Enzyme activity
was characterized in a buffer containing 100 mM phosphate (pH 7) with 0.2 mM NADH and 160
mM formate. Unless specifically stated, the final concentration of proteins in the enzymatic assay
was 1.0 μM FlDH (ε280= 44,544 M-1cm-1). To calculate specific activity, all kinetics measurements
were fit to a linear model and calculated with the following equation: [specific activity =
((slope/6220 M-1)*60s/min*Vf)/mf] where Vf is the final volume of the enzymatic assay and mf is
the mass (in mg) of the final concentration of protein. The molecular weight used to calculate
specific activity was 34,755 g/mol.
4.5.8. Kinetic assays for FlDH-puti
4.5.8.1. Conversion of formaldehyde to formate
All kinetic measurements were done on an Agilent 8453 UV-Vis Spectrophotometer
monitoring absorbance at 340 nm with a background absorbance at 800 nm. Unless specifically
stated, kinetic measurements were recorded every 20 s over a period of 5 min. Enzyme activity
was characterized in a buffer containing 100 mM phosphate (pH 7) with 1.0 mM NADH and 100
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mM formaldehyde. Unless specifically stated, the final concentration of proteins in the enzymatic
assay was 0.1 μM FlDH (ε280= 34,755 M-1cm-1). To calculate specific activity, all kinetics
measurements were fit to a linear model and calculated with the following equation: [specific
activity = ((slope/6220 M-1)*60s/min*Vf)/mf] where Vf is the final volume of the enzymatic assay
and mf is the mass (in mg) of the final concentration of protein. The molecular weight used to
calculate specific activity was 42,328 g/mol.
4.5.8.2. Conversion of formate to formaldehyde
All kinetic measurements were done on an Agilent 8453 UV-Vis Spectrophotometer
monitoring absorbance at 340 nm with a background absorbance at 800 nm. Unless specifically
stated, kinetic measurements were recorded every 20 s over a period of 2 min. Enzyme activity
was characterized in a buffer containing 100 mM phosphate (pH 7) with 0.1 mM NADH and 100
mM formate. Unless specifically stated, the final concentration of proteins in the enzymatic assay
was 12.0 μM FlDH (ε280= 34,755 M-1cm-1). To calculate specific activity, all kinetics measurements
were fit to a linear model and calculated with the following equation: [specific activity =
((slope/6220 M-1)*60s/min*Vf)/mf] where Vf is the final volume of the enzymatic assay and mf is
the mass (in mg) of the final concentration of protein. The molecular weight used to calculate
specific activity was 42,328 g/mol.
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4.5.9. Kinetic assay for ADH
4.5.9.1. Conversion of formaldehyde to methanol
All kinetic measurements were done on an Agilent 8453 UV-Vis Spectrophotometer
monitoring absorbance at 340 nm with a background absorbance at 800 nm. Unless specifically
stated, kinetic measurements were recorded every 10 s over a period of 1.5 min. Enzyme activity
was characterized in a buffer containing 100 mM phosphate (pH 7) with 1.0 mM NADH and 100
mM formaldehyde. Unless specifically stated, the final concentration of proteins in the enzymatic
assay was 16.0 μM ADH (ε280= 50,350 M-1cm-1). To calculate specific activity, all kinetics
measurements were fit to a linear model and calculated with the following equation: [specific
activity = ((slope/6220 M-1)*60s/min*Vf)/mf] where Vf is the final volume of the enzymatic assay
and mf is the mass (in mg) of the final concentration of protein. The molecular weight used to
calculate specific activity was 39,385 g/mol.
4.5.10. Tryptic digestion of FDH
Protein stock (~0.1 g protein), buffer (100 mM Tris, 6 M urea, pH 7.8), and reducing
agent (100 mM Tris, 200 mM DTT, pH 7.8) were combined was combined in a 1:1:0.1 volume
ratio (for a total volume of 105 L) and allowed to sit at room temperature for one hour. To
alkylate cysteines, 20 L of alkylating agent (100 mM Tris, 200 mM iodoacetamide, pH 7.8) was
added and mixture was allowed to sit for 1 h. To remove unreacted iodoacetamide, 20

L

reducing agent was added. The sample was diluted to 775 L using water and 100 L of porcine
trypsin (SAFC, 200 ng/ L, 100 mM Tris, pH 7.8) was added. The mixture was allowed to digest
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overnight at 37 C and was then stopped with the addition of acetic acid until the pH was below
six.
4.5.11. MALDI-TOF of FDH
A Bruker Autoflex III Smartbeam MALDI-TOF mass spectrometer was used to confirm the
molecular weights of proteins and protein fragments. Samples (~10 M concentration) were
mixed with a sinapic acid solution in a 1:2 volume ratio. Ovalbumin (44.3 kDa) was used as an
external standard).
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Chapter 5 NMR Directed Evolution of AlleyCat Series
5.0. Abstract
Directed evolution of proteins is a powerful method for optimizing desired traits, for
example, enzymatic activity. However, the process is often lengthy and requires multiple steps.
Computational analysis of proteins can help to narrow the possible sites for site-selected
mutation; however, even this method is not perfect. We propose to use a method, employing
15N-HSQC

NMR, to identify possible residues in the vicinity of weakly binding analogs of a desired

substrate. In this chapter we test an already known “hot spot” of the AlleyCat series, A128, which
when mutated to threonine increases activity dramatically. We also target a new residue for
mutation V108, as a possible method for creating a new Kemp elimination catalyst from the
calmodulin (Cam) scaffold.

5.1. Introduction
5.1.1. Limitations of directed evolution and rational design
While the computational methods that inform rational design are extremely powerful,
this approach also tends to produce proteins exhibiting only low activity. 1 Often subsequent
mutations, designed without the aid of sophisticated algorithms, are needed to fulfill the true
potential of the engineered protein scaffold. Using, for example, theozyme- and iterative-based
computational design, which calculate the most stable protein conformations based on the
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transition state of the substrate, various “hot spots” can be identified for mutation, limiting the
rounds of mutagenesis needed.2-3 This method assumes that the scaffold, or at least the area
around the active site, will retain its structural integrity after evolution. 4 However, identifying
potential mutations beyond the immediate active site is beyond the scope of computational
program. Therefore, even in the age of computers, being able identify possible mutation sites for
exploration is still very important.
Directed evolution utilizes a three-step process: first creating genetically diverse
“libraries” with random mutagenesis and then identifying possible hits based on desired traits
such as enzymatic activity.5 First, many variations of a gene are created using mutagenic PCR such
as site-directed mutagenesis, random mutagenesis, error-prone PCR, and DNA shuffling (for a
more in depth explanation of these methods, please refer to Chapter 1.2.1).6-9 Using an assay
designed to screen for a desired trait, genes that contain positive hits continue onto the next
stage while unfit variants are eliminated. The positive hit gene is then isolated and subjected to
additional mutagenesis for further optimization.
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Figure 5.1. Summary of the steps of directed evolution.10

The issue with directed evolution is that the overall process is time consuming and
requires vast libraries and a large number of samples.11 There is also an issue with choosing the
right form of mutagenesis. Error-prone PCR is good at introducing mutations into the entire gene,
but due to the degeneracy of codons, this method can show bias towards some amino acids
substantially reducing the number of variants. DNA shuffling requires that the different
sequences have a high amount of homology between them, and DNA fragmentation is
nonrandom for certain DNase enzymes.12 Finally, site-directed mutagenesis can be a powerful
tool but requires one to know the precise placement of the mutation needed.
Identifying new methods that take into account the dynamic changes in protein structures
is key to optimizing directed evolution. NMR is an important structural technique in chemistry
that allows for the identification of organic compounds, inorganic complexes, and proteins.13
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Certain nuclei have a property called spin such that when placed in a magnetic field, these nuclei
give rise to spin energy levels. NMR excites nuclei within the compound with a specific radio
frequency and then the energy that is released when the nuclei falls back down in energy is
measured. Depending on the nature of the nuclei and its local environment (i.e. neighboring
atoms, hydrogen bonds, etc.) and the local magnetic field they contribute, the excited state will
fall back to ground state releasing a photon of a specific frequency (i.e., energy). The frequencies
are translated into chemical shifts, which are indicative of the electronic environment of the
nucleus.
There are multiple types of NMR that can be used learn about a compound.13 The most
common is 1H NMR, which can give information such as the number of protons attached to the
same atom and the number of neighboring hydrogens on adjacent carbons. Other nuclei that are
able to be measured using this method include 13C, 15N, 19F, and 31P. Measuring the spin of these
isotopes gives information about the type of functional groups present and their placement.
Small proteins are often measured using 1H, 13C, and 15N to determine structure.14-15 By
studying the correlations between two different types of spectra, a lot of insight is gained based
on how different isotopes interact with each other. One of the most popular methods is 1H-15N
HSQC, which allows for the measurement of the peptide bonds in proteins and tells us how amide
protons interact with one another in the back bone and side chains.
HSQC takes measurements of positions and energies of proteins in their average current
state and if one were to take a HSQC of a protein when it is bound to the substrate (or a substrate
analog), and then take another HSQC of the protein without anything bound to it, the resulting
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difference in chemical shifts between the two structures can provide clues to which residues are
involved with substrate binding and activation. This could be potentially useful for identifying
residues outside the active site that computational analysis often can’t interpret. The hypothesis
is that residues with larger chemical shifts between bound and unbound states could be
appropriate places to begin directed evolution of the protein.
5.1.2. “Hot” and “Cold” Spots of AlleyCat
Previously, Korendovych lab has successfully carried out several projects on the re-design
of Cam into an allosterically regulated catalyst for Kemp elimination.14, 16-17 Since the initial
mutation, this new catalyst (named AlleyCat) has undergone seven rounds of mutation using
various methods of directed evolution to Kemp elimination optimize activity. We characterized
all rounds of AlleyCat extensively using 15N-1H HSQC NMR with and without a substrate analog
bound. Since the substrate of Kemp elimination, 5-nitro-1,2-benzisoxasole, would rapidly
undergo catalyzed elimination, we used a similar structure, 6-nitro-1H-benzotriazole, as an
inhibitor that would bind to the same active site but not react (Figure 5.2).

Figure 5.2. Structures of 5-nitro-1,2-benzisoxazole (left) and Kemp elimination antagonist 6-nitro-1Hbenzotriazole (right), which is used during NMR titrations to determine the chemical shifts of residues in the
AlleyCat series.
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We take a HSQC of AlleyCat7 without any substrate added in 20 mM Hepes, 100 mM NaCl,
pH 7.0 followed by adding two equivalents of 6-nitro-1H-benzotriazole and taking another HSQC.
We observed differences in the N-H chemical shifts of each amino acid during the inhibitor
titration and found that certain locations on the protein were ‘hot spots’, that is, residues that
exhibit particularly drastic chemical shifts changes with and without the inhibitor, which can be
calculated using Equation 5.1. The shift perturbation data are summarized in Figure 5.3. As seen
in the graph, one residue (i.e., A128) was found to be an especially ‘hot spot’ in comparison to
other amino acids in the sequence.

Equation 5.1. Equation used to determine the change in chemical shift between analog bound and nonbound
AlleyCat7 when determining hot and cold spots.
(𝒅𝑵) 𝟐
𝟐
√(𝒅𝑯) + ( 𝟓 )
∆𝒄𝒉𝒆𝒎𝒊𝒄𝒂𝒍 𝒔𝒉𝒊𝒇𝒕 𝒐𝒇 𝒓𝒆𝒔𝒊𝒅𝒖𝒆 =
𝟐

𝑤here 𝑑𝐻 = 1𝐻 𝑠ℎ𝑖𝑓𝑡 𝑜𝑓 𝑎𝑛𝑎𝑙𝑜𝑔 𝑏𝑜𝑢𝑛𝑑 𝑟𝑒𝑠𝑖𝑑𝑢𝑒 − 1𝐻 𝑠ℎ𝑖𝑓𝑡 𝑜𝑓 𝑛𝑜𝑛𝑏𝑜𝑢𝑛𝑑 𝑟𝑒𝑠𝑖𝑑𝑢𝑒
and 𝑑𝑁 =

15

𝑁 𝑠ℎ𝑖𝑓𝑡 𝑜𝑓 𝑎𝑛𝑎𝑙𝑜𝑔 𝑏𝑜𝑢𝑛𝑑 𝑟𝑒𝑠𝑖𝑑𝑢𝑒 =

15

𝑁 𝑠ℎ𝑖𝑓𝑡 𝑜𝑓 𝑛𝑜𝑛𝑏𝑜𝑢𝑛𝑑 𝑟𝑒𝑠𝑖𝑑𝑢𝑒
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Chemical Shift

Residue position
Figure 5.3. 15N-1H HSQC shift data for all residues in AlleyCat7. NMR data was collected and analyzed by I.
Korendovych and O. Makhlynets.

5.2. Analysis of the importance of A128T mutation in AlleyCat
To determine whether NMR ‘hot spots’ is a viable method for identifying residues for
mutation, the Kemp elimination activities for the AlleyCat series of proteins were compared
before and after the mutation of A128. It was the fifth round of mutation in the AlleyCat series
that introduced the A128T mutation resulting in an almost a two-fold increase in activity over its
predecessor, AlleyCat4. In principle, introducing that same mutation to previous generation in
the AlleyCat series should demonstrate a similar jump in activity. Conversely, removing the
mutation from a later generation, that is, AlleyCat6 and AlleyCat7, should show a significant
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decrease in activity. These specific mutants were prepared, purified, and characterized in the
Kemp elimination assay to determine the kinetic activity of each protein. The kinetic data are
shown in Figure 5.4.

Figure 5.4. Catalytic efficiency of Kemp elimination catalyzed by the AlleyCat series with and without the A128T
mutation (0.2 μM) in 20 mM Hepes buffer, pH 7.0 with 100 mM NaCl and 10 mM of CaCl2. The values for kcat/KM
are listed in Table 5.1. Ac5 is the equivalent of Ac4T. (MT4100)

Figure 5.5 shows the Michaelis-Menten graph of Kemp elimination catalyzed by AlleyCat0
with and without the A128T mutation. It is remarkable the even introducing this mutation to
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AlleyCat0, which only has the initial F92E mutation present and exhibits only a low Kemp
elimination activity, shows a significant increase after the A128T mutation.

Figure 5.5. Catalytic efficiency of Kemp elimination catalyzed by AlleyCat0 with and without the A128T mutation
(20 μM) in 20 mM Hepes buffer, pH 7.0 with 100 mM NaCl and 10 mM of CaCl2. The values for kcat/KM are listed
in Table 5.1. (MT4128)

Table 5.1 summarizes the Kemp elimination kinetic data of AlleyCat mutants with and
without Thr in 128 position. The Michaelis-Menten kinetics of the Kemp elimination catalyzed by
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each of these proteins fits our expectation based on the ‘hot spots’ hypothesis. Introducing the
A128T mutation to Ac0 and Ac3 gives the mutants (Ac0T and Ac3T) that exhibit increased catalytic
activity. Conversely, removing the mutation from Ac6 and Ac7 gives a mutant protein (Ac6A and
Ac7A) that shows a significant decrease in catalytic activity.

Table 5.1. Summarized data of AlleyCat mutants with and without T in 128 position. Ac0 and Ac0T were at a
concentration of 20 M; Ac6, Ac6A, Ac7, and Ac7A were at a concentration of 0.2 M; all other proteins were at
a concentration of 4.0 M.

Protein kcat/KM (M-1s-1) Protein kcat/KM (M-1s-1)
Ac0

1.42

Ac0T

6

Ac1

33 + 11

Ac1T

30 + 12

Ac2

84 + 21

Ac2T

91 + 30

Ac3

133 + 59

Ac3T

251 + 61

Ac4

190 + 60

Ac5

387 + 106

Ac6

512 + 107

Ac6A

190 + 103

Ac7

786 + 97

Ac7A

390 + 124

5.3. Analysis of V108 position as a site for Kemp elimination catalysis
The A128T mutation test, a mutation that been previously done in the AlleyCat series and
was also indicated by changes in NMR shift upon inhibitor binding, gives some confidence in using
the method. We therefore moved on to exploring mutations at other residues that had not been
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previously mutated in AlleyCat series for which the NMR titration method data obtained for Cam
and the Ac0 protein indicated a ‘hot spot’.6,7 Figure 5.6 shows the relative ‘hot spots’ of
calmodulin by examining the NMR chemical shifts of 15N HSQC with and without the 5-nitro-1Hbenzotriazole. Two residues stand out as having particularly large chemical shift values between
the bound and non-bound protein: F92 and V108. In the AlleyCat series, F92E is the mutation
responsible for the subsequent Kemp elimination. It stands to reason that V108 might also be
relevant for mutation since it shares similar chemical shift perturbations and is in a similar
position.

Figure 5.6. A diagram of the relative “hot” spots of calmodulin as determined by NMR titration. Red, orange, and
yellow colors signify “hot spots” with high chemical shift perturbations and cyan and blue colors signify “cold
spots” with small chemical shift perturbations (pdb 1cll).18

We mutated V108 to glutamate in wild-type Cam and Ac0 to determine if the mutations
would allow for catalysis much like F92E had. We reasoned that glutamate was the original
mutation in AlleyCat that gave it catalytic activity and that due to the hydrophobic nature of the
164

active site pocket, it would work well for the Kemp elimination reaction. The V108E mutation
actually decreased the Kemp elimination activity of the Ac0-V108E mutant relative to Ac0 (Figure
5.7, 5.8, and Table 5.2) and of the Ac1-V108E mutant relative to Cam (Figure 5.8). While this
position is unsuitable for creating a new catalyst, this valine seems to play a minor role in the
stability of the transition state during catalysis. While the failure of V108E mutation does not
discount our hypothesis completely, it does show that care must be taken when using this NMRdirected evolution and that it would work best in conjunction with other techniques.
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Figure 5.7. Catalytic efficiency of Kemp elimination catalyzed AlleyCat0 (20 μM) with and without the V108E
mutation in 20 mM Hepes buffer pH 7.0 with 100 mM NaCl and 10 mM of CaCl2. The values for kcat/KM are listed
in Table 5.2. (MT5051)
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Figure 5.8. Catalytic efficiency of Kemp elimination catalyzed wild-type Cam (20 μM) with and without the V108E
mutation in 20 mM Hepes buffer, pH 7.0 with 100 mM NaCl and 10 mM of CaCl2. The values for kcat/KM are listed
in Table 5.2. (MT5142)
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Table 5.2. Summarized data of V108E mutants with and without Glu in 108 position. All proteins were at 20 μM
concentration.

Protein

Mutations

kcat/KM (M-1s-1)

Wild-type Cam none

0.22

V108E

V108E

0.13

AlleyCat0

F92E

1.42

Ac0 V108E

F92E V108E 0.76

5.4. Conclusions
AlleyCat is a small protein that has been well characterized by NMR in the presence and
absence of substrate and inhibitors. The presence of inhibitor leads to perturbations in the
chemical shift that could be indicative of possible spots for mutagenesis, especially for residues
outside the active site. To test this theory, we focused on the residue exhibiting the largest
chemical shift change upon binding inhibitor (i.e., A128) and mutated it into Thr and back to Ala
in all generations of AlleyCat. The presence of Thr increased the Kemp elimination activity of the
Ac0T and Ac3T mutants approximately two-fold. However, when this technique was applied to
another identified position, V108E, the protein had no Kemp elimination activity. This project is
currently being continued in lab and promising results have been found using another ‘hot spot’
that has been identified. This new protein is almost twice as active and leads further credence to
our hypothesis. The next step is to examine another protein, the computationally designed Kemp
eliminase Baker’s KE07,19 and use our method to attempt to increase its catalytic activity.
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5.5. Experimental
5.5.1. Site-Directed Mutagenesis
The appropriate mutations were made using a standard mutagenesis protocol for pfu
high-Fidelity DNA Polymerase, which was provided by the manufacturer (NEB). After PCR, the
template was digested with DpnI restriction enzyme (NEB) and transformed into E. coli XL-10
cells. DNA was extracted from colonies using EZ-10 Spin Column Plasmid DNA kit and mutated
sequences were confirmed by Genescript using Sanger sequencing technique.
5.5.2. Purification of AlleyCat series
The pEXP5-NT vectors containing the genes of interest were transformed into E. coli
BL21(DE3) pLysS cells and expressed using LB broth. After cells reached an OD 600 of ~0.5, IPTG
was added to a final concentration of 0.5 mM and the temperature was lowered to 30oC. After
four hours, the cells were collected by centrifugation and stored at -80oC until needed.
Cell pellet was resuspended in lysis buffer containing 25 mM Hepes, 20 mM imidazole,
0.5 mM PMSF, 10 mM CaCl2, and 300 mM NaCl (pH 8). Cells were lysed by sonication, and then
the crude cell lysate was centrifuged at 20,000xg for 1 h. The supernatant was applied to a NiNTA column and washed with lysis buffer (without PMSF). The protein was then eluted with
buffer containing 25 mM Hepes, 250 mM imidazole, 10 mM CaCl2, and 300 mM NaCl (pH 8). The
sample was exchanged into buffer containing 25 mM Hepes, 10 mM CaCl 2, 100 mM NaCl (pH 7)
by applying it onto a Bio-Rad 10 DG desalting column.
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The purity of the protein was established by SDS-PAGE using a 15% acrylamide gel with
Unstained Precision Protein Plus ladder (BioRad). Protein concentration was determined using
UV-Vis spectroscopy where ε280= 5445 cm-1M-1.
5.5.3. Kinetics for Kemp elimination reaction
Kinetic measurements were done with either a Thermo Lab-systems Multiskan Spectrum
Platereader or a BioTek Eon Micro Platereader monitoring the absorbance at 380 nm at 22oC
using at least three independent measurements. The final protein concentration (determined by
UV-Vis spectroscopy using ε280= 5445 M-1 cm-1) for kinetic measurements was 0.25 μM. Final
substrate concentrations ranged from 0.12 to 0.96 mM. Kinetic parameters (kcat and KM) were
obtained by fitting the data to the Michaelis-Menten equation: [v0 = kcat[E]0[S]0/(KM + [S]0)] using
Kaleidagraph 4.5 (Synergy Software) and dividing the calculated kcat and KM values, or by fitting
the data to a linear slope to find the kcat/KM.
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M. Dolan performed GC analysis.

Chapter 6 Asymmetric Hydrogenation of Ketones Using Catalytic
Ruthenium- and Iridium-Peptide Aggregates
6.0. Abstract
Chiral catalysts are one of the most powerful tools at a synthetic organic chemist’s
disposal. They can impart the ability not only to speed reactions, but also impart
enantioselectivity onto products while being present in less than stoichiometric quantity as the
reagent. Despite these marked advantages, chiral catalysts also have several distinct
disadvantages. Organometallic catalysts in particular are a problem, because while they work
very effectively, they are also expensive, and their synthesis can be time consuming. However,
chiral amino acids are abundant, very cheap, easy to use, and share many characteristics with
other popular organic ligands. Furthermore, short peptides, for example the phenylalanine
dimer, aggregate in solution. Aggregation imparts structure and with a chiral peptide, it imparts
a chiral environment for catalysis. We propose a new catalyst system which uses a tripeptide as
a ligand. The first amino acid, 2,3-diaminopropionic acid, will complex transition metals such as
Ru2+ and Ir3+ that are often used as chiral catalysts. The two phenylalanine subunits will branch
off the C-terminal of the amino acid-ligand and impart aggregating properties onto the new
catalyst. In addition to creating a chiral environment for catalysis, the design will enable the
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catalyst to work in water and allow for easy separation using ultracentrifugation or by binding
the catalyst to other surfaces.

6.1. Introduction
6.1.1. Organometallic Catalysts
Catalysts are one of the most important tools in both nature (in the form of enzymes) and
in the laboratory. Like enzyme catalysts discussed in Chapter 1, chiral chemical catalysts in the
laboratory are able to lower the activation energy of reactions that would normally be difficult
to overcome and impart enantioselectivity onto reactions and products. Coordinated
organometallic catalysts use a large selection of metal ions, ligands, and substrates to achieve a
wide variety of different reactions, making them one of the most important tools at a synthetic
chemist’s disposal.
Most current available catalysts have distinct disadvantages. The catalyst and their
precursors can cost a significant amount of money and be difficult to use in scale up.
Furthermore, the ligands, which are responsible for reactivity and selectivity, can be difficult and
time consuming to make. While catalysts are in principle reusable and can be recollected from
reactions after use, this step can be time consuming and impractical in industrial settings at large
scale. Therefore, creating a catalyst that is both cheap to make and easily collectible is
advantageous for a variety of reasons. While expensive metals are necessary, ligands can impart
these properties unto a catalyst.
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6.1.2. Chiral Ligands
The ability to synthesize R- or S-chiral compounds selectively is one of the biggest
problems facing synthetic chemists today. To solve this problem, many chemists use metal
catalysts attached to specialized ligands, known as privileged ligands (Figure 6.1). 1-2 In general,
most privileged ligands possess rigid structures and contain multiple oxygen, nitrogen, and
phosphorous functional groups that allow them to coordinate with metal ions.
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Figure 6.1. Examples of privileged ligands.3
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Amino acid derived ligands are a popular alternative to complex ligands.4 Amino acids are
well known for their ability to coordinate to metals already (i.e. metalloproteins) and contain
carboxyl and amino groups like most privileged ligands do. Furthermore, amino acids are also
naturally chiral, readily available, and rather cheap.
6.1.3. Phenylalanine Aggregation
Phenylalanine chains are well documented for their tendency to form amyloid structures
in nature.5 With as little as two phenylalanine subunits, amyloids are formed between the
aromatic amino acids to create complex amyloid structures (Figure 6.2).6-8

Figure 6.2. TEM image of phenylalanine fibrils.5

By using small peptide chains as ligands, we are proposing a system of chiral ligands that
will not only be cheaper and easier to make than most popularly used ligands but will also solve
the problem of catalyst recovery. Amino acids, for example threonine, lysine, and serine, share
many of the functional groups that more complex ligands have. Therefore, amino acids should
be able to act as suitable replacements for many of the commonly used ligands.4, 9 While one end
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of the peptide complexes with the metal ion to form the catalytic portion of the small molecule,
the phenylalanines (Phe, F) will be attached at the other end of the peptides. Therefore, by
attaching the diphenylalanine chain to the peptide (Figure 6.3), the catalyst will be able to
aggregate and could be filtered out of solution once the reaction of interest complete.

Figure 6.3. Example of new ligand design. X represents variable amino acid side chain.

6.1.4. Noyori catalysts
Ryōji Noyori won the Nobel Prize in Chemistry in 2001 for the development of an
asymmetric hydrogenation catalyst that utilized Ru2+ and Ir3+ chiral centers.9-11 The catalyst can
carry out selective asymmetric hydrogenation and reductions of ketones, aldehydes, and
imines.10,

12-13

The catalysts contain a Ru2+ or Ir3+ chiral center with a N-tosylated

diphenylethylenediamine (pTsDPEN) at two of the metal ion’s coordination sites (Figure 6.4). The
pTsDPEN ligand can have either have the R,R-stereochemistry or the S,S-stereochemistry, which
imparts enantioselectivity unto the final product of the reaction. One of the benefits from this
catalyst, aside from the high percent enantiomeric excess of the products, is its ability to catalyze
reactions in water. It can be considered a ‘green catalyst.’14-15 The similarity of the pTsDPEN
functional groups to those found in amino acids, as well as the capability for this reaction to be
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run in water, makes the Noyori ruthenium catalysts an ideal starting point for testing our design
hypothesis.

Figure 6.4. Examples of common Noyori catalysts with ruthenium and iridium metal centers.

While peptide-metal complexes have been explored as catalyst systems in the past, our
method targets not only reactivity, but practicality.9 When applied, our catalytic constructs will
solve a major problem in organic synthesis in preventing waste and the time-consuming step of
recollecting and recycling catalysts. In the future, we aim for a catalyst that can simply be
collected by centrifugation of a reaction mixture. In principle, the peptide catalysts can be bound
to a membrane or filter and a substrate can simply be ‘pushed through’. 16 Such a dream process
would eliminate the need for extractions and provide a catalytic system that is easy to clean and
reuse. We hope that our system can be applied effectively not only to the Noyori catalysts, but
other common catalysts as well.
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6.2. Design of Tripeptide Ruthenium Catalysts
6.2.1. NMR
We chose 2,3-diaminopropionic acid (Dap) as a base amino acid from which to build upon
our ligand. Dap (Figure 6.5.a) is an “unnatural amino acid” that is not found in normal genetic
code but instead found in secondary metabolites such as zwittermicin A and
tuberactinomycin34,35. It is commercially available and structurally similar to ethylenediamine,
which is a backbone for TsDPEN. To create our ligand, we purchased Dap with a Boc-protecting
group on the main chain, added a Tosyl group to the side chain amine, and then removed the
Boc-protecting group to form L-Dap(Ts)-OH (Figure 6.5.b). The ligand was dissolved in water and
coupled with 0.4 equivalence of either [RuCl2(p-cymene)]2 or [Cp*IrCl2]2 to form two new metal
complexes (Figure 6.5.c).

a)

b)

c)

Figure 6.5. a) Structure of L-2,3-diaminopropionic acid. b) Synthesis of L-Dap(Ts)-OH from L-(Boc)Dap-OH.
c)Proposed structure of Ru2+ and Ir3+ after coupling with L-Dap(Ts)-OH
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Figure 6.6. Mechanism of acetophenone hydrogenation and subsequent catalyst regeneration using sodium
formate as a proton source. Iridium can be used in replace of ruthenium.

Acetophenone and sodium formate were then added to the in situ generated catalysts
and stirred for one hour at 40oC (Figure 6.6). Afterwards, the reaction was quickly worked up and
the reduction of acetophenone to 1-phenylethanol was determined by H1 NMR. In addition to
multiplets in the aromatic region, acetophenone has an observable singlet at 2.58 ppm, while 1phenylethanol has a quartet at 4.88 ppm and a doublet at 1.48 ppm (Figure 6.7).
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Figure 6.7. Identifying 1H NMR chemical shifts of acetophenone (left) and 1-phenylethanol (right).

This latter resonances were used to determine the extent to which reaction occurred. 33 To
get an estimate to the percent reduction that took place, we compare the integrated area of the
peak due to the methyl group in the phenethyl alcohol (a doublet at 1.48 ppm) to the total
integrated area for peaks due to CH3 groups in the acetophenone (a singlet at 2.58 ppm) and
phenethyl alcohol times 100. The quartet at 4.88 ppm was set to an integrated area of 1.0
hydrogen to confirm a 3:1 ratio of areas due to the methyl group doublet and methine proton
quartet as required for the phenethyl alcohol product. While this does not give a true quantitative
yield, the use of an internal standard is necessary for that, it gives an good estimate whether our
catalyst is capable of reducing acetophenone. As a control, the metal precursors were coupled
with pTsDPEN and the reaction with acetophenone carried out under the same conditions. The
NMR spectral data are shown in Figures 6.8-6.11. We find the following results:
•

Ru2+ coupled with (R,R)-pTsDPEN: 28% conversion of acetophenone to 1-phenylethanol

•

Ru2+ coupled with L-Dap(Ts)-OH: no conversion of acetophenone to 1-phenylethanol

•

Ir3+ coupled with (R,R)-pTsDPEN: 37% conversion of acetophenone to 1-phenylethanol

•

Ir3+ coupled with L-Dap(Ts)-OH: 5% conversion of acetophenone to 1-phenylethanol.

While the yield is low, 1H NMR shows that iridium coupled with L-Dap(Ts)-OH will catalyze the
reduction of acetophenone (Figure 6.8-6.11).
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A)

B)

Figure 6.8. A) Synthesis of 1-phenylethanol from acetophenone using Ru 2+ coupled with (R,R)-pTsDPEN. B) 1H
NMR spectrum of acetophenone reduction after one hour (the aromatic region is not shown). There was a 28%
conversion of acetophenone to 1-phenylethanol.
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A)

B)

Figure 6.9. A) Synthesis of 1-phenylethanol from acetophenone using Ru 2+ coupled with L-Dap(Ts)-OH. B) 1H
NMR spectrum of acetophenone reduction after one hour. There was no conversion of acetophenone to 1phenylethanol.
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A)

B)

Figure 6.10. A) Synthesis of 1-phenylethanol from acetophenone using Ir3+ coupled with (R,R)-pTsDPEN. B) 1H
NMR spectrum of acetophenone reduction after one hour (the aromatic region is not shown). There was a 37%
conversion of acetophenone to 1-phenylethanol.
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A)

B)

Figure 6.11. A) Synthesis of 1-phenylethanol from acetophenone using Ir3+ coupled with L-Dap(Ts)-OH. B) 1H
NMR spectrum of acetophenone reduction after one hour (the aromatic region is not shown). There was a 5%
conversion of acetophenone to 1-phenylethanol.
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6.3. Design of Tripeptide Iridium Catalysts
With the success of L-Dap(Ts)-OH in catalyzing the hydrogenation of acetophenone, the
next step was to attach an amino acid that can coordinate to iridium and attach two
phenylalanine residues to the C-terminal end of the peptide. We chose to use L-allo-threonine,
which has the S,S-configuration and should theoretically impart enantioselectivity on any
products. When analyzed by atomic force microscopy, there was evidence of fibril formation
(Figure 6.11). With optimized reaction conditions, catalyst using L-allo-TFF as a ligand gave a yield
of 85%. However, the product was only 5% ee making this an unsuitable catalyst for our needs.

Figure 6.11. Atomic force microscopy image of L-allo-TFF peptide. Image was taken by Z. Lengyel.
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6.4. Conclusions
We proposed a new catalyst system which uses a tripeptide as a ligand. The first amino
acid, 2,3-diaminopropionic acid, will complex typical transition metals such as Ru 2+ and Ir3+ that
are often used in chiral catalysts. The two phenylalanine subunits branch off the C-terminal of
the amino acid-ligand and impart aggregating properties onto the new catalyst. In addition to
creating a chiral environment for catalysis, the design will enable easy separation using
ultracentrifugation or by binding the catalyst to other surfaces. In preliminary studies, iridium
coupled with L-Dap(Ts)-OH catalyzed the reduction of acetophenone in water. When analyzed by
atomic force microscopy, there was evidence of fibril formation by the L-allo-TFF iridium
complex. Under optimized reaction conditions, L-allo-TFF gave a yield of 85% for the reduction
of acetophenone, however, the product was formed in only 5% ee. Further studies were
continued by M. Dolan in the Korendovych lab.

6.5. Experimental
6.5.1. Solid-phase peptide synthesis
Peptides were synthesized manually using FMOC (fluorenylmethyloxycarbonyl)
protection and rink amide resin was used for solid support.17 The resin was first swelled in DMF
(dimethylformamide) for at least 30 minutes and then was deprotected using 5% piperazine in
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DMF for 5 minutes at 65 C. Amino acids were coupled to the resin using an AA:HCTU:DIEA:Resin
(2:1.8:4:1) volume ratio in DMF for 4 minutes at 65 C. The resin was washed 4 times with DMF
for 30 seconds between deprotection and coupling steps. After the final residue was coupled to
the resin, the amino acid was deprotected. Cleavage of peptides and side chain deprotection
were achieved my treating the resin with a solution of TFA (trifluoroacetic acid), water, and TIS
(triisopropyl silane) in a 95:2.5:2.5 v/v ratio for two hours at room temperature. The resin was
filtered off with a glass wool plug. TFA was removed from the peptide by bubbling N 2 into the
solution until it was dried. Crude peptide was stored at -20 C.
6.5.2. Preparation of L-Dap(Ts)OH
L-(Boc)Dap-OH (2.45 mmol) was first dissolved in 15 mL of 1:5 1,4-dioxane:hexane
solvent. Sodium carbonate (12.25 mmol) was added to solution18. The reaction was cooled to 0oC
and TsCl (6.1 mmol) dissolved in 1,4-dioxane was slowly added to the reaction. The reaction
mixture was allowed to warm to room temperature and stir overnight. The reaction was worked
up by decreasing the pH of the reaction until it becomes cloudy (pH ~3), then extracted with ethyl
acetate 3 times. The organic fractions were combined and washed with brine and water, then
dried using Na2SO4. The product had a 92% yield and was a yellow oil.
To cleave the Boc protecting group, the compound was stirred in a mixture of
TFA/TIS/water (95:2.5:2.5, vol/vol) for two hours.19 The compound was precipitated with N2 flow
until all TFA was removed and compound was yellow oil. The compound had a yield of 99% after
Boc removal (91% overall yield).
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6.5.3. Preparation of L-allo-Thr(Ts)-OH
Protocol was designed based on Roemmele et. al.20 Amino acid L-allo-Thr-OH was
dissolved in 5 mL of water. Sodium carbonate was added at 2.25 equivalents and stirred until it
was dissolved. Meanwhile, 1.1 equivalents of TsCl (p-toluenesulfonyl chloride) was dissolved in
2.5 mL of 1,4-dioxane. TsCl solution was added to L-allo-Thr-OH solution dropwise and then
allowed to stir overnight at room temperature.
To isolate the compound, 20 mL of water was added to the mixture. The mixture was
extracted twice with MTBE (methyl tert-butyl ether). The aqueous layer was acidified to pH ~1
using phosphoric acid. Solid crystals were isolated by allowing the mixture to cool and
recrystallize, then isolating the crystals via vacuum filtration.
6.5.4. Hydrogenation of acetophenone
Protocol was designed based on Wu et. al.21 A suspension of either [RuCl2(p-cymene)]2
(0.005 mmol) or [IrCl2Cp*]2 (0.005 mmol) and either (R,R)-TsDPEN (0.012 mmol) or L-Dap(Ts)-OH
(0.012 mmol) in 2 mL H2O was degassed three times using the freeze-pump-thaw method and
then stirred in the shaker at 40oC. After one hour, NaHCO2 (5.0 mmol) and acetophenone (1.0
mmol) were added and solution was degassed again. Reaction mixture was then shaken at 40oC
for another hour. Organic compounds were extracted three times using diethyl ether (3 mL),
concentrated, and analyzed by H1 NMR in CDCl3. As these were preliminary experiments to
determine if our peptides were plausible catalysts, no internal standard was used (future
experiments by M. Dolan did use internal standard to obtain yields).
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6.5.4. NMR
All samples were run on a 400 MHz Bruker NMR in acetone-d6. To estimate yield, the
quartet at 4.88 ppm was equilibrate to an area of 1.0. To determine the estimated conversion,
the area of the doublet at 1.48 ppm was divided by the total area of the singlet (2.58 ppm) and
the doublet (1.48 ppm).
6.5.5. Gas Chromatography
All experiments were done using Nancy Totah’s Agilent 7820A instrument with an Agilent
J&W Cyclodex-B GC dolumn (30 m x 0.25 mm x 0.25 m, 7 inch cage) and performed by M. Dolan
of Korendovych lab. GC was run at isothermal conditions at 115 C with a 1.0 mL/min flow rate of
He gas. The split ratio was 100:1. The retention time of the R-isomer was 29.7 minutes and the
retention time of the S-isomer was 31.3 minutes.9-14 ee% was calculated by taking the area of the
peak from the R isomer ([R]) and the area of the peak from the S isomer ([S]) in the following
equation: ([R]-[S])/([R]+[S])*100.
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Appendix II. Supplemental Data
S.1. Sequencing
Table S.1.1. Sequencing for Chapter 2

CuSeCat

MKDTDSEEEI REAFRVEDKD GNGYISAAEL RIVMTNLGEK
LTDEEVDEMI READIDGDGQ VNYEEFVQRM TAK

CuSeCat DD

MKDTDSEEEI REAFRVEDKD GNGYIDAAEL RIVMTNLGEK
LTDEEVDEMI READIDGDGQ VDYEEFVQRM TAK

CuSeCat EE

MKDTDSEEEI REAFRVEDKD GNGYIEAAEL RIVMTNLGEK
LTDEEVDEMI READIDGDGQ VEYEEFVQRM TAK

Ac7

MKDTDSEEEL REQFRVEDKD GNGYISAAEL RIVMTNRGEK
LTDEEVDELI RETDIDGDGQ VNYEEFVQRM TAK

AcDD

MKDTDSEEEL REQFRVEDKD GNGYIDAAEL RIVMTNRGEK
LTDEEVDELI RETDIDGDGQ VDYEEFVQRM TAK

AcEE

MKDTDSEEEL REQFRVEDKD GNGYIEAAEL RIVMTNRGEK
LTDEEVDELI RETDIDGDGQ VEYEEFVQRM TAK

AcCC

MKDTDSEEEL REQFRVEDKD GNGYICAAEL RIVMTNRGEK
LTDEEVDELI RETDIDGDGQ VCYEEFVQRM TAK

Y99E

MKDTDSEEEL REQFRVEDKD GNGEISAAEL RIVMTNRGEK
LTDEEVDELI RETDIDGDGQ VNYEEFVQRM TAK

Y99C

MKDTDSEEEL REQFRVEDKD GNGCISAAEL RIVMTNRGEK
LTDEEVDELI RETDIDGDGQ VNYEEFVQRM TAK
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Q135E

MKDTDSEEEL REQFRVEDKD GNGYISAAEL RIVMTNRGEK
LTDEEVDELI RETDIDGDGE VNYEEFVQRM TAK

HollEE

MKDTDSEEEL REQFRVEDKE GNGYISAAEL RIVMTNRGEK
LTDEEVDELI RETDIEGDGQ VNYEEFVQRM TAK

ReCCes

MKDTDSEEEL REQFRVEDKC GNGYISAAEL RIVMTNRGEK
LTDEEVDELI RETDICGDGQ VNYEEFVQRM TAK

Table S.1.2. Sequencing for Chapter 3

2E10-HollEE

MHHHHHHSSG
PASISCRSSQ
NRDSGVPDRF
HWPPVFGPGT
GPGLVKPSET
EWIGSIYYSG
TAADTAVYYC
GSAGSAAGSG
ELRIVMTNRG
RMTAK

VDLGTENLYF
SLVYSDGNTY
SGSGSGTDFT
KVDIKGGSSR
LSLTCTVSGG
STYYNPSLKS
ARVHDGHRYG
EFMKDTDSEE
EKLTDEEVDE

QSNDIVMTRS
LNWFQQRPGQ
LKISRVEAED
SSSSGGGGSG
SISSSNYYWG
RVTISVDTSK
TYYYYGLDVW
ELREQFRVED
LIRETDIEGD

PLSLPVTLGQ
SPRRLIYKVS
VGVYYCMQGT
GGGQVQLQES
WIRQPPGKGL
NQFSLKLSSV
GQGTAVTVSS
KEGNGYISAA
GQVNYEEFVQ

Table S.1.3. Sequencing for Chapter 4

FDH-N

FDH-C

HHHHHHSSGV
EKLYGCTENK
IPDADIIITT
IDLDYINQTG
FVPAHEQIIN
RVLERLLPFN
LVAQADIVTV
RGAICVAEDV
MRNKYGAGNA
KFDYRPQDII

DLGTENLYFQ
LGIANWLKDQ
PFHPAYITKE
KKISVLEVTG
HDWEVAAIAK
PKELLYYDYQ
NAPLHAGTKG
AAALESGQLR
MTPHYSGTTL
LLNGEYVTKA

SNAMKIVLVL
GHELITTSDK
RLDKAKNLKL
SNVVSVAEHV
DAYDIEGKTI
ALPKEAEEKV
LINKELLSKF
GYGGDVWFPQ
DAQTRYAEGT
YGKHDKK

YDAGKHAADE
EGETSELDKH
VVVAGVGSDH
VMTMLVLVRN
ATIGAGRIGY
GARRVENIEE
KKGAWLVNTA
PAPKDHPWRD
KNILESFFTG

MKIVLVLYDA
LITTSDKEGE
KAKNLKLVVV
VSVAEHVVMT
DIEGKTIATI
KEAEEKVGAR

GKHAADEEKL
TSELDKHIPD
AGVGSDHIDL
MLVLVRNFVP
GAGRIGYRVL
RVENIEELVA

YGCTENKLGI
ADIIITTPFH
DYINQTGKKI
AHEQIINHDW
ERLLPFNPKE
QADIVTVNAP

ANWLKDQGHE
PAYITKERLD
SVLEVTGSNV
EVAAIAKDAY
LLYYDYQALP
LHAGTKGLIN
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FDH-N-y

FDH-C-y

FlDH-aeru

FlDH-puti

KELLSKFKKG
GDVWFPQPAP
TRYAEGTKNI
HDKKVDKLAA

AWLVNTARGA ICVAEDVAAA LESGQLRGYG
KDHPWRDMRN KYGAGNAMTP HYSGTTLDAQ
LESFFTGKFD YRPQDIILLN GEYVTKAYGK
ALEHHHHHH

EAEAYVEFHH
AGKHAADEEK
ETSELDKHIP
VAGVGSDHID
TMLVLVRNFV
IGAGRIGYRV
RRVENIEELV
GAWLVNTARG
PKDHPWRDMR
ILESFFTGKF

HHHHSSGVDL
LYGCTENKLG
DADIIITTPF
LDYINQTGKK
PAHEQIINHD
LERLLPFNPK
AQADIVTVNA
AICVAEDVAA
NKYGAGNAMT
DYRPQDIILL

GTENLYFQSN
IANWLKDQGH
HPAYITKERL
ISVLEVTGSN
WEVAAIAKDA
ELLYYDYQAL
PLHAGTKGLI
ALESGQLRGY
PHYSGTTLDA
NGEYVTKAYG

AMKIVLVLYD
ELITTSDKEG
DKAKNLKLVV
VVSVAEHVVM
YDIEGKTIAT
PKEAEEKVGA
NKELLSKFKK
GGDVWFPQPA
QTRYAEGTKN
KHDKK

EAEAYVEFMK
WLKDQGHELI
YITKERLDKA
LEVTGSNVVS
AAIAKDAYDI
YYDYQALPKE
AGTKGLINKE
SGQLRGYGGD
SGTTLDAQTR
YVTKAYGKHD

IVLVLYDAGK
TTSDKEGETS
KNLKLVVVAG
VAEHVVMTML
EGKTIATIGA
AEEKVGARRV
LLSKFKKGAW
VWFPQPAPKD
YAEGTKNILE
KKGENLYFQS

HAADEEKLYG
ELDKHIPDAD
VGSDHIDLDY
VLVRNFVPAH
GRIGYRVLER
ENIEELVAQA
LVNTARGAIC
HPWRDMRNKY
SFFTGKFDYR
HHHHHH

CTENKLGIAN
IIITTPFHPA
INQTGKKISV
EQIINHDWEV
LLPFNPKELL
DIVTVNAPLH
VAEDVAAALE
GAGNAMTPHY
PQDIILLNGE

MSGNRGVVYL
VVSTNICGSD
VETMKIGDLV
GGAYGYVDMG
KIRDLTCLSD
AAAASARLLG
TPLHEQIAAL
ATVLNSLMGI
SIRFGLGWAK
DIVGVEVITL

GPGKVEVQNI
QHMVRGRTTA
SVPFNVACGH
GWVGGQAEYV
ILPTGYHGAV
AAVVIVGDVN
LGEPEVDCAV
TRVAGKIGIP
SHSFHTGQTP
DDAPKGYGEF

PYPKMQDPQG
PEGLVLGHEI
CRTCKEQHTG
LVPYADFNLL
TAGVGPGSTV
PTRLAHAKKQ
DAVGFEARGH
GLYVTEDPGA
VMKYNRQLMQ
DAGVPKKFVI

RQIDHGVILR
TGEVVEIGRG
VCLTVNPARA
KLPNREAAME
YIAGAGPVGL
GFEIADLSKD
GHSGSQQEAP
VDAAAKHGAL
AIMWDRIKIA
DPHNLFRAA

MSGNRGVVYL
VVSTNICGSD
VERMQIGDLV
GGAYGYVDMG
KIRDLTCLSD
AAAASARLLG

GAGKVEVQKI
QHMVRGRTTA
SVPFNVACGR
DWTGGQAEYV
ILPTGYHGAV
AACVIVGDLN

DYPKMQDPRG
QVGLVLGHEI
CRSCKEMHTG
LVPYADFNLL
TAGVGPGSTV
PARLAHAKSQ

KKIEHGVILK
TGEIVEKGRD
VCLTVNPARA
KLPERDKAME
YVAGAGPVGL
GFEVVDLSKD
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ADH

TPLHEQIVDI
ATVLNSLMQV
SIRFGLGWAK
EVVGVQVINL

LGEPEVDCAV
TRVAGNIGIP
SHSFHTGQTP
DQAPEGYGEF

DAVGFEARGH
GLYVTEDPGA
TMKYNRQLMQ
DAGVPKKFVI

GHEGAKHEAP
VDAAAKIGAL
AIMWDRINIA
DPHKMWGAA

MSIPETQKGV
SGVCHTDLHA
KGWKIGDYAG
THDGSFQQYA
KALKSANLMA
IDGGEGKEEL
HGVINVSVSE
VFNQVVKSIS
VGLSTLPEIY

IFYESHGKLE
WHGDWPLPVK
IKWLNGSCMA
TADAVQAAHI
GHWVAISGAA
FRSIGGEVFI
AAIEASTRYV
IVGSYVGNRA
EKMEKGQIVG

YKDIPVPKPK
LPLVGGHEGA
CEYCELGNES
PQGTDLAQVA
GGLGSLAVQY
DFTKEKDIVG
RANGTTVLVG
DTREALDFFA
RYVVDTSK

ANELLINVKY
GVVVGMGENV
NCPHADLSGY
PILCAGITVY
AKAMGYRVLG
AVLKATDGGA
MPAGAKCCSD
RGLVKSPIKV

Table S.1.4. Sequencing data for Chapter 5

cCam

MKDTDSEEEI REAFRVFDKD GNGYISAAEL RHVMTNLGEK
LTDEEVDEMI READIDGDGQ VNYEEFVQMM TAK

Ac0

MKDTDSEEEI REAFRVEDKD GNGYISAAEL RHVMTNLGEK
LTDEEVDEMI READIDGDGQ VNYEEFVQMM TAK

Ac0T

MKDTDSEEEI REAFRVEDKD GNGYISAAEL RHVMTNLGEK
LTDEEVDEMI RETDIDGDGQ VNYEEFVQMM TAK

Ac1

MKDTDSEEEI REAFRVEDKD GNGYISAAEL RHVMTNLGEK
LTDEEVDEMI READIDGDGQ VNYEEFVQRM TAK

Ac1T

MKDTDSEEEI REAFRVEDKD GNGYISAAEL RHVMTNLGEK
LTDEEVDEMI RETDIDGDGQ VNYEEFVQRM TAK

Ac2

MKDTDSEEEI REAFRVEDKD GNGYISAAEL RIVMTNLGEK
LTDEEVDEMI READIDGDGQ VNYEEFVQRM TAK

Ac2T

MKDTDSEEEI REAFRVEDKD GNGYISAAEL RIVMTNLGEK
LTDEEVDEMI RETDIDGDGQ VNYEEFVQRM TAK

Ac3

MKDTDSEEEI REAFRVEDKD GNGYISAAEL RIVMTNRGEK
LTDEEVDEMI READIDGDGQ VNYEEFVQRM TAK
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Ac3T

MKDTDSEEEI REAFRVEDKD GNGYISAAEL RIVMTNRGEK
LTDEEVDEMI RETDIDGDGQ VNYEEFVQRM TAK

Ac4

MKDTDSEEEL REAFRVEDKD GNGYISAAEL RIVMTNRGEK
LTDEEVDEMI READIDGDGQ VNYEEFVQRM TAK

Ac5

MKDTDSEEEL REAFRVEDKD GNGYISAAEL RIVMTNRGEK
LTDEEVDEMI RETDIDGDGQ VNYEEFVQRM TAK

Ac6

MKDTDSEEEL REAFRVEDKD GNGYISAAEL RIVMTNRGEK
LTDEEVDELI RETDIDGDGQ VNYEEFVQRM TAK

Ac6A

MKDTDSEEEL REAFRVEDKD GNGYISAAEL RIVMTNRGEK
LTDEEVDELI READIDGDGQ VNYEEFVQRM TAK

Ac7

MKDTDSEEEL REQFRVEDKD GNGYISAAEL RIVMTNRGEK
LTDEEVDELI RETDIDGDGQ VNYEEFVQRM TAK

Ac7A

MKDTDSEEEL REQFRVEDKD GNGYISAAEL RIVMTNRGEK
LTDEEVDELI READIDGDGQ VNYEEFVQRM TAK

c-V108E

MKDTDSEEEI REAFRVFDKD GNGYISAAEL RHEMTNLGEK
LTDEEVDEMI READIDGDGQ VNYEEFVQMM TAK

Ac0-V108E

MKDTDSEEEI REAFRVEDKD GNGYISAAEL RHEMTNLGEK
LTDEEVDEMI READIDGDGQ VNYEEFVQMM TAK

Ac1-V108E

MKDTDSEEEI REAFRVEDKD GNGYISAAEL RHEMTNLGEK
LTDEEVDEMI READIDGDGQ VNYEEFVQRM TAK
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S.2. Supplemental data for Chapter 2
S.2.1. Gel Electrophoresis

Figure S.1. 15% acrylamide SDS-PAGE gel of Ac7 purification. Samples were taken at various stages of the
purification and labelled as follows: 2) Ac7 after induction, 3) Ac7 cell debris, 4) Ac7 Ni-NTA flow through, 5) Ac7
Ni-NTA wash, 6) Ac7 uncut, 7) Ac7 + TEV protease, 8) Ac7 cut pure.

Figure S.2. 15% acrylamide SDS-PAGE gel of AcDD (lanes 2-7) and AcEE (lanes 8-13) purification. Aliquots were
taken at various stages of the purification and labelled as follows: 2) AcDD after induction, 3) AcDD cell debris, 4)
AcDD Ni-NTA flow through, 5) AcDD uncut, 6) AcDD + TEV protease, 7) AcDD cut pure, 8) AcEE after induction, 9)
AcEE cell debris, 10) AcEE Ni-NTA flow through, 11) AcEE uncut, 12) AcEE + TEV protease, 13) AcEE cut pure.
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Figure S.3. A 15% acrylamide SDS-PAGE gel of purified Y99E and Q135E. “Uncut” refers to proteins with SUMOtag still attached to the protein while “cut” proteins have SUMO-tag removed. No expression was seen for the
Q135E mutant.
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Figure S.4. A 15% acrylamide SDS-PAGE gel of purified Y99C, S101C, and N137C. While the protein is normally
expected around 8-12 kDa, bands at double that molecular weight were seen. “Uncut” refers to proteins with
SUMO-tag still attached to the protein while “cut” proteins have SUMO-tag removed.
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Figure S.5. A 15% acrylamide SDS-PAGE gel of ReCCes purification. The expected molecular weight of ReCCes is
approximately 8 kDa after cleavage. Before cleavage of the His-tag, ReCCes forms a dimer due to disulfide bonds
between cysteine residues.
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Figure S.6. A 15% acrylamide SDS-PAGE gel of HollEE purification. The expected MW of HollEE is 8 kDa after
cleavage of His-tag. Debris refers to the cell debris after sonification and centrifugation, and flow through and
wash refer to steps during Ni-NTA purification.
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S.2.2. Kemp elimination kinetics

Figure S.7. Catalytic efficiency graph of Kemp elimination catalyzed by Ac7, AcDD, AcEE, S101C, and N137C (after
His-tag cleavage) in 20 mM Hepes buffer pH 7.0 with addition of 0.2 mM Ca(NO3)2 and without reducing agent
(β-ME). (MT3114-8)
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Figure S.8. Catalytic efficiencyof Kemp elimination catalyzed by Ac7, AcDD, AcEE, S101C, and N137C in 20 mM
Hepes buffer, pH 7.0 with addition of 0.2 mM Pb(NO3)2 and without reducing agent (β-ME). (MT3117-8)
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Figure S.9. Michaelis-Menten graph of Kemp elimination catalyzed by Y99E and Y99C in 20 mM Hepes buffer, pH
7.0, with addition of 0.2 mM Ca(NO3)2 or 0.2 mM Pb(NO3)2 and without reducing agent (β-ME).
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Figure S.10. Catalytic efficiency of Kemp elimination catalyzed by Ac7, AcDD, AcEE, Y99E, Y99C, S101C, and
N137C (2.5 M) in 20 mM Hepes buffer pH 7.0 with addition of 0.2 mM Y(NO3)2. The kcat/KM values are 32 M-1s1(Ac7), 18 M-1s-1 (AcDD), 5 M-1s-1 (AcEE), n/a (S101E), 6 M-1s-1 (N137E), n/a (S101C), and n/a (N137C). (MT3131)
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Figure S.11. Catalytic efficiency of Kemp elimination catalyzed by D95C D131C mutant (5.0 μM) in 20 mM Hepes
buffer with addition of 0.1 mM or 0.25 mM of either Ca(NO3)2, Pb(NO3)2, or Y(NO3)2.
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Figure S.12. Catalytic efficiency of Kemp elimination catalyzed by D95C D131C mutant (5.0 μM) in 20 mM Hepes
buffer and 0.25 mM of either Ca(NO3)2, Pb(NO3)2, or Y(NO3)3, with the addition or omission of 1.2 equivalence of
β-mercaptoethanol. (MT5107)
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Figure S.13. Catalytic efficiency of Kemp elimination catalyzed by D95E D131E mutant (5.0 μM) in 20 mM Hepes
buffer with addition of 0.1 mM or 0.25 mM of either Ca(NO3)2, Pb(NO3)2, or Y(NO3)2.
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S.2.3. pH profiles of HollEE

Figure S.14. pH rate profile of HollEE (1 M) with 80 M calcium. At different pH, the rate of 600 M final
concentration of Kemp was found. At buffers 4.5-5.5, 20 mM acetate buffer was used. At pH 5.5 and 6.0 20 mM
Mes buffer was used. At pH 7.0 and 7.5, 20 mM Mops buffer was used. At pH 8.0, 20 mM Tris buffer was
used.(AG1049)
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Figure S.15. pH profile of HollEE (1 M) with 80 M lutetium. At different pH, the rate of 600 M final
concentration of Kemp was found. At buffers 4.5-5.5, 20 mM acetate buffer was used. At pH 5.5 and 6.0 20 mM
Mes buffer was used. At pH 7.0 and 7.5, 20 mM Mops buffer was used. At pH 8.0, 20 mM Tris buffer was used.
(AG1049)

213

Figure S.16. pH profile of HollEE (1 M) with 80 M ytterbium. At different pH, the rate of 600 M final
concentration of Kemp was found. At buffers 4.5-5.5, 20 mM acetate buffer was used. At pH 5.5 and 6.0 20 mM
Mes buffer was used. At pH 7.0 and 7.5, 20 mM Mops buffer was used. At pH 8.0, 20 mM Tris buffer was used.
(AG1049)
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Figure S.17. pH profile of HollEE (1 M) with 80 M terbium. At different pH, the rate of 600 M final
concentration of Kemp was found. At buffers 4.5-5.5, 20 mM acetate buffer was used. At pH 5.5 and 6.0 20 mM
Mes buffer was used. At pH 7.0 and 7.5, 20 mM Mops buffer was used. At pH 8.0, 20 mM Tris buffer was used.
(AG1049)
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Figure S.18. pH profile of HollEE (1 M) with 80 M gadolinium. At different pH, the rate of 600 M final
concentration of Kemp was found. At buffers 4.5-5.5, 20 mM acetate buffer was used. At pH 5.5 and 6.0 20 mM
Mes buffer was used. At pH 7.0 and 7.5, 20 mM Mops buffer was used. At pH 8.0, 20 mM Tris buffer was used.
(AG1049)
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Figure S.19. pH profile of HollEE (1 M) with 80 M samarium. At different pH, the rate of 600 M final
concentration of Kemp was found. At buffers 4.5-5.5, 20 mM acetate buffer was used. At pH 5.5 and 6.0 20 mM
Mes buffer was used. At pH 7.0 and 7.5, 20 mM Mops buffer was used. At pH 8.0, 20 mM Tris buffer was
used.(AG1049)
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Figure S.20. pH profile of HollEE (1 M) with 80 M neodymium. At different pH, the rate of 600 M final
concentration of Kemp was found. At buffers 4.5-5.5, 20 mM acetate buffer was used. At pH 5.5 and 6.0 20 mM
Mes buffer was used. At pH 7.0 and 7.5, 20 mM Mops buffer was used. At pH 8.0, 20 mM Tris buffer was
used.(AG1049)
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Figure S.21. pH profile of HollEE (1 M) with 80 M praseodymium. At different pH, the rate of 600 M final
concentration of Kemp was found. At buffers 4.5-5.5, 20 mM acetate buffer was used. At pH 5.5 and 6.0 20 mM
Mes buffer was used. At pH 7.0 and 7.5, 20 mM Mops buffer was used. At pH 8.0, 20 mM Tris buffer was
used.(AG1049)
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Figure S.22. pH profile of HollEE (1 M) with 80 M cerium. At different pH, the rate of 600 M final
concentration of Kemp was found. At buffers 4.5-5.5, 20 mM acetate buffer was used. At pH 5.5 and 6.0 20 mM
Mes buffer was used. At pH 7.0 and 7.5, 20 mM Mops buffer was used. At pH 8.0, 20 mM Tris buffer was
used.(AG1049)
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Figure S.23. pH profile of HollEE (1 M) with 80 M lanthanum. At different pH, the rate of 600 M final
concentration of Kemp was found. At buffers 4.5-5.5, 20 mM acetate buffer was used. At pH 5.5 and 6.0 20 mM
Mes buffer was used. At pH 7.0 and 7.5, 20 mM Mops buffer was used. At pH 8.0, 20 mM Tris buffer was
used.(AG1049)
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Figure S.24. pH profile of HollEE (1 M) with 80 M yttrium. At different pH, the rate of 600 M final
concentration of Kemp was found. At buffers 4.5-5.5, 20 mM acetate buffer was used. At pH 5.5 and 6.0 20 mM
Mes buffer was used. At pH 7.0 and 7.5, 20 mM Mops buffer was used. At pH 8.0, 20 mM Tris buffer was
used.(AG1049)
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S.2.4. Isothermal Titration Calorimetry

Figure S.25. ITC data of AlleyCat7 titrated with Ca(NO3)2. The sample cell contained 0.1mM Ac7 in 20mM Mops
pH 7.0 at 25 C and was slowly titrated with 5mM Ca(NO3)2 in 5 L injections with an equilibration time of 240
seconds.
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S.2.4. Circular dichroism

Figure S.26. Circular dichroism spectrum of Ac7 (4.75 M) with 4mM Hepes pH 7.0 in presence of 500 μM Ca2+
(red), 25 μM Ca2+ (blue), Pb2+ (green), and 25 μM EDTA (black). Ac7 demonstrates an α-helical structure in the
presence of all the metal ions tested. Despite no Ca2+ ions in the EDTA sample, Ac7 kept its structure. (MT3045)
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Figure S.27. Circular dichroism spectrum of AcDD (4.75 M) in 4mM Hepes pH 7.0 in presence of 500 μM Ca2+
(red), 25 μM Ca2+ (blue), Pb2+ (green), and 25 μM EDTA (black). AcDD demonstrates an α-helical structure in the
presence of all the metal ions tested as well as EDTA. (MT3045)
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Figure S.28. Circular dichroism spectrum of AcEE (4.75 M) with 4mM Hepes pH 7.0 in presence of 500 μM Ca2+
(red), 25 μM Ca2+ (blue), Pb2+ (green), and 25 μM EDTA (black). AcEE demonstrates an α-helical structure in the
presence of all the metal ions tested as well as EDTA. (MT3045)
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Figure S.29. Circular dichroism of HollEE (25 M) in 4 mM Mops pH 7.0 with YCl3 titration. Increasing the
concentration of metal leads to changes at 207 nm and 220 nm that can be potentially evaluated for K D.
(AG1018)
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Figure S.30. Circular dichroism of HollEE (25 M) in 4 mM Mops pH 7.0 with PrCl3 titration. Increasing the
concentration of metal leads to changes at 207 nm and 220 nm that can be potentially evaluated for K D.
(AG1022)
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Figure S.31. Circular dichroism of HollEE (25 M) in 4 mM Mops pH 7.0 with LaCl3 titration. Increasing the
concentration of metal leads to changes at 207 nm and 220 nm that can be potentially evaluated for K D.
(AG1020)
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Figure S.32. Circular dichroism of HollEE (25 M) in 4 mM Mops pH 7.0 with CaCl2 titration. (AG1025)
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Figure S.33. Circular dichroism of HollEE (25 M) in 4 mM Mops pH 7.0 with CeCl3 titration. Increasing the
concentration of metal leads to changes at 207 nm and 220 nm that can be potentially evaluated for K D.
(MT7012)
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S.3. Supplemental data for Chapter 4
S.3.1. Gel Electrophoresis

Figure S.34. A 10% acrylamide SDS-PAGE gel of purification of FDH-N expressed in BL21(DE3) E. coli cells.
Aliquots were taken before IPTG induction, after IPTG induction, from the pellet after sonication and
centrifugation (labeled debris 1 on gel), from the pellet after streptomycin sulfate addition and centrifugation
(labeled debris 2), from the Ni-NTA column flow through, from the Ni-NTA column wash, and before and after Qsepharose column. The protein band was ~45 kDa, where it was expected to appear.
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Figure S.35. Catalytic efficiency of FlDH-aeru (10 μM) measuring the conversion of NAD+ (1 mM) to NADH during
the oxidation of formaldehyde(100 mM) to formate in 100 mM sodium phosphate buffer at pH 7. The specific
activity is 2.6 U/mg. (MT1102)
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Figure S.36. Catalytic efficiency of FlDH-aeru (1 μM) measuring the conversion of NADH (0.2 mM) to NAD+ during
the reduction of formate (160 mM) to formaldehyde in 100 mM sodium phosphate buffer at pH 7. The specific
activity is 0.26 U/mg. (MT1102)
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Figure S.37. Catalytic efficiency of FlDH-puti (0.1 μM) measuring the conversion of NAD+ (1 mM) to NADH during
the oxidation of formaldehyde (100 mM) to formate in 100 mM sodium phosphate buffer at pH 7. The specific
activity is 3.13 U/mg. (MT1146)
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Figure S.38. Catalytic efficiency of FlDH-puti (12 μM) measuring the conversion of NADH (0.1 mM) to NAD+
during the reduction of formate (100 mM) to formaldehyde in 100 mM sodium phosphate buffer at pH 7. The
specific activity is 0.0003 U/mg. (MT1146)
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Figure S.39. Catalytic efficiency of ADH (16 nM) measuring the conversion of NADH (0.2 mM) to NAD+ during the
reduction of formaldhyde (100 mM) to methanol in 100 mM sodium phosphate buffer at pH 7. The specific
activity is 84 U/mg. (MT1064)

S.3.2. Tryptic digest
Table S.3.2.1. List of peptide fragments of FDH-C-y after trypsin digestion.

Position of
cleavage site
2
76

Peptide sequence
MR
FPSIFTAVLFAASSALAAPVNTTTEDETAQIP
AEAVIGYSDLEGDFDVAVLPFSNSTNNGLLFI
NTTIASIAAK

Peptide
length [aa]
2

Peptide
mass [Da]
305.395

74

7623.502
237

84
85
95
105
112
120
128
140
149
169
171
174
176
179
201
202
229
250
258
267
271
275
282
294
299
303
304
329
334
339
341
342
351
370
384
389
392
394
415
421

EEGVSLEK
R
EAEAYVEFMK
IVLVLYDAGK
HAADEEK
LYGCTENK
LGIANWLK
DQGHELITTSDK
EGETSELDK
HIPDADIIITTPFHPAYITK
ER
LDK
AK
NLK
LVVVAGVGSDHIDLDYINQTGK
K
ISVLEVTGSNVVSVAEHVVMTMLVLVR
NFVPAHEQIINHDWEVAAIAK
DAYDIEGK
TIATIGAGR
IGYR
VLER
LLPFNPK
ELLYYDYQALPK
EAEEK
VGAR
R
VENIEELVAQADIVTVNAPLHAGTK
GLINK
ELLSK
FK
K
GAWLVNTAR
GAICVAEDVAAALESGQLR
GYGGDVWFPQPAPK
DHPWR
DMR
NK
YGAGNAMTPHYSGTTLDAQTR
YAEGTK

8
1
10
10
7
8
8
12
9
20
2
3
2
3
22
1
27
21
8
9
4
4
7
12
5
4
1
25
5
5
2
1
9
19
14
5
3
2
21
6

889.958
174.203
1216.371
1090.328
798.808
927.04
914.115
1343.413
1007.019
2263.621
303.318
374.437
217.268
373.453
2313.593
146.189
2882.47
2402.695
909.948
858.993
507.59
515.61
828.022
1515.726
604.615
401.466
174.203
2631.966
543.664
588.702
293.366
146.189
987.126
1873.111
1518.692
709.762
420.484
260.293
2212.378
667.717
238

431
435
449
453
456
457
471

NILESFFTGK
FDYR
PQDIILLNGEYVTK
AYGK
HDK
K
GENLYFQSHHHHHH

10
4
14
4
3
1
14

1155.316
599.644
1602.848
437.496
398.419
146.189
1779.854

S.4. Supplemental data for Chapter 5
S.4.1. Gel electrophoresis

Figure S.40. 15% acrylamide SDS-PAGE gel of Ac0 and Ac0-V108E purification. The expected MW of Ac0 and Ac0V108E uncut is ~12 kDa and the expected MW of the cut proteins is ~8 kDa.
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Figure S.41. 15% acrylamide SDS-PAGE gel of wild-type (wt; cCam) and wtV108E (cV108E). Debris refers to the
pellet left behind after sonication and centrifugation, and flow and wash refer to steps in Ni-NTA purification.
The expected masses of the uncut proteins is ~12 kDa.
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Abstract
Biofuels are an important tool for the reduction of carbon dioxide and other greenhouse emissions. NAD+-dependent formate dehydrogenase has been previously shown to be capable of the
electrochemical reduction of carbon dioxide into formate, which can be ultimately converted to
methanol. We established that a functional enzyme, tagged for immobilization, could be continuously secreted by Pichia pastoris. The protein can be easily separated from the growth media and its
activity remains constant over an extended period of time. This is an important ﬁrst step in creating a
self-sustaining system capable of producing biofuels with minimal resources and space required.
Key words: Formate dehydrogenase, Pichia pastoris, protein engineering

Introduction
Enzymes are capable of facilitating chemical reactions with exceptional versatility and efﬁciency. While the repertoire of enzymes is
vast, many practically useful reactions still cannot be catalyzed with
sufﬁcient efﬁciency. Moreover, even if an enzyme is known to catalyze a particular chemical transformation well, production cost and
stability issues may preclude its use in laboratory and industry.
Biofuel production is an important strategy for keeping CO2
greenhouse gas emissions to a minimum. Most biofuel in the USA is
produced by fermentation of sugars obtained from corn (Bhatia
et al., 2012; Kondratenko et al., 2013). However, making land useable for these crops requires clearing current ﬂora by either burning
or microbial decomposition, both of which release more CO2 into
the atmosphere than the produced biofuels can compensate for
(Fargione et al., 2008). While biofuels are important for the future of
environmental protection, alternative, more sustainable methods of
production are urgently needed.
Capture of CO2 by employing enzymes provides a very appealing
opportunity. Direct capture of carbon dioxide is the ultimate carbon
neutral process; however, apart from Rubisco, which is the primary
tool for CO2 capture in plants, there are no other known means for
enzymatic capture of carbon dioxide. Initial ﬁxation of carbon

dioxide in solution is critically important; once the gas is trapped, it
could be fed into multiple one carbon metabolic pathways.
Immobilized nicotinamide adenine dinucleotide (NAD)-dependent
formate dehydrogenase (FDH, EC 1.2.1.2) has been recently used to
electrochemically reduce carbon dioxide to formate, which can be in turn
enzymatically reduced to methanol, a usable biofuel, by utilizing NAD+dependent formaldehyde dehydrogenase (FlDH, EC 1.2.1.1) and NAD+dependent alcohol dehydrogenase (ADH, EC 1.1.1.1) (Scheme 1) (Kim
et al., 2013; Liu et al., 2013). The native function of all these enzymes is
to produce NADH by oxidation of their respective substrates: formate,
formaldehyde and methanol. The overall strategy is based on the fact
that catalysts equally facilitate both forward and reverse reactions, thus
given excess of the product and sufﬁcient reducing power, NAD+dependent dehydrogenases can reduce carbon dioxide to methanol.
While partial hydrogenation of carbon dioxide has been accomplished through multiple pathways such as heterogeneous catalysis,
electrocatalysis and photocatalysis, the enzymatic process is advantageous due to its ability to operate under mild conditions (Obert and
Dave, 1999; Cazelles et al., 2013; Aresta et al., 2014). However, this
multi-step reduction of carbon dioxide faces its own challenges, such
as a low pH and elevated temperature required for maximum efﬁciency, which can cause the enzymes to degrade (Baskaya et al., 2009).

© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com

1

2

M.Takacs et al.

Scheme 1 Overview of the proposed bioengineered pathway for the production of methanol from CO2 utilizing a multi-step enzyme pathway.

Our goal is to develop an economic and renewable approach to
produce active dehydrogenase through continuous secretion in
yeast. The yeast will continuously secrete the protein into media,
which eliminates the time-consuming step of growing, expressing and
extensive puriﬁcation of the desired proteins from Escherichia coli.
Yeast will also replace enzymes as they degrade and extend the lifetime of any device engineered to capture CO2. We chose Pichia pastoris, a methylotrophic yeast capable of expressing and secreting
non-native proteins, due to its many important beneﬁts: (i) recombinantly produced enzymes (including large proteins with molecular
weight >50 kDa) can be secreted; (ii) P. pastoris is tolerant to high
concentrations of methanol; (iii) methanol can serve as the only
energy source for the culture, eliminating the need for complex media
formulations that would increase production costs; (iv) a typical P. pastoris strain would use methanol as an inducer for recombinant production of proteins; (v) P. pastoris cultures grow to high-density improving
the costs and diminishing the size of fermentors and (vi) P. pastoris generally does not secrete its own proteins, simplifying downstream puriﬁcation of the secreted dehydrogenases (Kovar et al., 2010).
Development of an efﬁcient secretion system for functional enzymes
is commonly plagued with difﬁculties related to posttranslational processing (most often glycosylation) of proteins in yeast that may interfere
with activity. Therefore, optimization of expression is often necessary.
Additionally, we set on determining the optimal position of the afﬁnity
tag necessary for attaching the protein to solid support.
We focused our efforts on FDH from yeast Candida boidinii,
which has been previously structurally and functionally characterized (Slusarczyk et al., 2000; Schirwitz et al., 2007). In this work,
we established that a tagged, functional enzyme could be continuously secreted by P. pastoris. The protein can be easily separated
from the growth media using Ni-NTA resin and enzyme’s activity
remained constant even after prolonged growth at 29°C.

Materials and methods
Cloning of FDH gene into pMCSG49 and pET28a
vectors
cDNA of C. boidinii FDH (without His6-tag) was synthesized by
GenScript. To obtain FDH with N-terminal His6-tag (FDH-N), FDH
gene was cloned into pMCSG49 vector (DNASU plasmid repository)
through ligation-independent cloning site (Stols et al., 2002). To obtain
FDH with C-terminal His6-tag (FDH-C), the FDH gene was cloned
into pET28a (Novagen) using SalI and NcoI restriction enzymes. The
DNA sequences were conﬁrmed using Sanger sequencing.

Expression of FDH-N and FDH-C in E. coli and protein
puriﬁcation
The appropriate vectors containing the genes of interest were transformed into E. coli BL21(DE3) cells and plated on Luria-Bertani (LB)
agar plates containing ampicillin (FDH-N) or kanamycin (FDH-C).
For the FDH seed culture, LB (50 ml) supplemented with antibiotic (100 μg/μl Amp for FDH-N or 50 μg/μl Kan for FDH-C) was
inoculated with a single colony and incubated overnight at 37°C

with shaking at 230 r.p.m. The seed culture (10 ml) was then diluted
into LB (1 l) supplemented with antibiotic and the culture was
grown at 37°C. When the culture reached an OD600 of ~0.6, isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to a ﬁnal concentration of 0.4 mM. FDH was expressed for 4 h at 30°C and the
cells were then collected by centrifugation (4000 g × 20 min), ﬂash
frozen in liquid nitrogen and stored at −80°C. The typical yield of
wet cell paste was 4 g per liter of culture.
Cells were resuspended in working buffer (50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; HEPES, 5% glycerol, pH
7.6) at a ratio of 5 ml of buffer for every 1 g of cells.
Phenylmethanesulfonyl ﬂuoride (PMSF) was added to a ﬁnal concentration of 0.5 mM. Cells were lysed by sonication on ice for 10 min
(20 s lyse cycle, 20 s rest), and then the crude cell lysate was centrifuged at 20 000 g for 30 min. To precipitate DNA, a solution of streptomycin sulfate in working buffer was added to the supernatant on
ice to a ﬁnal concentration of 1% w/v and the mixture was allowed
to stir for 15 min. Precipitate was pelleted by centrifugation at 20 000 g
for 30 min. The supernatant was applied onto a Ni-NTA column
(2 ml, Clontech) and washed with 2 column volumes (CV) of working
buffer. Column was washed with 30 mM imidazole in working buffer
to remove impurities, and then FDH was eluted with 200 mM imidazole in buffer (pH 7.6). Fractions containing protein were identiﬁed
using Pierce BCA Protein Assay kit (Thermo Scientiﬁc). Combined protein fractions were diluted two-fold and applied onto a Q Sepharose
Fast Flow column (6 ml, GE Healthcare), then washed with working buffer. Protein was eluted with 300 mM NaCl in working buffer. The purity (>95%) of the ﬁnal protein was checked on sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and the protein was concentrated to 500 µM using a 30 kDa
MWCO spin ﬁlter (Vivaspin, Sartorius). Protein concentrations
were determined by measuring the absorbance at 280 nm using
the calculated (ExPASy) extinction coefﬁcient 51 465 M−1 cm−1
(FDH-C) and 52 955 M−1 cm−1 (FDH-N).

Cloning of FDH into pPIC9
Sequences coding for FDH-N and FDH-C were cloned into pPIC9
vector (Invitrogen) using EcoRI and NotI restriction sites. This procedure inserts FDH gene in frame with the secretion signal open
reading frame. Gene product is a fusion of α-factor with Glu-LysArg*Glu-Ala-Glu-Ala at the end, followed by FDH protein. The preliminary cleavage of the signal sequence occurs between arginine
and glutamine and is denoted with an asterisk. Glu-Ala repeats can
be further cleaved off. FDH gene ﬂanked by EcoRI and NotI restriction sites and empty pPIC9 vector were digested using EcoRI and
NotI restriction enzymes (New England Biolabs; NEB). The digested
products were puriﬁed using Nucleospin Extract II (BioBasic) kit.
The digested pPIC9 vector and FDH gene were mixed in 1:8 vector to gene ratio (based on DNA concentration in ng/μl) and then
ligated using T4 DNA Ligase (NEB). The mixture was incubated at
room temperature for 30 min and transformed into E. coli XL-10
cells. DNA was puriﬁed using EZ-10 Spin Column Plasmid DNA kit
(BioBasic) and the sequence conﬁrmed by Sanger sequencing.
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Transformation of pPIC9 into P. pastoris
Transformation into P. pastoris was done using previously published protocol with minor modiﬁcations (Wu and Letchworth,
2004). The pPIC9 vector containing the genes of interest was cut
using SalI restriction enzyme (NEB). Cut vector was puriﬁed using
Nucleospin Extract II kit protocol.
Pichia pastoris GS115 yeast culture was started from a glycerol
stock by inoculating 2 ml of yeast extract peptone dextrose (YPD)
media and the culture was grown at 28.5°C with shaking at 230 r.p.
m. overnight. Next day this culture was transferred into 100 ml of
YPD and grown until OD600 reached 1.5. The cells were pelleted at
3000 g and then resuspended in ice-cold sterile LiAc-DTT buffer
(100 mM lithium acetate, 10 mM dithiothreitol; DTT, 600 mM
sorbitol, 10 mM Tris pH 7.5) and allowed to incubate at room temperature for 40 min. Cells were centrifuged at 3000 g and the pellet
was washed twice with 1 ml of ice-cold sterile 1 M sorbitol. Cells were
resuspended in 400 µl of 1 M sorbitol to reach OD600 between 100 and
200. Digested plasmid (3.5 μg) was mixed with GS115 cells (200 µl),
the mixture was incubated on ice for 10 min and then transferred into
Electroporation cuvette (2 mm electrode gap, 450 µl, Bulldog Bio). The
electroporation pulse was applied to the cells at 1.5 kV using an
Eppendorf 2510 electroporator. After transformation, the culture was
immediately diluted 10-fold using 1 M sorbitol and variable amounts
were plated on Regeneration Dextrose Base (RDB-) plates.
The same transformation procedure was repeated using empty
pPIC9 digested with SalI. This step generated P. pastoris strain that
does not have any proteins attached to α-factor. The strain was used
to evaluate background secretion.

Screening for P. pastoris Mut+ phenotype (ability to
grow on methanol as a sole carbon source)
Colonies that successfully grow on RDB- plates are assumed to have
undergone successful homologous recombination upon transformation. To determine if transformed P. pastoris was capable of growing in the presence of methanol, several colonies from RDB- plates
were streaked on Minimal Methanol (MM) plates and the plates
were allowed to incubate for 3–4 days at 30°C. A colony from MM
plate was used to prepare glycerol stock, 50 µl aliquots were ﬂash
frozen using acetone/dry ice bath and kept at −80°C until needed.
To conﬁrm the presence of FDH gene, a single colony was used
to inoculate 20 μl of sterile H2O. The yeast cells were lysed by freezing the inoculated solution for 1 min in liquid N2 followed by
thawing for 1 min in a 42°C water bath. This process was repeated
15–20 times for best results. For PCR screening, 10 μl of lysate was
mixed with 1.2 μl α-factor forward primer (Integrated DNA
Technologies; IDT), 1.2 μl 3′AOX1 reverse primer (IDT) and 12 μl
GoTaq DNA Polymerase master mix (Promega). After PCR, samples
were analyzed using a 1% agarose DNA gel run in TAE buffer. A
DNA band for the FDH gene was present at ~1.2 kb.

Expression and puriﬁcation of FDH secreted from
P. pastoris
A small volume of YPD (2 ml) was inoculated with glycerol stock
(10 μl). After growing the culture for 16 h, the cells were pelleted at
2000 g and resuspended in 20 ml of buffered methanol-complex
medium (BMMY; 1% yeast extract, 2% peptone, 1.34% yeast
nitrogen base, 4 × 10−5% biotin,100 mM sodium phosphate pH
6.0, 0.5% methanol) and allowed to grow for 120 h at 28.5°C.
Every 24 h, an aliquot was taken for analysis and methanol was
added to BMMY to a ﬁnal concentration of 0.5%.
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The cells were removed by centrifugation at 5000 g for 2 min and
the media was decanted. After pH of the media was raised to approximately pH 7–8 using NaOH, it was added to Ni-NTA resin (2 ml)
pre-equilibrated with working buffer (50 mM HEPES, 5% glycerol,
pH 7.6). The mixture was then rocked on ice for 2 h. Media-resin mixture was washed with working buffer (~100 ml buffer for every 1 ml
of resin). Protein was eluted with 300 mM imidazole in working buffer
(pH 7.6). The purity (>95%) of the ﬁnal protein was checked on SDSPAGE. The protein was concentrated using a 30 kDa MWCO spin ﬁlter (Vivaspin, Sartorius) and the imidazole concentration adjusted to
~3 mM. Protein concentrations were determined by measuring the
absorbance at 280 nm using the calculated (ExPASy) extinction coefﬁcient 54 445 M−1 cm−1 (FDH-C and FDH-N).

Kinetic assays
All kinetic measurements were done at room temperature (22°C) on
an Agilent 8453 UV-Vis Spectrophotometer monitoring absorbance
at 340 nm with a background absorbance at 800 nm. Enzyme activity was characterized in a buffer containing 100 mM sodium phosphate (pH 7), 1.0 mM NAD+, 160 mM formate. Unless speciﬁcally
stated, the ﬁnal concentration of proteins in the enzymatic assay was
0.5 μM FDH and kinetic measurements were recorded every 20 s
over a period of 5 min. Change in absorbance at 340 nm was ﬁt to a
linear model. One unit of activity (U) is deﬁned as the production/
consumption of 1 µmol of NADH per min. The speciﬁc activity of
enzyme was calculated with the following equation:

specific activity =

slope ∗ Vf
6220 ∗ mf

,

where Vf is the ﬁnal volume of the enzymatic assay and mf is the
mass (mg) of FDH enzyme.

Tryptic digestion
For tryptic digestion, 50 µl of protein stock (~0.1 µg protein) was
mixed with 50 µl buffer (6 M urea, 100 mM Tris, pH 7.8) and 5 µl of
reducing agent (200 mM DTT, 100 mM Tris, pH 7.8) and allowed to
sit at room temperature for 1 h. To alkylate cysteines, 20 µl of alkylating agent (200 mM iodoacetamide, 100 mM Tris, pH 7.8) was added
and protein mixture was allowed to sit at room temperature for 1 h.
To consume unreacted iodoacetamide, 20 µl of reducing agent was
added to the mixture. The sample was then diluted with water
(775 µl) and 100 µl of porcine trypsin (SAFC, 200 ng/µl ﬁnal concentration, 100 mM Tris, pH 7.8) was added. Protein mixture was
allowed to digest overnight at 37°C. To stop the reaction, acetic acid
was added to the mixture until pH was below six.

Mass spectrometry
The molecular weights of the puriﬁed proteins were conﬁrmed by
matrix-assisted laser desorption ionization time-of-ﬂight (MALDITOF) mass spectrometry using a Bruker Autoﬂex III Smartbeam
MALDI-TOF mass spectrometer. Puriﬁed protein samples and tryptic
digest samples (~10 µM concentration) were mixed with saturated
solution of sinapic acid in a 1:2 volume ratio. Ovalbumin (molecular
weight; MW of 44.3 kDa) was used as an external standard.

Protein sequences of the constructs used in this work
FDH-N in pPIC9 vector (MW = 43 915 Da ε280 = 54 445 M−1)
EAEAYVEFHH HHHHSSGVDL GTENLYFQSN AMKIVLVLYD
AGKHAADEEK LYGCTENKLG IANWLKDQGH ELITTSDKEG

4
ETSELDKHIP DADIIITTPF HPAYITKERL DKAKNLKLVV VAG
VGSDHID LDYINQTGKK ISVLEVTGSN VVSVAEHVVM TML
VLVRNFV PAHEQIINHD WEVAAIAKDA YDIEGKTIAT IGAGR
IGYRV LERLLPFNPK ELLYYDYQAL PKEAEEKVGA RRVENIEELV
AQADIVTVNA PLHAGTKGLI NKELLSKFKK GAWLVNTARG
AICVAEDVAA ALESGQLRGY GGDVWFPQPA PKDHPWRDMR
NKYGAGNAMT PHYSGTTLDA QTRYAEGTKN ILESFFTGKF
DYRPQDIILL NGEYVTKAYG KHDKK.
FDH-N in pMCSG49 vector (MW = 43 108 Da ε280 = 52 955 M-1)
HHHHHHSSGV DLGTENLYFQ SNAMKIVLVL YDAGKHAADE
EKLYGCTENK LGIANWLKDQ GHELITTSDK EGETSELDKH IP
DADIIITT PFHPAYITKE RLDKAKNLKL VVVAGVGSDH IDLD
YINQTG KKISVLEVTG SNVVSVAEHV VMTMLVLVRN FVPA
HEQIIN HDWEVAAIAK DAYDIEGKTI ATIGAGRIGY RVLERLL
PFN PKELLYYDYQ ALPKEAEEKV GARRVENIEE LVAQADIVTV
NAPLHAGTKG LINKELLSKF KKGAWLVNTA RGAICVAEDV
AAALESGQLR GYGGDVWFPQ PAPKDHPWRD MRNKYGAGNA
MTPHYSGTTL DAQTRYAEGT KNILESFFTG KFDYRPQDII LL
NGEYVTKA YGKHDKK.
FDH-C in pET28a vector (MW = 42 104 Da ε280 = 51 465 M-1)
MKIVLVLYDA GKHAADEEKL YGCTENKLGIANWLKDQGHEL
ITTSDKEGET SELDKHIPDA DIIITTPFHP AYITKERLDK AKNLK
LVVVA GVGSDHIDLD YINQTGKKIS VLEVTGSNVV SVAEHVV
MTM LVLVRNFVPA HEQIINHDWE VAAIAKDAYD IEGKTIATIG
AGRIGYRVLE RLLPFNPKEL LYYDYQALPK EAEEKVGARR VEN
IEELVAQ ADIVTVNAPL HAGTKGLINK ELLSKFKKGA WLVN
TARGAI CVAEDVAAAL ESGQLRGYGG DVWFPQPAPK DHPWR
DMRNK YGAGNAMTPH YSGTTLDAQT RYAEGTKNIL ESFFTG
KFDY RPQDIILLNG EYVTKAYGKH DKKVDKLAAA LEHHHHHH.
FDH-C in pPIC9 (MW = 43 071 Da ε280 = 54 445 M-1)
EAEAYVEFMK IVLVLYDAGK HAADEEKLYG CTENKLGIAN
WLKDQGHELI TTSDKEGETS ELDKHIPDAD IIITTPFHPA YIT
KERLDKA KNLKLVVVAG VGSDHIDLDY INQTGKKISV LE
VTGSNVVS VAEHVVMTML VLVRNFVPAH EQIINHDWEV AA
IAKDAYDI EGKTIATIGA GRIGYRVLER LLPFNPKELL YYDYQ
ALPKE AEEKVGARRV ENIEELVAQA DIVTVNAPLH AGTKG
LINKE LLSKFKKGAW LVNTARGAIC VAEDVAAALE SGQLRG
YGGD VWFPQPAPKD HPWRDMRNKY GAGNAMTPHY SGTT
LDAQTR YAEGTKNILE SFFTGKFDYR PQDIILLNGE YVTKA
YGKHD KKGENLYFQS HHHHHH.
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(Ni-NTA afﬁnity chromatography followed by ion exchange on Q
Sepharose), as seen in Fig. 1.
Speciﬁc activity of FDH was dependent upon the placement of the
His6-tag, where FDH-N was more active than FDH-C in the reduction
of NAD+ to NADH and consequently the conversion of formate to
carbon dioxide (Fig. 2). Both FDH-C and FDH-N exhibited slightly
lower activities compared to previously reported value (Krahulec et al.,
2008) measured at higher temperature (30°C) and higher pH (7.5).
Next, we introduced the genes encoding FDH-C and FDH-N into
the genome of P. pastoris. While FDH-N had a higher speciﬁc activity in bacteria, we determined the expression yield of FDH-N in yeast
was much lower when compared to FDH-C, thus we focused our
efforts on characterization of FDH-C. In both cases, FDH was
expressed with α-factor at the N-terminus to induce extracellular secretion in P. pastoris. The α-factor signal derived from Saccharomyces
cerevisiae consists of a 19 amino acid sequence (pre-signal) responsible
for signaling that the expressed protein must be transferred to the
endoplasmic reticulum after translation, and a 67 residue pro-signal,
which is responsible for transferring the protein into the Golgi compartment where it can then be secreted outside the cell (Cregg et al.,
2000; Lin-Cereghino et al., 2012; Ahmad et al., 2014).
At pH 6, the P. pastoris strain encoding FDH-C was able to
secrete FDH upon the addition of 0.5% methanol to the media. Over
time, the amount of the enzyme in the media increased, as visualized
by SDS-PAGE (Fig. 3). After 48 h, the approximate concentration of
protein in media was 8–10 mg/l. Upon puriﬁcation of FDH-C from
the BMMY media, the major product had the same size as the enzyme
isolated from E. coli, therefore it was not degraded by natural yeast
proteases (Fig. 3). Speciﬁc activity of secreted FDH was measured
using the puriﬁed protein to ensure an accurate reading of concentration. On occasion, the puriﬁed protein would have a slight yellow color leftover after Ni-NTA column, however, this did not affect
enzymatic activity of the protein. Overall, the secreted protein showed
about a 10-fold decrease in activity compared to protein expressed in
E. coli (Table I). Secreted FDH retains its activity in media despite the
prolonged incubation at elevated temperature (29°C) and proteases. A
kinetic assay of puriﬁed protein isolated from media grown for 24, 48
and 120 h shows little difference in speciﬁc activity for the reduction
of NAD+ (Fig. 4, Table I).

Results and Discussion
FDH from C. boidinii is fairly small (43 kDa) and thermostable up
to 50°C (Slusarczyk et al., 2000; Tishkov and Popov, 2004). It has
been structurally characterized (Schirwitz et al., 2007; Guo et al.,
2016), and its speciﬁc activity was reported to be 4.4 U/mg
(Krahulec et al., 2008) and 6.5 U/mg at pH 7.5 at 30°C (Slusarczyk
et al., 2000). The location of afﬁnity tags in the sequence of the protein can interfere with enzymatic activity, thus we have cloned the
FDH gene into the pMCSG49 vector and into the pET28a vector to
be able to obtain a protein with N-terminal His6-tag (FDH-N) and
C-terminal His6-tag (FDH-C), respectively. Both constructs were
successfully expressed in E. coli upon induction with 0.4 mM IPTG,
which was visualized in a well-deﬁned protein band at ~45 kDa.
The proteins were successfully puriﬁed using a two-step puriﬁcation

Fig. 1 SDS-PAGE analysis (10% acrylamide gel) of FDH-N at various stages of
puriﬁcation. FDH-N was expressed in E. coli BL21(DE3). Lane 1− before IPTG
induction; Lane 2− after IPTG induction; Lane 3− cell debris; Lane 4− after
streptomycin sulfate precipitation; Lane 5− Ni-NTA column ﬂow through;
Lane 6− Ni-NTA column wash; Lane 7− before Q Sepharose column; Lane 8
− after Q Sepharose column, ﬁnal protein.
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Fig. 2 The kinetic assay graph of FDH-C (0.5 μM, left) and FDH-N (0.1 μM, right) proteins measuring the conversion of NAD+ to NADH during the oxidation of
sodium formate to carbon dioxide at pH 7. The speciﬁc activity of FDH-C is 1.1 U/mg and the speciﬁc activity of FDH-N is 2.7 U/mg.

Fig. 3 SDS-PAGE (10% acrylamide) analysis of media after growing yeast
with empty pPIC9 for 120 h (Lane 1); media after growing yeast with FDH-C
for 0 h (Lane 2), 8 h (Lane 3), 24 h (Lane 4), 48 h (Lane 5), 72 h (Lane 6), 96 h
(Lane 7) and 120 h (Lane 8).

Table I. Activity of various FDH constructs expressed in E. coli and
P. pastoris
Construct

Expression host

Speciﬁc Activity, U/mg

FDH-N
FDH-C
FDH-C, 24 h
FDH-C, 48 h
FDH-C, 120 h

E. coli
E. coli
P. pastoris
P. pastoris
P. pastoris

2.7
1.1
0.11
0.13
0.10

Puzzled by the signiﬁcant drop in enzymatic activity of the FDH
secreted from P. pastoris, we hypothesized that the protein produced
in yeast may be glycosylated. However, the MALDI-TOF analysis of
the protein expressed in P. pastoris (Fig. 5) shows no signs of signiﬁcant posttranslational modiﬁcations. Another possibility for the
reduced activity is imprecise cleavage of the prepro-signal on the Nterminus. The placement of linkers or fusion proteins in relation to the
protein of interest can affect secretion efﬁciency and yeast-secreted proteins can be degraded and/or proteolyzed on their N- or C-terminus
(Park et al., 1997; Moua et al., 2016). To determine the possibility of
the incomplete or impartial cleavage of the α-factor, we digested the
secreted enzyme with trypsin. Indeed, we have observed a peak with a
mass of 7624 Da in the MALDI spectrum of the tryptic digest, which

Fig. 4 The kinetic assay graphs measuring the conversion of NAD+ to NADH
and the oxidation of sodium formate to carbon dioxide at pH 7 as catalyzed
by secreted FDH-C protein (0.5 μM). The speciﬁc activity of FDH at 24 h is
0.11 U/mg, at 48 h is 0.13 U/mg and at 120 h is 0.10 U/mg.

Fig. 5 MALDI-TOF spectrum of FDH-C secreted from P. pastoris. The calculated mass for the protein is 43.07 kDa.
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